[
{
"drug": "Acetaminophen",
"interacting_drug": "Warfarin",
"description": "Combining Acetaminophen with Warfarin can increase the risk of bleeding by elevating INR levels.",
"extended_description": "Chronic use of Acetaminophen at high doses (4,000 mg/day) has been shown to elevate INR levels in patients on Warfarin, heightening the risk of serious bleeding complications. Careful monitoring of INR is recommended."
},
{
"drug": "Aspirin",
"interacting_drug": "Ibuprofen",
"description": "Concurrent use of Aspirin and Ibuprofen may increase the risk of gastrointestinal bleeding and reduce the cardioprotective effects of Aspirin.",
"extended_description": "Ibuprofen can antagonize the irreversible antiplatelet effect of Aspirin, particularly when taken concurrently. This interaction increases the risk of gastrointestinal ulceration and bleeding, especially in high-risk individuals."
},
{
"drug": "Simvastatin",
"interacting_drug": "Amiodarone",
"description": "Amiodarone significantly increases Simvastatin levels, raising the risk of muscle toxicity, including rhabdomyolysis.",
"extended_description": "Amiodarone inhibits the CYP3A4 enzyme, which metabolizes Simvastatin. This inhibition causes elevated Simvastatin concentrations, increasing the likelihood of severe adverse effects such as muscle pain, weakness, and rhabdomyolysis."
},
{
"drug": "Metformin",
"interacting_drug": "Furosemide",
"description": "Chronic use of Furosemide may decrease Metformin’s glucose-lowering effect and alter its bioavailability.",
"extended_description": "Furosemide can reduce Metformin absorption and bioavailability, potentially compromising blood sugar control. Additionally, both drugs may increase the risk of lactic acidosis in certain patients."
},
{
"drug": "Ciprofloxacin",
"interacting_drug": "Tizanidine",
"description": "Ciprofloxacin may drastically increase Tizanidine levels, leading to excessive sedation, hypotension, and bradycardia.",
"extended_description": "Ciprofloxacin inhibits CYP1A2, the enzyme responsible for metabolizing Tizanidine. This results in elevated Tizanidine plasma concentrations, increasing the risk of severe hypotension, profound sedation, and cardiac effects."
},
{
"drug": "Digoxin",
"interacting_drug": "Verapamil",
"description": "Verapamil elevates Digoxin levels, increasing the risk of toxicity, including arrhythmias and nausea.",
"extended_description": "Verapamil reduces the renal and hepatic clearance of Digoxin, leading to higher serum concentrations. This interaction can cause symptoms such as nausea, visual disturbances, and life-threatening arrhythmias."
},
{
"drug": "Clopidogrel",
"interacting_drug": "Omeprazole",
"description": "Omeprazole reduces Clopidogrel’s effectiveness by inhibiting its activation, increasing the risk of blood clots.",
"extended_description": "Omeprazole inhibits the CYP2C19 enzyme required for Clopidogrel’s bioactivation. This reduces its antiplatelet efficacy, potentially leading to adverse cardiovascular events in high-risk patients."
},
{
"drug": "Warfarin",
"interacting_drug": "Ciprofloxacin",
"description": "Ciprofloxacin enhances Warfarin's anticoagulant effect, increasing the risk of severe bleeding.",
"extended_description": "Ciprofloxacin inhibits Warfarin metabolism by affecting CYP enzymes, leading to increased INR levels. This interaction requires close monitoring of INR and dose adjustments of Warfarin."
},
{
"drug": "Lisinopril",
"interacting_drug": "Spironolactone",
"description": "Combining Lisinopril with Spironolactone can significantly increase potassium levels, leading to hyperkalemia.",
"extended_description": "Both Lisinopril (an ACE inhibitor) and Spironolactone (a potassium-sparing diuretic) can elevate potassium concentrations. This increases the risk of hyperkalemia, which may result in cardiac arrhythmias or muscle weakness."
},
{
"drug": "Levothyroxine",
"interacting_drug": "Calcium Carbonate",
"description": "Calcium Carbonate reduces the absorption of Levothyroxine, diminishing its efficacy.",
"extended_description": "Calcium Carbonate binds to Levothyroxine in the gastrointestinal tract, impairing its absorption. To avoid interaction, Levothyroxine should be taken at least 4 hours apart from calcium supplements."
},
{
"drug": "Sertraline",
"interacting_drug": "Tramadol",
"description": "Using Sertraline with Tramadol may increase the risk of serotonin syndrome, a potentially life-threatening condition.",
"extended_description": "Both Sertraline (an SSRI) and Tramadol increase serotonin levels. When combined, they can trigger serotonin syndrome, characterized by confusion, hyperreflexia, agitation, and, in severe cases, seizures or coma."
},
{
"drug": "Metoprolol",
"interacting_drug": "Verapamil",
"description": "Verapamil enhances Metoprolol’s effects, potentially causing excessive bradycardia and hypotension.",
"extended_description": "Both Metoprolol (a beta-blocker) and Verapamil (a calcium channel blocker) slow the heart rate and reduce blood pressure. Concurrent use may result in profound bradycardia and dangerously low blood pressure."
},
{
"drug": "Phenytoin",
"interacting_drug": "Doxycycline",
"description": "Phenytoin decreases Doxycycline's effectiveness by accelerating its metabolism.",
"extended_description": "Phenytoin induces hepatic enzymes, leading to increased clearance of Doxycycline. This reduces Doxycycline's therapeutic efficacy in treating bacterial infections."
},
{
"drug": "Fluoxetine",
"interacting_drug": "Clozapine",
"description": "Fluoxetine increases Clozapine levels, heightening the risk of toxicity, including seizures and sedation.",
"extended_description": "Fluoxetine inhibits the CYP2D6 enzyme responsible for metabolizing Clozapine. This interaction can lead to excessive drug levels, increasing the likelihood of adverse effects such as severe sedation and seizures."
},
{
"drug": "Allopurinol",
"interacting_drug": "Azathioprine",
"description": "Allopurinol increases Azathioprine toxicity, leading to bone marrow suppression and other severe effects.",
"extended_description": "Allopurinol inhibits xanthine oxidase, an enzyme needed to metabolize Azathioprine. This leads to elevated levels of Azathioprine and a higher risk of myelosuppression and hepatotoxicity."
},
{
"drug": "Lithium",
"interacting_drug": "NSAIDs",
"description": "NSAIDs increase Lithium levels, raising the risk of toxicity, including tremors, confusion, and renal damage.",
"extended_description": "NSAIDs reduce the renal clearance of Lithium, leading to its accumulation in the bloodstream. High Lithium levels can cause neurotoxicity, tremors, and potential kidney damage."
},
{
"drug": "Methotrexate",
"interacting_drug": "Penicillin",
"description": "Penicillin increases Methotrexate toxicity by reducing its clearance.",
"extended_description": "Penicillin inhibits renal tubular secretion of Methotrexate, leading to elevated serum concentrations. This can result in bone marrow suppression, hepatotoxicity, and severe gastrointestinal side effects."
},

{
"drug": "Atorvastatin",
"interacting_drug": "Clarithromycin",
"description": "Clarithromycin may increase the plasma concentration of Atorvastatin, increasing the risk of rhabdomyolysis.",
"extended_description": "Clarithromycin inhibits CYP3A4, an enzyme responsible for metabolizing Atorvastatin, resulting in elevated levels of the statin and an increased risk of muscle toxicity. Symptoms of rhabdomyolysis include muscle pain, weakness, and dark urine. Monitoring of creatine kinase levels is recommended."
},
{
"drug": "Sildenafil",
"interacting_drug": "Nitrates",
"description": "Nitrates can significantly enhance the hypotensive effects of Sildenafil, leading to dangerous drops in blood pressure.",
"extended_description": "The combination of Sildenafil (used for erectile dysfunction) and Nitrates (used for heart disease) can lead to profound hypotension, potentially resulting in fainting, stroke, or heart attack. Patients should avoid using these medications within 24-48 hours of each other."
},
{
"drug": "Citalopram",
"interacting_drug": "Ondansetron",
"description": "Citalopram and Ondansetron may increase the risk of QT prolongation and cardiac arrhythmias.",
"extended_description": "Both Citalopram (an SSRI) and Ondansetron (a serotonin antagonist) can prolong the QT interval on an ECG, increasing the risk of potentially life-threatening heart arrhythmias like Torsades de Pointes. Close ECG monitoring is recommended for at-risk patients."
},
{
"drug": "Simvastatin",
"interacting_drug": "Grapefruit juice",
"description": "Grapefruit juice can increase the blood levels of Simvastatin, potentially leading to muscle damage.",
"extended_description": "Grapefruit juice inhibits the CYP3A4 enzyme in the intestine, which is responsible for metabolizing Simvastatin. This interaction can lead to increased absorption of the drug, potentially causing myopathy or rhabdomyolysis. Patients are advised to avoid grapefruit products while on Simvastatin."
},
{
"drug": "Metformin",
"interacting_drug": "Alcohol",
"description": "Alcohol consumption while taking Metformin may increase the risk of lactic acidosis.",
"extended_description": "Both Metformin and alcohol can impair lactate metabolism, increasing the risk of lactic acidosis, especially in patients with preexisting liver or kidney dysfunction. Symptoms include nausea, muscle pain, and rapid breathing. Patients should limit alcohol intake."
},
{
"drug": "Ciprofloxacin",
"interacting_drug": "Calcium supplements",
"description": "Calcium supplements can reduce the absorption of Ciprofloxacin, making it less effective.",
"extended_description": "Calcium ions can form insoluble complexes with Ciprofloxacin in the gastrointestinal tract, reducing its absorption. Patients should take Ciprofloxacin at least 2 hours before or 6 hours after calcium supplements or calcium-rich foods like milk or yogurt."
},
{
"drug": "Levothyroxine",
"interacting_drug": "Iron supplements",
"description": "Iron supplements can interfere with the absorption of Levothyroxine, potentially reducing its effectiveness.",
"extended_description": "Iron can bind to Levothyroxine in the gastrointestinal tract, forming insoluble complexes that are poorly absorbed. It's recommended to separate the administration of these drugs by at least 4 hours to ensure proper thyroid hormone replacement."
},
{
"drug": "Fluoxetine",
"interacting_drug": "Tramadol",
"description": "The combination of Fluoxetine and Tramadol may increase the risk of serotonin syndrome.",
"extended_description": "Both Fluoxetine (an SSRI) and Tramadol (an opioid) increase serotonin levels in the brain. When used together, they can lead to serotonin syndrome, which presents with symptoms like agitation, confusion, rapid heart rate, high blood pressure, and muscle rigidity. Immediate medical attention is required if these symptoms appear."
},
{
"drug": "Warfarin",
"interacting_drug": "Vitamin K",
"description": "Vitamin K can decrease the effectiveness of Warfarin.",
"extended_description": "Warfarin works by inhibiting vitamin K-dependent clotting factors. High dietary intake of Vitamin K (e.g., from green leafy vegetables) can counteract Warfarin's effects, potentially leading to blood clot formation. Patients should maintain a consistent intake of Vitamin K and monitor INR levels regularly."
},
{
"drug": "Lisinopril",
"interacting_drug": "Potassium supplements",
"description": "Combining Lisinopril with potassium supplements can lead to hyperkalemia.",
"extended_description": "Lisinopril, an ACE inhibitor, reduces aldosterone production, which can increase potassium retention. When combined with potassium supplements, it may lead to dangerously high potassium levels, causing symptoms like irregular heartbeats, weakness, or paralysis. Potassium levels should be closely monitored."
},
{
"drug": "Omeprazole",
"interacting_drug": "Clopidogrel",
"description": "Omeprazole can reduce the effectiveness of Clopidogrel.",
"extended_description": "Omeprazole inhibits CYP2C19, an enzyme necessary for converting Clopidogrel to its active form. This can reduce Clopidogrel's antiplatelet effects, potentially increasing the risk of cardiovascular events like stroke or heart attack. Alternatives like Pantoprazole may be considered."
},
{
"drug": "Digoxin",
"interacting_drug": "Amiodarone",
"description": "Amiodarone can increase Digoxin levels, potentially leading to toxicity.",
"extended_description": "Amiodarone inhibits P-glycoprotein, which is involved in Digoxin elimination. This can lead to increased Digoxin levels, causing toxicity with symptoms like nausea, vomiting, dizziness, and arrhythmias. Therapeutic drug monitoring is essential."
},

{
"drug": "Theophylline",
"interacting_drug": "Ciprofloxacin",
"description": "Ciprofloxacin can increase Theophylline levels, potentially causing toxicity.",
"extended_description": "Ciprofloxacin inhibits CYP1A2, an enzyme responsible for metabolizing theophylline. This can lead to increased theophylline levels and potential toxicity, including nausea, seizures, and cardiac arrhythmias."
},
{
"drug": "Sildenafil",
"interacting_drug": "Nitrates",
"description": "Combining Sildenafil with Nitrates can cause severe hypotension.",
"extended_description": "Both sildenafil and nitrates cause vasodilation through the nitric oxide pathway. When used together, they can cause a dangerous drop in blood pressure, potentially leading to cardiovascular collapse."
},
{
"drug": "Carbamazepine",
"interacting_drug": "Erythromycin",
"description": "Erythromycin can increase Carbamazepine levels, potentially causing toxicity.",
"extended_description": "Erythromycin inhibits CYP3A4, which metabolizes carbamazepine. This can lead to increased carbamazepine levels and potential toxicity, including dizziness, ataxia, and diplopia."
},
{
"drug": "Lithium",
"interacting_drug": "NSAIDs",
"description": "NSAIDs can increase Lithium levels, potentially leading to toxicity.",
"extended_description": "NSAIDs can reduce renal lithium clearance, leading to increased lithium levels. This can result in lithium toxicity, manifesting as tremor, confusion, and potentially seizures or coma."
},
{
"drug": "Methotrexate",
"interacting_drug": "Probenecid",
"description": "Probenecid can increase Methotrexate levels, potentially causing toxicity.",
"extended_description": "Probenecid inhibits the renal tubular secretion of methotrexate, leading to increased methotrexate levels. This can result in methotrexate toxicity, including bone marrow suppression and liver damage."
},
{
"drug": "Phenytoin",
"interacting_drug": "Valproic acid",
"description": "Valproic acid can increase free Phenytoin levels, potentially leading to toxicity.",
"extended_description": "Valproic acid displaces phenytoin from protein binding sites and inhibits its metabolism, leading to increased free phenytoin levels. This can result in phenytoin toxicity, including ataxia and nystagmus."
},
{
"drug": "Cyclosporine",
"interacting_drug": "St. John's Wort",
"description": "St. John's Wort can decrease Cyclosporine levels, potentially reducing its effectiveness.",
"extended_description": "St. John's Wort induces CYP3A4, which metabolizes cyclosporine. This can lead to decreased cyclosporine levels and potential transplant rejection in organ transplant patients."
},
{
"drug": "Allopurinol",
"interacting_drug": "Azathioprine",
"description": "Allopurinol can increase Azathioprine toxicity.",
"extended_description": "Allopurinol inhibits xanthine oxidase, which is involved in azathioprine metabolism. This can lead to increased azathioprine levels and potential toxicity, including severe bone marrow suppression."
},
{
"drug": "Rifampin",
"interacting_drug": "Oral contraceptives",
"description": "Rifampin can decrease the effectiveness of oral contraceptives.",
"extended_description": "Rifampin induces CYP3A4, which metabolizes many oral contraceptives. This can lead to decreased contraceptive hormone levels and potential unintended pregnancy."
},
{
"drug": "ACE inhibitors",
"interacting_drug": "Spironolactone",
"description": "Combining ACE inhibitors with Spironolactone can increase the risk of hyperkalemia.",
"extended_description": "Both ACE inhibitors and spironolactone can increase potassium retention. When used together, they can lead to dangerously high potassium levels, potentially causing cardiac arrhythmias."
},
{
"drug": "Clarithromycin",
"interacting_drug": "Simvastatin",
"description": "Clarithromycin can increase Simvastatin levels, potentially leading to muscle damage.",
"extended_description": "Clarithromycin inhibits CYP3A4, which metabolizes simvastatin. This can lead to increased simvastatin levels and potential myopathy or rhabdomyolysis."
},
{
"drug": "Artemether/Lumefantrine",
"interacting_drug": "Efavirenz",
"description": "Efavirenz can decrease the effectiveness of Artemether/Lumefantrine, potentially reducing antimalarial efficacy.",
"extended_description": "Efavirenz induces CYP3A4, which metabolizes artemether and lumefantrine. This can lead to decreased blood levels of the antimalarial drugs, potentially reducing their effectiveness in treating malaria."
},
{
"drug": "Tenofovir",
"interacting_drug": "Non-steroidal anti-inflammatory drugs (NSAIDs)",
"description": "NSAIDs may increase the risk of kidney injury when used with Tenofovir.",
"extended_description": "Both tenofovir and NSAIDs can affect kidney function. When used together, especially in patients with pre-existing kidney issues, they may increase the risk of acute kidney injury or exacerbate chronic kidney disease."
},
{
"drug": "Nevirapine",
"interacting_drug": "Rifampicin",
"description": "Rifampicin can significantly decrease Nevirapine levels, potentially leading to HIV treatment failure.",
"extended_description": "Rifampicin is a potent inducer of CYP3A4 and CYP2B6, which metabolize nevirapine. This can lead to subtherapeutic levels of nevirapine, increasing the risk of HIV treatment failure and development of drug resistance."
},
{
"drug": "Metformin",
"interacting_drug": "Alcohol",
"description": "Alcohol consumption while taking Metformin may increase the risk of lactic acidosis.",
"extended_description": "Both metformin and alcohol can cause lactic acidosis. When combined, especially in patients with liver or kidney problems, the risk is significantly increased, which can be life-threatening."
},
{
"drug": "Cotrimoxazole",
"interacting_drug": "Methotrexate",
"description": "Cotrimoxazole can increase Methotrexate toxicity.",
"extended_description": "Cotrimoxazole inhibits the renal tubular secretion of methotrexate and can displace it from protein binding sites. This can lead to increased methotrexate levels and potential toxicity, including severe bone marrow suppression and liver damage."
},
{
"drug": "Isoniazid",
"interacting_drug": "Rifampicin",
"description": "Rifampicin can decrease Isoniazid levels, but this combination is still used in tuberculosis treatment.",
"extended_description": "Rifampicin induces the metabolism of isoniazid. However, this combination is still used as part of standard tuberculosis treatment regimens due to their synergistic effects against Mycobacterium tuberculosis."
},
{
"drug": "Efavirenz",
"interacting_drug": "Carbamazepine",
"description": "Carbamazepine can significantly decrease Efavirenz levels, potentially leading to HIV treatment failure.",
"extended_description": "Carbamazepine is a potent inducer of CYP3A4, which metabolizes efavirenz. This can lead to subtherapeutic levels of efavirenz, increasing the risk of HIV treatment failure and development of drug resistance."
},
{
"drug": "Quinine",
"interacting_drug": "Ritonavir",
"description": "Ritonavir can increase Quinine levels, potentially leading to toxicity.",
"extended_description": "Ritonavir inhibits CYP3A4, which metabolizes quinine. This can lead to increased quinine levels and potential toxicity, including cardiac arrhythmias, visual disturbances, and cinchonism."
},
{
"drug": "Warfarin",
"interacting_drug": "Aspirin",
"description": "Aspirin can increase the risk of bleeding when used with Warfarin.",
"extended_description": "Both warfarin and aspirin affect blood clotting. Aspirin inhibits platelet aggregation and can irritate the gastric mucosa. When used with warfarin, it significantly increases the risk of serious bleeding, including gastrointestinal bleeding."
},
{
"drug": "Amoxicillin",
"interacting_drug": "Oral contraceptives",
"description": "Amoxicillin may reduce the effectiveness of oral contraceptives.",
"extended_description": "Amoxicillin can alter gut flora, potentially affecting the enterohepatic recirculation of estrogens in oral contraceptives. This may lead to reduced contraceptive efficacy, although the clinical significance is debated."
},
{
"drug": "Phenytoin",
"interacting_drug": "Folic acid",
"description": "Folic acid can decrease Phenytoin levels, potentially reducing its anticonvulsant effect.",
"extended_description": "Folic acid can increase the metabolism of phenytoin, leading to decreased phenytoin levels. This can potentially reduce its effectiveness in controlling seizures. Conversely, phenytoin can also decrease folic acid absorption."
},
{
"drug": "Fluconazole",
"interacting_drug": "Nevirapine",
"description": "Fluconazole can increase Nevirapine levels, potentially increasing the risk of liver toxicity.",
"extended_description": "Fluconazole inhibits CYP3A4, which metabolizes nevirapine. This can lead to increased nevirapine levels and a higher risk of hepatotoxicity, especially in patients with higher CD4 counts or hepatitis coinfection."
},
{
"drug": "Diazepam",
"interacting_drug": "Alcohol",
"description": "Alcohol can enhance the sedative effects of Diazepam, increasing the risk of respiratory depression.",
"extended_description": "Both diazepam and alcohol are central nervous system depressants. When used together, they can cause excessive sedation, impaired cognitive function, and potentially dangerous respiratory depression."
},
{
"drug": "Amlodipine",
"interacting_drug": "Grapefruit juice",
"description": "Grapefruit juice can increase Amlodipine levels, potentially leading to increased side effects.",
"extended_description": "Grapefruit juice inhibits CYP3A4 in the intestine, which metabolizes amlodipine. This can lead to increased absorption and blood levels of amlodipine, potentially causing exaggerated hypotension and peripheral edema."
},
{
"drug": "Metronidazole",
"interacting_drug": "Alcohol",
"description": "Alcohol consumption while taking Metronidazole can cause a disulfiram-like reaction.",
"extended_description": "Metronidazole inhibits aldehyde dehydrogenase, which is necessary for alcohol metabolism. Consuming alcohol while on metronidazole can lead to accumulation of acetaldehyde, causing flushing, headache, nausea, vomiting, and tachycardia."
},
{
"drug": "Acetaminophen",
"interacting_drug": "Warfarin",
"description": "The risk or severity of adverse effects can be increased when Acetaminophen is combined with Warfarin.",
"extended_description": "Chronic oral acetaminophen use at a dose of 4,000 mg/day has been shown to cause an increase in INR in patients stabilized on sodium warfarin, increasing the risk of bleeding."
},
{
"drug": "Aspirin",
"interacting_drug": "Ibuprofen",
"description": "Aspirin and Ibuprofen may increase the risk of gastrointestinal bleeding.",
"extended_description": "Ibuprofen can interfere with the antiplatelet effects of aspirin, especially when taken together, increasing the risk of gastrointestinal ulceration and bleeding."
},
{
"drug": "Simvastatin",
"interacting_drug": "Amiodarone",
"description": "Amiodarone can increase the serum concentration of Simvastatin, leading to an increased risk of muscle damage.",
"extended_description": "Amiodarone inhibits the metabolism of Simvastatin via the CYP3A4 enzyme, which increases the risk of rhabdomyolysis (muscle breakdown)."
},
{
"drug": "Metformin",
"interacting_drug": "Furosemide",
"description": "Furosemide may decrease the effectiveness of Metformin in controlling blood sugar levels.",
"extended_description": "Chronic administration of Furosemide can lead to a decrease in the bioavailability of Metformin, thereby reducing its blood sugar-lowering effect."
},
{
"drug": "Ciprofloxacin",
"interacting_drug": "Tizanidine",
"description": "Ciprofloxacin can increase the levels of Tizanidine, leading to excessive sedation and hypotension.",
"extended_description": "Ciprofloxacin inhibits the CYP1A2 enzyme, which can increase the concentration of Tizanidine, causing severe hypotension, bradycardia, and excessive sedation."
},
{
"drug": "Digoxin",
"interacting_drug": "Verapamil",
"description": "Verapamil increases the plasma levels of Digoxin, which may result in toxicity.",
"extended_description": "Verapamil inhibits the renal and non-renal clearance of Digoxin, leading to elevated levels of the drug in the body, increasing the risk of toxicity."
},
{
"drug": "Clopidogrel",
"interacting_drug": "Omeprazole",
"description": "Omeprazole may reduce the effectiveness of Clopidogrel in preventing blood clots.",
"extended_description": "Omeprazole inhibits CYP2C19, an enzyme required to activate Clopidogrel, thus reducing the drug's ability to prevent blood clots."
},
{
"drug": "Warfarin",
"interacting_drug": "Ciprofloxacin",
"description": "Ciprofloxacin may enhance the effects of Warfarin, increasing the risk of bleeding.",
"extended_description": "Ciprofloxacin inhibits enzymes that metabolize Warfarin, leading to an increased INR and a higher risk of bleeding."
},
{
"drug": "Lisinopril",
"interacting_drug": "Spironolactone",
"description": "The combination of Lisinopril and Spironolactone may increase the risk of hyperkalemia.",
"extended_description": "Both Lisinopril (an ACE inhibitor) and Spironolactone (a potassium-sparing diuretic) can raise potassium levels, increasing the risk of dangerous hyperkalemia."
},
{
"drug": "Levothyroxine",
"interacting_drug": "Calcium Carbonate",
"description": "Calcium Carbonate may reduce the absorption of Levothyroxine, reducing its effectiveness.",
"extended_description": "Calcium supplements like Calcium Carbonate can bind to Levothyroxine in the gastrointestinal tract, reducing its absorption and making thyroid hormone replacement less effective."
},
{
"drug": "Sertraline",
"interacting_drug": "Tramadol",
"description": "The combination of Sertraline and Tramadol may increase the risk of serotonin syndrome.",
"extended_description": "Both Sertraline (an SSRI) and Tramadol (an opioid) can increase serotonin levels, which may result in a potentially life-threatening condition called serotonin syndrome."
},
{
"drug": "Metoprolol",
"interacting_drug": "Verapamil",
"description": "Verapamil may enhance the effects of Metoprolol, increasing the risk of bradycardia and hypotension.",
"extended_description": "Both Metoprolol (a beta-blocker) and Verapamil (a calcium channel blocker) slow down the heart rate, which can cause excessive bradycardia and hypotension when used together."
},
{
"drug": "Phenytoin",
"interacting_drug": "Doxycycline",
"description": "Phenytoin may decrease the effectiveness of Doxycycline by increasing its metabolism.",
"extended_description": "Phenytoin induces hepatic enzymes, which can lead to faster clearance of Doxycycline from the body, reducing its effectiveness in treating infections."
},
{
"drug": "Fluoxetine",
"interacting_drug": "Clozapine",
"description": "Fluoxetine may increase Clozapine levels, increasing the risk of toxicity.",
"extended_description": "Fluoxetine inhibits CYP2D6, leading to higher plasma concentrations of Clozapine, which can result in serious side effects like seizures and severe sedation."
},
{
"drug": "Allopurinol",
"interacting_drug": "Azathioprine",
"description": "Allopurinol may increase the toxicity of Azathioprine.",
"extended_description": "Allopurinol inhibits xanthine oxidase, an enzyme responsible for metabolizing Azathioprine, leading to elevated levels of Azathioprine and an increased risk of bone marrow suppression."
},
{
"drug": "Lithium",
"interacting_drug": "NSAIDs",
"description": "NSAIDs may increase the serum concentration of Lithium, leading to toxicity.",
"extended_description": "NSAIDs reduce renal clearance of Lithium, leading to an accumulation of Lithium in the blood and a higher risk of side effects such as tremors, confusion, and kidney damage."
},
{
"drug": "Methotrexate",
"interacting_drug": "Penicillin",
"description": "Penicillin may increase the serum concentration of Methotrexate, leading to toxicity.",
"extended_description": "Penicillin inhibits the renal clearance of Methotrexate, which can result in elevated drug levels, increasing the risk of bone marrow suppression and liver toxicity."
},
{
"drug": "Atorvastatin",
"interacting_drug": "Clarithromycin",
"description": "Clarithromycin may increase the plasma concentration of Atorvastatin, increasing the risk of rhabdomyolysis.",
"extended_description": "Clarithromycin inhibits CYP3A4, an enzyme responsible for metabolizing Atorvastatin, resulting in elevated levels of the statin and an increased risk of muscle toxicity."
},
{
"drug": "Sildenafil",
"interacting_drug": "Nitrates",
"description": "Nitrates can significantly enhance the hypotensive effects of Sildenafil, leading to dangerous drops in blood pressure.",
"extended_description": "The combination of Sildenafil (used for erectile dysfunction) and Nitrates (used for heart disease) can lead to profound hypotension, potentially resulting in fainting, stroke, or heart attack."
},
{
"drug": "Citalopram",
"interacting_drug": "Ondansetron",
"description": "Citalopram and Ondansetron may increase the risk of QT prolongation and cardiac arrhythmias.",
"extended_description": "Both Citalopram (an SSRI) and Ondansetron (a serotonin antagonist) can prolong the QT interval on an ECG, increasing the risk of potentially life-threatening heart arrhythmias."
},
{
"drug": "Amoxicillin",
"interacting_drug": "Methotrexate",
"description": "Amoxicillin may increase the toxicity of Methotrexate by reducing its excretion.",
"extended_description": "Amoxicillin decreases the renal clearance of Methotrexate, which can lead to higher levels of the drug in the blood, increasing the risk of toxic side effects."
},
{
"drug": "Simvastatin",
"interacting_drug": "Grapefruit Juice",
"description": "Grapefruit juice may increase the concentration of Simvastatin in the blood, leading to an increased risk of muscle toxicity.",
"extended_description": "Grapefruit juice inhibits the CYP3A4 enzyme responsible for metabolizing Simvastatin, leading to higher levels of the drug and an increased risk of rhabdomyolysis."
},
{
"drug": "Metformin",
"interacting_drug": "Alcohol",
"description": "Alcohol may increase the risk of lactic acidosis in patients taking Metformin.",
"extended_description": "Heavy alcohol consumption can impair gluconeogenesis and may lead to lactic acidosis, a rare but serious side effect associated with Metformin."
},
{
"drug": "Duloxetine",
"interacting_drug": "NSAIDs",
"description": "The risk of gastrointestinal bleeding may be increased when Duloxetine is taken with NSAIDs.",
"extended_description": "Duloxetine can increase the risk of bleeding, and when combined with NSAIDs, this risk is further heightened due to the gastrointestinal effects of NSAIDs."
},
{
"drug": "Gabapentin",
"interacting_drug": "Morphine",
"description": "Gabapentin and Morphine may enhance central nervous system depression, leading to increased sedation.",
"extended_description": "The combination can lead to respiratory depression and increased sedation, requiring close monitoring and dosage adjustments."
},
{
"drug": "Propranolol",
"interacting_drug": "Rifampin",
"description": "Rifampin may decrease the effectiveness of Propranolol by increasing its metabolism.",
"extended_description": "Rifampin induces hepatic enzymes that metabolize Propranolol, leading to decreased plasma levels and potentially reducing its antihypertensive effects."
},
{
"drug": "Bupropion",
"interacting_drug": "Venlafaxine",
"description": "The combination may increase the risk of seizures, especially in susceptible individuals.",
"extended_description": "Both Bupropion and Venlafaxine can lower the seizure threshold, making the combination potentially dangerous for certain patients."
},
{
"drug": "Trazodone",
"interacting_drug": "Fluoxetine",
"description": "Fluoxetine may increase Trazodone levels, leading to enhanced sedation and increased risk of serotonin syndrome.",
"extended_description": "Fluoxetine inhibits CYP2D6, affecting the metabolism of Trazodone and increasing its concentration, which may enhance its sedative effects."
},
{
"drug": "Chlordiazepoxide",
"interacting_drug": "Phenobarbital",
"description": "The combination may enhance central nervous system depressant effects, increasing sedation.",
"extended_description": "Both Chlordiazepoxide (a benzodiazepine) and Phenobarbital (a barbiturate) are central nervous system depressants that may lead to significant sedation and respiratory depression when taken together."
},
{
"drug": "Nifedipine",
"interacting_drug": "Quinidine",
"description": "Quinidine may increase the levels of Nifedipine, leading to hypotension.",
"extended_description": "Quinidine inhibits the metabolism of Nifedipine, which can lead to increased drug levels and a risk of excessive blood pressure lowering."
},
{
"drug": "Lansoprazole",
"interacting_drug": "Ketoconazole",
"description": "Lansoprazole may reduce the absorption of Ketoconazole, decreasing its effectiveness.",
"extended_description": "Lansoprazole, a proton pump inhibitor, can raise gastric pH, which interferes with the absorption of Ketoconazole, an antifungal medication."
},
{
"drug": "Clonazepam",
"interacting_drug": "Alcohol",
"description": "The combination of Clonazepam and alcohol can enhance CNS depression, leading to respiratory depression.",
"extended_description": "Both substances can significantly impair motor function and respiratory drive, increasing the risk of severe sedation and overdose."
},
{
"drug": "Rizatriptan",
"interacting_drug": "Ergotamine",
"description": "The combination can increase the risk of serious cardiovascular effects.",
"extended_description": "Using Rizatriptan (a migraine medication) with Ergotamine (another migraine treatment) can lead to vasoconstriction and other cardiovascular complications."
},
{
"drug": "Sodium Bicarbonate",
"interacting_drug": "Digoxin",
"description": "Sodium Bicarbonate may increase the risk of Digoxin toxicity by decreasing its clearance.",
"extended_description": "Alkalinization of the urine can reduce renal excretion of Digoxin, leading to higher serum levels and a risk of toxicity."
},
{
"drug": "Insulin",
"interacting_drug": "Beta-Blockers",
"description": "Beta-Blockers may mask the symptoms of hypoglycemia in patients using Insulin.",
"extended_description": "Beta-Blockers can inhibit the sympathetic nervous system response to hypoglycemia, which may delay the recognition of low blood sugar levels."
},
{
"drug": "Valproate",
"interacting_drug": "Carbapenem Antibiotics",
"description": "Carbapenem antibiotics may reduce Valproate levels, increasing the risk of seizure.",
"extended_description": "Carbapenems can induce the metabolism of Valproate, leading to decreased drug levels and a potential increase in seizure frequency."
},
{
"drug": "Carvedilol",
"interacting_drug": "Cimetidine",
"description": "Cimetidine may increase Carvedilol levels, enhancing its hypotensive effects.",
"extended_description": "Cimetidine inhibits the hepatic metabolism of Carvedilol, leading to increased plasma concentrations and a higher risk of hypotension."
},
{
"drug": "Amlodipine",
"interacting_drug": "Simvastatin",
"description": "Amlodipine may increase the levels of Simvastatin, raising the risk of myopathy.",
"extended_description": "The combination may lead to increased concentrations of Simvastatin, resulting in an elevated risk of muscle-related side effects."
},
{
"drug": "Ipratropium",
"interacting_drug": "Tiotropium",
"description": "Using Ipratropium with Tiotropium may increase the risk of anticholinergic side effects.",
"extended_description": "Both Ipratropium and Tiotropium are anticholinergics, and using them together can lead to increased side effects like dry mouth and urinary retention."
},
{
"drug": "Isosorbide Mononitrate",
"interacting_drug": "Sildenafil",
"description": "The combination can cause severe hypotension and cardiovascular complications.",
"extended_description": "Both Isosorbide Mononitrate and Sildenafil lower blood pressure, which can lead to dangerous hypotension when used together."
},
{
"drug": "Tamsulosin",
"interacting_drug": "Cimetidine",
"description": "Cimetidine may increase the plasma concentration of Tamsulosin, leading to hypotension.",
"extended_description": "Cimetidine inhibits hepatic metabolism of Tamsulosin, resulting in increased levels and a risk of excessive blood pressure lowering."
},
{
"drug": "Enalapril",
"interacting_drug": "Potassium Supplements",
"description": "Potassium supplements may increase the risk of hyperkalemia when taken with Enalapril.",
"extended_description": "Enalapril can reduce potassium excretion, and when combined with potassium supplements, there is a higher risk of dangerously elevated potassium levels."
},
{
"drug": "Oral Contraceptives",
"interacting_drug": "Antibiotics",
"description": "Certain antibiotics may reduce the effectiveness of Oral Contraceptives.",
"extended_description": "Antibiotics like Rifampin can induce liver enzymes that metabolize contraceptive hormones, potentially leading to unintended pregnancy."
},
{
"drug": "Hydrochlorothiazide",
"interacting_drug": "Lithium",
"description": "Hydrochlorothiazide may increase the serum concentration of Lithium, leading to toxicity.",
"extended_description": "Thiazide diuretics like Hydrochlorothiazide can decrease renal clearance of Lithium, resulting in higher serum levels and increased risk of side effects."
},
{
"drug": "Artemether/Lumefantrine",
"interacting_drug": "Efavirenz",
"description": "Efavirenz can decrease the effectiveness of Artemether/Lumefantrine, potentially reducing antimalarial efficacy.",
"extended_description": "Efavirenz induces CYP3A4, which metabolizes artemether and lumefantrine. This can lead to decreased blood levels of the antimalarial drugs, potentially reducing their effectiveness in treating malaria."
},
{
"drug": "Tenofovir",
"interacting_drug": "Non-steroidal anti-inflammatory drugs (NSAIDs)",
"description": "NSAIDs may increase the risk of kidney injury when used with Tenofovir.",
"extended_description": "Both tenofovir and NSAIDs can affect kidney function. When used together, especially in patients with pre-existing kidney issues, they may increase the risk of acute kidney injury or exacerbate chronic kidney disease."
},
{
"drug": "Metronidazole",
"interacting_drug": "Alcohol",
"description": "Alcohol consumption while taking Metronidazole can cause a disulfiram-like reaction.",
"extended_description": "Metronidazole inhibits aldehyde dehydrogenase, which is necessary for alcohol metabolism. Consuming alcohol while on metronidazole can lead to accumulation of acetaldehyde, causing flushing, headache, nausea, vomiting, and tachycardia."
},
{
"drug": "Dolutegravir",
"interacting_drug": "Rifampicin",
"description": "Rifampicin can decrease Dolutegravir levels, potentially reducing its efficacy in HIV treatment.",
"extended_description": "Rifampicin is a potent inducer of UGT1A1 and CYP3A4, which metabolize dolutegravir. This can lead to reduced dolutegravir levels, necessitating dose adjustments in patients receiving both drugs for HIV and tuberculosis treatment."
},
{
"drug": "Atazanavir",
"interacting_drug": "Omeprazole",
"description": "Omeprazole can decrease Atazanavir absorption, potentially leading to HIV treatment failure.",
"extended_description": "Atazanavir requires an acidic environment for absorption. Omeprazole, by reducing stomach acid, can significantly decrease atazanavir absorption, potentially leading to subtherapeutic levels and treatment failure."
},
{
"drug": "Lopinavir/Ritonavir",
"interacting_drug": "Rifampicin",
"description": "Rifampicin can significantly decrease Lopinavir/Ritonavir levels, potentially leading to HIV treatment failure.",
"extended_description": "Rifampicin induces CYP3A4, which metabolizes lopinavir and ritonavir. This can lead to subtherapeutic levels of these antiretroviral drugs, increasing the risk of HIV treatment failure and drug resistance."
},
{
"drug": "Zidovudine",
"interacting_drug": "Ribavirin",
"description": "Ribavirin can increase the risk of anemia when used with Zidovudine.",
"extended_description": "Both zidovudine and ribavirin can cause anemia. When used together, especially in patients with HIV and hepatitis C co-infection, the risk of severe anemia is significantly increased."
},
{
"drug": "Lamivudine",
"interacting_drug": "Trimethoprim",
"description": "Trimethoprim can increase Lamivudine levels, potentially increasing the risk of side effects.",
"extended_description": "Trimethoprim inhibits the renal tubular secretion of lamivudine. This can lead to increased lamivudine levels, potentially increasing the risk of side effects such as headache, nausea, and fatigue."
},
{
"drug": "Efavirenz",
"interacting_drug": "Artemether/Lumefantrine",
"description": "Efavirenz can decrease the effectiveness of Artemether/Lumefantrine, potentially reducing antimalarial efficacy.",
"extended_description": "Efavirenz induces CYP3A4, which metabolizes artemether and lumefantrine. This can lead to decreased blood levels of the antimalarial drugs, potentially reducing their effectiveness in treating malaria."
},
{
"drug": "Isoniazid",
"interacting_drug": "Acetaminophen",
"description": "Isoniazid can increase the risk of acetaminophen-induced hepatotoxicity.",
"extended_description": "Isoniazid can induce CYP2E1, which is involved in the metabolism of acetaminophen to its toxic metabolite. This can increase the risk of liver damage, especially with high doses or chronic use of acetaminophen."
},
{
"drug": "Pyrazinamide",
"interacting_drug": "Allopurinol",
"description": "Allopurinol can decrease the effectiveness of Pyrazinamide in tuberculosis treatment.",
"extended_description": "Allopurinol inhibits xanthine oxidase, which is necessary for the conversion of pyrazinamide to its active form. This can reduce the effectiveness of pyrazinamide in treating tuberculosis."
},
{
"drug": "Ethambutol",
"interacting_drug": "Antacids",
"description": "Antacids can decrease the absorption of Ethambutol, potentially reducing its efficacy.",
"extended_description": "Antacids containing aluminum hydroxide can form complexes with ethambutol in the gastrointestinal tract, reducing its absorption. It's recommended to separate the administration of these drugs by at least 4 hours."
},
{
"drug": "Artemether/Lumefantrine",
"interacting_drug": "Grapefruit juice",
"description": "Grapefruit juice can increase Artemether/Lumefantrine levels, potentially increasing the risk of side effects.",
"extended_description": "Grapefruit juice inhibits CYP3A4, which metabolizes artemether and lumefantrine. This can lead to increased blood levels of these antimalarial drugs, potentially increasing the risk of side effects such as headache, dizziness, and palpitations."
},
{
"drug": "Quinine",
"interacting_drug": "Ciprofloxacin",
"description": "Ciprofloxacin can increase Quinine levels, potentially leading to toxicity.",
"extended_description": "Ciprofloxacin inhibits CYP3A4, which metabolizes quinine. This can lead to increased quinine levels and potential toxicity, including cardiac arrhythmias, visual disturbances, and cinchonism."
},
{
"drug": "Metformin",
"interacting_drug": "Furosemide",
"description": "Furosemide can increase the risk of lactic acidosis in patients taking Metformin.",
"extended_description": "Furosemide can cause dehydration and electrolyte imbalances, which may increase the risk of lactic acidosis in patients taking metformin, especially in those with impaired kidney function."
},
{
"drug": "Glibenclamide",
"interacting_drug": "Trimethoprim/Sulfamethoxazole",
"description": "Trimethoprim/Sulfamethoxazole can increase the hypoglycemic effect of Glibenclamide.",
"extended_description": "Trimethoprim/Sulfamethoxazole can displace glibenclamide from protein binding sites and inhibit its metabolism, leading to increased free drug levels. This can potentiate the hypoglycemic effect of glibenclamide, increasing the risk of low blood sugar."
},
{
"drug": "Amoxicillin",
"interacting_drug": "Methotrexate",
"description": "Amoxicillin may increase the toxicity of Methotrexate.",
"extended_description": "Amoxicillin can reduce the renal clearance of Methotrexate, potentially leading to increased serum levels and toxicity."
},
{
"drug": "Ciprofloxacin",
"interacting_drug": "Theophylline",
"description": "Ciprofloxacin may increase the serum concentration of Theophylline.",
"extended_description": "Ciprofloxacin can inhibit the metabolism of Theophylline, leading to elevated levels and increased risk of toxicity."
},
{
"drug": "Doxycycline",
"interacting_drug": "Warfarin",
"description": "Doxycycline may enhance the anticoagulant effect of Warfarin.",
"extended_description": "Doxycycline can interfere with the gut flora, affecting vitamin K production and potentially increasing the effects of Warfarin."
},
{
"drug": "Clindamycin",
"interacting_drug": "Erythromycin",
"description": "Clindamycin may antagonize the effects of Erythromycin.",
"extended_description": "The combination of Clindamycin and Erythromycin can lead to reduced efficacy of Erythromycin due to competitive inhibition."
},
{
"drug": "Azithromycin",
"interacting_drug": "Statins",
"description": "Azithromycin may increase the risk of statin-related myopathy.",
"extended_description": "Azithromycin can inhibit the metabolism of certain statins, increasing the risk of muscle-related side effects."
},
{
"drug": "Cephalexin",
"interacting_drug": "Probenecid",
"description": "Probenecid may decrease the renal excretion of Cephalexin.",
"extended_description": "The combination may lead to increased serum levels of Cephalexin and an enhanced risk of side effects."
},
{
"drug": "Levofloxacin",
"interacting_drug": "Corticosteroids",
"description": "Levofloxacin may increase the risk of tendon rupture when taken with corticosteroids.",
"extended_description": "The concurrent use of Levofloxacin and corticosteroids has been associated with an increased risk of tendon damage and rupture."
},
{
"drug": "Sulfamethoxazole/Trimethoprim",
"interacting_drug": "Warfarin",
"description": "Sulfamethoxazole/Trimethoprim may potentiate the effects of Warfarin.",
"extended_description": "This combination can enhance anticoagulation effects and increase the risk of bleeding due to potential interactions with Warfarin metabolism."
},
{
"drug": "Metronidazole",
"interacting_drug": "Alcohol",
"description": "Metronidazole may cause disulfiram-like reactions with alcohol.",
"extended_description": "The combination can lead to severe nausea, vomiting, and abdominal cramps when alcohol is consumed during or shortly after Metronidazole treatment."
},
{
"drug": "Nitrofurantoin",
"interacting_drug": "Antacids",
"description": "Antacids containing magnesium may reduce the absorption of Nitrofurantoin.",
"extended_description": "The presence of antacids can impair the absorption of Nitrofurantoin, potentially reducing its effectiveness."
},
{
"drug": "Vancomycin",
"interacting_drug": "Aminoglycosides",
"description": "Vancomycin may increase the risk of nephrotoxicity when used with Aminoglycosides.",
"extended_description": "The combination can lead to cumulative nephrotoxic effects, requiring monitoring of renal function during co-administration."
},
{
"drug": "Gentamicin",
"interacting_drug": "Loop Diuretics",
"description": "Gentamicin may increase the risk of ototoxicity when used with loop diuretics.",
"extended_description": "The concurrent use of Gentamicin and loop diuretics can lead to increased risk of hearing loss and balance issues."
},
{
"drug": "Ceftriaxone",
"interacting_drug": "Calcium Salts",
"description": "Ceftriaxone should not be administered with calcium salts due to risk of precipitation.",
"extended_description": "The combination can lead to serious complications like lung or kidney damage due to precipitate formation in the lungs or kidneys."
},
{
"drug": "Clarithromycin",
"interacting_drug": "Atorvastatin",
"description": "Clarithromycin may increase Atorvastatin levels, raising the risk of myopathy.",
"extended_description": "Clarithromycin inhibits CYP3A4, which metabolizes Atorvastatin, potentially leading to increased side effects associated with statins."
},
{
"drug": "Rifampin",
"interacting_drug": "Oral Contraceptives",
"description": "Rifampin may reduce the effectiveness of oral contraceptives.",
"extended_description": "Rifampin induces hepatic enzymes that metabolize contraceptive hormones, potentially leading to unintended pregnancy."
},
{
"drug": "Moxifloxacin",
"interacting_drug": "Antidiabetic medications",
"description": "Moxifloxacin may affect blood sugar levels when taken with antidiabetic medications.",
"extended_description": "Moxifloxacin can cause both hyperglycemia and hypoglycemia, necessitating close monitoring of blood glucose levels."
},
{
"drug": "Ampicillin",
"interacting_drug": "Allopurinol",
"description": "Ampicillin may increase the risk of skin rash when taken with Allopurinol.",
"extended_description": "The combination can lead to a higher incidence of skin reactions, which can be severe in some cases."
},
{
"drug": "Tetracycline",
"interacting_drug": "Antacids",
"description": "Antacids containing aluminum, calcium, or magnesium may reduce the absorption of Tetracycline.",
"extended_description": "The effectiveness of Tetracycline can be decreased due to impaired absorption when taken with these antacids."
},
{
"drug": "Cefazolin",
"interacting_drug": "Probenecid",
"description": "Probenecid may increase the serum concentration of Cefazolin.",
"extended_description": "By inhibiting the renal excretion of Cefazolin, Probenecid can lead to elevated drug levels and increased risk of side effects."
},
{
"drug": "Sulfamethoxazole",
"interacting_drug": "Cyclophosphamide",
"description": "Sulfamethoxazole may increase the risk of toxicity when taken with Cyclophosphamide.",
"extended_description": "The combination can elevate the risk of myelosuppression and other toxic effects associated with Cyclophosphamide."
},
{
"drug": "Tobramycin",
"interacting_drug": "Neuromuscular Blockers",
"description": "Tobramycin may enhance the effects of neuromuscular blockers.",
"extended_description": "The combination can lead to prolonged muscle paralysis and respiratory depression."
},
{
"drug": "Chloramphenicol",
"interacting_drug": "Warfarin",
"description": "Chloramphenicol may increase the anticoagulant effect of Warfarin.",
"extended_description": "Chloramphenicol can displace Warfarin from protein binding sites, leading to higher active drug levels and increased bleeding risk."
},
{
"drug": "Daptomycin",
"interacting_drug": "Statins",
"description": "Daptomycin may increase the risk of muscle toxicity when used with Statins.",
"extended_description": "Both Daptomycin and Statins have been associated with muscle-related side effects, requiring monitoring of muscle function."
},
{
"drug": "Quinupristin/Dalfopristin",
"interacting_drug": "Warfarin",
"description": "Quinupristin/Dalfopristin may increase Warfarin levels.",
"extended_description": "The combination may lead to an increased anticoagulant effect and necessitates close monitoring of INR levels."
},
{
"drug": "Fosfomycin",
"interacting_drug": "Antacids",
"description": "Antacids may reduce the absorption of Fosfomycin.",
"extended_description": "The presence of antacids can impair the effectiveness of Fosfomycin by reducing its absorption."
},
{
"drug": "Nafcillin",
"interacting_drug": "Probenecid",
"description": "Probenecid may increase the serum concentration of Nafcillin.",
"extended_description": "Probenecid inhibits renal excretion of Nafcillin, leading to increased levels and risk of toxicity."
},
{
"drug": "Penicillin",
"interacting_drug": "Methotrexate",
"description": "Penicillin may increase the toxicity of Methotrexate.",
"extended_description": "Penicillin can reduce renal clearance of Methotrexate, potentially leading to elevated serum levels and toxicity."
},
{
"drug": "Oxacillin",
"interacting_drug": "Corticosteroids",
"description": "Oxacillin may enhance the effects of corticosteroids.",
"extended_description": "The combination can lead to increased cortisol levels and a heightened risk of corticosteroid side effects."
},
{
"drug": "Cefepime",
"interacting_drug": "Vancomycin",
"description": "Cefepime may enhance the nephrotoxic effects of Vancomycin.",
"extended_description": "The combination can lead to increased risk of renal impairment, requiring close monitoring of kidney function."
},
{
"drug": "Rifaximin",
"interacting_drug": "Antiepileptic drugs",
"description": "Rifaximin may affect the absorption of antiepileptic drugs.",
"extended_description": "The presence of Rifaximin can potentially alter the effectiveness of antiepileptic medications, necessitating monitoring of seizure control."
},
{
"drug": "Artemether/Lumefantrine",
"interacting_drug": "Efavirenz",
"description": "Efavirenz can decrease the effectiveness of Artemether/Lumefantrine, potentially reducing antimalarial efficacy.",
"extended_description": "Efavirenz induces CYP3A4, which metabolizes artemether and lumefantrine. This can lead to decreased blood levels of the antimalarial drugs, potentially reducing their effectiveness in treating malaria."
},
{
"drug": "Tenofovir",
"interacting_drug": "Non-steroidal anti-inflammatory drugs (NSAIDs)",
"description": "NSAIDs may increase the risk of kidney injury when used with Tenofovir.",
"extended_description": "Both tenofovir and NSAIDs can affect kidney function. When used together, especially in patients with pre-existing kidney issues, they may increase the risk of acute kidney injury or exacerbate chronic kidney disease."
},
{
"drug": "Nevirapine",
"interacting_drug": "Rifampicin",
"description": "Rifampicin can significantly decrease Nevirapine levels, potentially leading to HIV treatment failure.",
"extended_description": "Rifampicin is a potent inducer of CYP3A4 and CYP2B6, which metabolize nevirapine. This can lead to subtherapeutic levels of nevirapine, increasing the risk of HIV treatment failure and development of drug resistance."
},
{
"drug": "Metformin",
"interacting_drug": "Alcohol",
"description": "Alcohol consumption while taking Metformin may increase the risk of lactic acidosis.",
"extended_description": "Both metformin and alcohol can cause lactic acidosis. When combined, especially in patients with liver or kidney problems, the risk is significantly increased, which can be life-threatening."
},
{
"drug": "Cotrimoxazole",
"interacting_drug": "Methotrexate",
"description": "Cotrimoxazole can increase Methotrexate toxicity.",
"extended_description": "Cotrimoxazole inhibits the renal tubular secretion of methotrexate and can displace it from protein binding sites. This can lead to increased methotrexate levels and potential toxicity, including severe bone marrow suppression and liver damage."
},
{
"drug": "Isoniazid",
"interacting_drug": "Rifampicin",
"description": "Rifampicin can decrease Isoniazid levels, but this combination is still used in tuberculosis treatment.",
"extended_description": "Rifampicin induces the metabolism of isoniazid. However, this combination is still used as part of standard tuberculosis treatment regimens due to their synergistic effects against Mycobacterium tuberculosis."
},
{
"drug": "Efavirenz",
"interacting_drug": "Carbamazepine",
"description": "Carbamazepine can significantly decrease Efavirenz levels, potentially leading to HIV treatment failure.",
"extended_description": "Carbamazepine is a potent inducer of CYP3A4, which metabolizes efavirenz. This can lead to subtherapeutic levels of efavirenz, increasing the risk of HIV treatment failure and development of drug resistance."
},
{
"drug": "Quinine",
"interacting_drug": "Ritonavir",
"description": "Ritonavir can increase Quinine levels, potentially leading to toxicity.",
"extended_description": "Ritonavir inhibits CYP3A4, which metabolizes quinine. This can lead to increased quinine levels and potential toxicity, including cardiac arrhythmias, visual disturbances, and cinchonism."
},
{
"drug": "Warfarin",
"interacting_drug": "Aspirin",
"description": "Aspirin can increase the risk of bleeding when used with Warfarin.",
"extended_description": "Both warfarin and aspirin affect blood clotting. Aspirin inhibits platelet aggregation and can irritate the gastric mucosa. When used with warfarin, it significantly increases the risk of serious bleeding, including gastrointestinal bleeding."
},
{
"drug": "Amoxicillin",
"interacting_drug": "Oral contraceptives",
"description": "Amoxicillin may reduce the effectiveness of oral contraceptives.",
"extended_description": "Amoxicillin can alter gut flora, potentially affecting the enterohepatic recirculation of estrogens in oral contraceptives. This may lead to reduced contraceptive efficacy, although the clinical significance is debated."
},
{
"drug": "Phenytoin",
"interacting_drug": "Folic acid",
"description": "Folic acid can decrease Phenytoin levels, potentially reducing its anticonvulsant effect.",
"extended_description": "Folic acid can increase the metabolism of phenytoin, leading to decreased phenytoin levels. This can potentially reduce its effectiveness in controlling seizures. Conversely, phenytoin can also decrease folic acid absorption."
},
{
"drug": "Fluconazole",
"interacting_drug": "Nevirapine",
"description": "Fluconazole can increase Nevirapine levels, potentially increasing the risk of liver toxicity.",
"extended_description": "Fluconazole inhibits CYP3A4, which metabolizes nevirapine. This can lead to increased nevirapine levels and a higher risk of hepatotoxicity, especially in patients with higher CD4 counts or hepatitis coinfection."
},
{
"drug": "Diazepam",
"interacting_drug": "Alcohol",
"description": "Alcohol can enhance the sedative effects of Diazepam, increasing the risk of respiratory depression.",
"extended_description": "Both diazepam and alcohol are central nervous system depressants. When used together, they can cause excessive sedation, impaired cognitive function, and potentially dangerous respiratory depression."
},
{
"drug": "Amlodipine",
"interacting_drug": "Grapefruit juice",
"description": "Grapefruit juice can increase Amlodipine levels, potentially leading to increased side effects.",
"extended_description": "Grapefruit juice inhibits CYP3A4 in the intestine, which metabolizes amlodipine. This can lead to increased absorption and blood levels of amlodipine, potentially causing exaggerated hypotension and peripheral edema."
},
{
"drug": "Metronidazole",
"interacting_drug": "Alcohol",
"description": "Alcohol consumption while taking Metronidazole can cause a disulfiram-like reaction.",
"extended_description": "Metronidazole inhibits aldehyde dehydrogenase, which is necessary for alcohol metabolism. Consuming alcohol while on metronidazole can lead to accumulation of acetaldehyde, causing flushing, headache, nausea, vomiting, and tachycardia."
},
{
"drug": "Dolutegravir",
"interacting_drug": "Rifampicin",
"description": "Rifampicin can decrease Dolutegravir levels, potentially reducing its efficacy in HIV treatment.",
"extended_description": "Rifampicin is a potent inducer of UGT1A1 and CYP3A4, which metabolize dolutegravir. This can lead to reduced dolutegravir levels, necessitating dose adjustments in patients receiving both drugs for HIV and tuberculosis treatment."
},
{
"drug": "Atazanavir",
"interacting_drug": "Omeprazole",
"description": "Omeprazole can decrease Atazanavir absorption, potentially leading to HIV treatment failure.",
"extended_description": "Atazanavir requires an acidic environment for absorption. Omeprazole, by reducing stomach acid, can significantly decrease atazanavir absorption, potentially leading to subtherapeutic levels and treatment failure."
},
{
"drug": "Lopinavir/Ritonavir",
"interacting_drug": "Rifampicin",
"description": "Rifampicin can significantly decrease Lopinavir/Ritonavir levels, potentially leading to HIV treatment failure.",
"extended_description": "Rifampicin induces CYP3A4, which metabolizes lopinavir and ritonavir. This can lead to subtherapeutic levels of these antiretroviral drugs, increasing the risk of HIV treatment failure and drug resistance."
},
{
"drug": "Zidovudine",
"interacting_drug": "Ribavirin",
"description": "Ribavirin can increase the risk of anemia when used with Zidovudine.",
"extended_description": "Both zidovudine and ribavirin can cause anemia. When used together, especially in patients with HIV and hepatitis C co-infection, the risk of severe anemia is significantly increased."
},
{
"drug": "Lamivudine",
"interacting_drug": "Trimethoprim",
"description": "Trimethoprim can increase Lamivudine levels, potentially increasing the risk of side effects.",
"extended_description": "Trimethoprim inhibits the renal tubular secretion of lamivudine. This can lead to increased lamivudine levels, potentially increasing the risk of side effects such as headache, nausea, and fatigue."
},
{
"drug": "Isoniazid",
"interacting_drug": "Acetaminophen",
"description": "Isoniazid can increase the risk of acetaminophen-induced hepatotoxicity.",
"extended_description": "Isoniazid can induce CYP2E1, which is involved in the metabolism of acetaminophen to its toxic metabolite. This can increase the risk of liver damage, especially with high doses or chronic use of acetaminophen."
},
{
"drug": "Pyrazinamide",
"interacting_drug": "Allopurinol",
"description": "Allopurinol can decrease the effectiveness of Pyrazinamide in tuberculosis treatment.",
"extended_description": "Allopurinol inhibits xanthine oxidase, which is necessary for the conversion of pyrazinamide to its active form. This can reduce the effectiveness of pyrazinamide in treating tuberculosis."
},
{
"drug": "Ethambutol",
"interacting_drug": "Antacids",
"description": "Antacids can decrease the absorption of Ethambutol, potentially reducing its efficacy.",
"extended_description": "Antacids containing aluminum hydroxide can form complexes with ethambutol in the gastrointestinal tract, reducing its absorption. It's recommended to separate the administration of these drugs by at least 4 hours."
},
{
"drug": "Artemether/Lumefantrine",
"interacting_drug": "Grapefruit juice",
"description": "Grapefruit juice can increase Artemether/Lumefantrine levels, potentially increasing the risk of side effects.",
"extended_description": "Grapefruit juice inhibits CYP3A4, which metabolizes artemether and lumefantrine. This can lead to increased blood levels of these antimalarial drugs, potentially increasing the risk of side effects such as headache, dizziness, and palpitations."
},
{
"drug": "Quinine",
"interacting_drug": "Ciprofloxacin",
"description": "Ciprofloxacin can increase Quinine levels, potentially leading to toxicity.",
"extended_description": "Ciprofloxacin inhibits CYP3A4, which metabolizes quinine. This can lead to increased quinine levels and potential toxicity, including cardiac arrhythmias, visual disturbances, and cinchonism."
},
{
"drug": "Metformin",
"interacting_drug": "Furosemide",
"description": "Furosemide can increase the risk of lactic acidosis in patients taking Metformin.",
"extended_description": "Furosemide can cause dehydration and electrolyte imbalances, which may increase the risk of lactic acidosis in patients taking metformin, especially in those with impaired kidney function."
},
{
"drug": "Glibenclamide",
"interacting_drug": "Trimethoprim/Sulfamethoxazole",
"description": "Trimethoprim/Sulfamethoxazole can increase the hypoglycemic effect of Glibenclamide.",
"extended_description": "Trimethoprim/Sulfamethoxazole can displace glibenclamide from protein binding sites and inhibit its metabolism, leading to increased free drug levels. This can potentiate the hypoglycemic effect of glibenclamide, increasing the risk of low blood sugar."
},
{
"drug": "Tenofovir",
"interacting_drug": "Ledipasvir/Sofosbuvir",
"description": "Ledipasvir/Sofosbuvir can increase Tenofovir levels, potentially increasing the risk of kidney toxicity.",
"extended_description": "Ledipasvir inhibits P-glycoprotein and BCRP, which are involved in tenofovir elimination. This can lead to increased tenofovir levels, potentially increasing the risk of kidney toxicity, especially in patients with pre-existing kidney disease."
},
{
"drug": "Efavirenz",
"interacting_drug": "Voriconazole",
"description": "Efavirenz can significantly decrease Voriconazole levels, potentially reducing its antifungal efficacy.",
"extended_description": "Efavirenz is a potent inducer of CYP2C19 and CYP3A4, which metabolize voriconazole. This can lead to subtherapeutic levels of voriconazole, potentially compromising its effectiveness in treating fungal infections."
},
{
"drug": "Dolutegravir",
"interacting_drug": "Iron supplements",
"description": "Iron supplements can decrease Dolutegravir absorption, potentially reducing its efficacy.",
"extended_description": "Iron supplements can form complexes with dolutegravir in the gastrointestinal tract, reducing its absorption. It's recommended to separate the administration of these drugs by at least 2 hours."
},
{
"drug": "Atazanavir",
"interacting_drug": "Tenofovir",
"description": "Tenofovir can decrease Atazanavir levels, potentially reducing its efficacy in HIV treatment.",
"extended_description": "Tenofovir can reduce atazanavir absorption and increase its renal clearance. This can lead to subtherapeutic levels of atazanavir, potentially compromising HIV treatment efficacy."
},
{
"drug": "Rifampicin",
"interacting_drug": "Clarithromycin",
"description": "Rifampicin can significantly decrease Clarithromycin levels, potentially reducing its antibacterial efficacy.",
"extended_description": "Rifampicin is a potent inducer of CYP3A4, which metabolizes clarithromycin. This can lead to subtherapeutic levels of clarithromycin, potentially compromising its effectiveness in treating bacterial infections."
},

{
"drug": "Rifampicin",
"interacting_drug": "Clarithromycin",
"description": "Rifampicin can significantly decrease Clarithromycin levels, potentially reducing its antibacterial efficacy.",
"extended_description": "Rifampicin is a potent inducer of CYP3A4, which metabolizes clarithromycin. This can lead to subtherapeutic levels of clarithromycin, potentially compromising its effectiveness in treating bacterial infections."
},
{
"drug": "Efavirenz",
"interacting_drug": "Amlodipine",
"description": "Efavirenz can decrease Amlodipine levels, potentially reducing its antihypertensive effect.",
"extended_description": "Efavirenz induces CYP3A4, which metabolizes amlodipine. This can lead to reduced amlodipine levels and potentially inadequate blood pressure control."
},
{
"drug": "Artemether/Lumefantrine",
"interacting_drug": "Lopinavir/Ritonavir",
"description": "Lopinavir/Ritonavir can increase Artemether/Lumefantrine levels, potentially increasing the risk of side effects.",
"extended_description": "Lopinavir/Ritonavir inhibits CYP3A4, which metabolizes artemether and lumefantrine. This can lead to increased levels of the antimalarial drugs, potentially causing more side effects such as headache and palpitations."
},
{
"drug": "Tenofovir",
"interacting_drug": "Gentamicin",
"description": "Concurrent use of Tenofovir and Gentamicin may increase the risk of nephrotoxicity.",
"extended_description": "Both tenofovir and gentamicin can cause kidney damage. When used together, especially in patients with pre-existing kidney issues, the risk of acute kidney injury is significantly increased."
},
{
"drug": "Metformin",
"interacting_drug": "Cimetidine",
"description": "Cimetidine can increase Metformin levels, potentially increasing the risk of lactic acidosis.",
"extended_description": "Cimetidine inhibits the renal tubular secretion of metformin, leading to increased metformin levels. This can potentially increase the risk of lactic acidosis, especially in patients with impaired kidney function."
},
{
"drug": "Isoniazid",
"interacting_drug": "Phenytoin",
"description": "Isoniazid can increase Phenytoin levels, potentially leading to toxicity.",
"extended_description": "Isoniazid inhibits CYP2C9 and CYP2C19, which metabolize phenytoin. This can lead to increased phenytoin levels and potential toxicity, including ataxia, nystagmus, and confusion."
},
{
"drug": "Dolutegravir",
"interacting_drug": "Metformin",
"description": "Dolutegravir can increase Metformin levels, potentially increasing the risk of lactic acidosis.",
"extended_description": "Dolutegravir inhibits the renal organic cation transporter 2 (OCT2), which is involved in metformin elimination. This can lead to increased metformin levels and a higher risk of lactic acidosis."
},
{
"drug": "Nevirapine",
"interacting_drug": "Ketoconazole",
"description": "Nevirapine can significantly decrease Ketoconazole levels, potentially reducing its antifungal efficacy.",
"extended_description": "Nevirapine induces CYP3A4, which metabolizes ketoconazole. This can lead to subtherapeutic levels of ketoconazole, potentially compromising its effectiveness in treating fungal infections."
},
{
"drug": "Rifampicin",
"interacting_drug": "Doxycycline",
"description": "Rifampicin can decrease Doxycycline levels, potentially reducing its antibacterial efficacy.",
"extended_description": "Rifampicin induces hepatic enzymes that metabolize doxycycline, leading to reduced doxycycline levels. This can potentially compromise its effectiveness in treating bacterial infections."
},
{
"drug": "Efavirenz",
"interacting_drug": "Simvastatin",
"description": "Efavirenz can decrease Simvastatin levels, potentially reducing its lipid-lowering effect.",
"extended_description": "Efavirenz induces CYP3A4, which metabolizes simvastatin. This can lead to reduced simvastatin levels and potentially inadequate cholesterol control."
},
{
"drug": "Atazanavir",
"interacting_drug": "Rifabutin",
"description": "Atazanavir can increase Rifabutin levels, potentially increasing the risk of side effects.",
"extended_description": "Atazanavir inhibits CYP3A4, which metabolizes rifabutin. This can lead to increased rifabutin levels and a higher risk of side effects such as uveitis and neutropenia."
},
{
"drug": "Zidovudine",
"interacting_drug": "Fluconazole",
"description": "Fluconazole can increase Zidovudine levels, potentially increasing the risk of side effects.",
"extended_description": "Fluconazole inhibits the glucuronidation of zidovudine, leading to increased zidovudine levels. This can potentially increase the risk of side effects such as anemia and neutropenia."
},
{
"drug": "Tenofovir",
"interacting_drug": "Acyclovir",
"description": "Concurrent use of Tenofovir and Acyclovir may increase the risk of nephrotoxicity.",
"extended_description": "Both tenofovir and acyclovir are eliminated by the kidneys. When used together, especially in patients with pre-existing kidney issues, the risk of acute kidney injury is increased."
},
{
"drug": "Lopinavir/Ritonavir",
"interacting_drug": "Phenytoin",
"description": "Lopinavir/Ritonavir can decrease Phenytoin levels, potentially reducing its anticonvulsant effect.",
"extended_description": "Lopinavir/Ritonavir induces the metabolism of phenytoin, leading to reduced phenytoin levels. This can potentially compromise seizure control in epileptic patients."
},
{
"drug": "Artemether/Lumefantrine",
"interacting_drug": "Metoclopramide",
"description": "Metoclopramide can decrease the absorption of Artemether/Lumefantrine, potentially reducing its antimalarial efficacy.",
"extended_description": "Metoclopramide increases gastric emptying, which can reduce the absorption of artemether and lumefantrine. This can potentially compromise the effectiveness of malaria treatment."
},
{
"drug": "Amlodipine",
"interacting_drug": "Simvastatin",
"description": "Amlodipine may increase the serum concentration of Simvastatin.",
"extended_description": "The combination can enhance the risk of statin-related side effects, such as muscle pain and liver damage."
},
{
"drug": "Metformin",
"interacting_drug": "Rifampin",
"description": "Rifampin may reduce the effectiveness of Metformin.",
"extended_description": "Rifampin can induce hepatic enzymes, potentially decreasing Metformin levels and worsening glycemic control."
},
{
"drug": "Lisinopril",
"interacting_drug": "Potassium Supplements",
"description": "Lisinopril may increase potassium levels when used with potassium supplements.",
"extended_description": "The combination can lead to hyperkalemia, necessitating monitoring of serum potassium levels."
},
{
"drug": "Hydrochlorothiazide",
"interacting_drug": "Lithium",
"description": "Hydrochlorothiazide may increase lithium levels.",
"extended_description": "Thiazide diuretics can reduce renal clearance of lithium, leading to elevated levels and toxicity."
},
{
"drug": "Warfarin",
"interacting_drug": "Ciprofloxacin",
"description": "Ciprofloxacin may enhance the anticoagulant effects of Warfarin.",
"extended_description": "This combination can increase the risk of bleeding, requiring careful monitoring of INR."
},
{
"drug": "Losartan",
"interacting_drug": "NSAIDs",
"description": "NSAIDs may reduce the effectiveness of Losartan.",
"extended_description": "The combination can lead to decreased antihypertensive effects due to reduced renal blood flow."
},
{
"drug": "Simvastatin",
"interacting_drug": "Diltiazem",
"description": "Diltiazem may increase the levels of Simvastatin.",
"extended_description": "This combination can enhance the risk of statin-related side effects, including muscle pain and liver injury."
},
{
"drug": "Furosemide",
"interacting_drug": "Aminoglycosides",
"description": "Furosemide may enhance the ototoxic effects of Aminoglycosides.",
"extended_description": "This combination can increase the risk of hearing loss, requiring monitoring of auditory function."
},
{
"drug": "Aspirin",
"interacting_drug": "Anticoagulants",
"description": "Aspirin may increase the risk of bleeding when taken with anticoagulants.",
"extended_description": "The combination can lead to a higher incidence of gastrointestinal bleeding and requires careful monitoring."
},
{
"drug": "Omeprazole",
"interacting_drug": "Clopidogrel",
"description": "Omeprazole may reduce the effectiveness of Clopidogrel.",
"extended_description": "Omeprazole can inhibit CYP2C19, which is necessary for converting Clopidogrel into its active form, reducing its antiplatelet effect."
},
{
"drug": "Gabapentin",
"interacting_drug": "Opioids",
"description": "Gabapentin may enhance the sedative effects of Opioids.",
"extended_description": "The combination can lead to increased sedation and respiratory depression, requiring close monitoring."
},
{
"drug": "Metoprolol",
"interacting_drug": "Verapamil",
"description": "Verapamil may increase the levels of Metoprolol.",
"extended_description": "The combination can lead to bradycardia and hypotension due to additive effects on heart rate."
},
{
"drug": "Candesartan",
"interacting_drug": "Lithium",
"description": "Candesartan may increase lithium levels.",
"extended_description": "The combination can lead to lithium toxicity, requiring careful monitoring of serum lithium levels."
},
{
"drug": "Atorvastatin",
"interacting_drug": "Gemfibrozil",
"description": "Gemfibrozil may significantly increase the levels of Atorvastatin.",
"extended_description": "This combination can lead to a higher risk of statin-related side effects, such as myopathy and rhabdomyolysis."
},
{
"drug": "Diphenhydramine",
"interacting_drug": "Alcohol",
"description": "Diphenhydramine may enhance the sedative effects of Alcohol.",
"extended_description": "The combination can lead to increased drowsiness and impaired motor skills."
},
{
"drug": "Levothyroxine",
"interacting_drug": "Calcium Supplements",
"description": "Calcium supplements may reduce the absorption of Levothyroxine.",
"extended_description": "The presence of calcium can interfere with the absorption of Levothyroxine, leading to suboptimal thyroid hormone levels."
},
{
"drug": "Sitagliptin",
"interacting_drug": "Digoxin",
"description": "Sitagliptin may increase Digoxin levels.",
"extended_description": "The combination may require monitoring of Digoxin levels due to potential increases in serum concentration."
},
{
"drug": "Ranitidine",
"interacting_drug": "Ketoconazole",
"description": "Ranitidine may reduce the absorption of Ketoconazole.",
"extended_description": "The combination can lead to decreased effectiveness of Ketoconazole due to altered gastric pH."
},
{
"drug": "Allopurinol",
"interacting_drug": "Azathioprine",
"description": "Allopurinol may increase the toxicity of Azathioprine.",
"extended_description": "The combination can lead to elevated levels of Azathioprine, increasing the risk of myelosuppression."
},
{
"drug": "Sertraline",
"interacting_drug": "Tramadol",
"description": "Sertraline may enhance the effects of Tramadol.",
"extended_description": "The combination can increase the risk of serotonin syndrome, characterized by symptoms like confusion and agitation."
},
{
"drug": "Citalopram",
"interacting_drug": "St. John's Wort",
"description": "St. John's Wort may reduce the effectiveness of Citalopram.",
"extended_description": "This herbal supplement can induce CYP enzymes, decreasing the levels of Citalopram and leading to potential recurrence of depressive symptoms."
},
{
"drug": "Dexamethasone",
"interacting_drug": "CYP3A4 Inhibitors",
"description": "CYP3A4 inhibitors may increase the levels of Dexamethasone.",
"extended_description": "This combination can enhance the effects of Dexamethasone and increase the risk of side effects, including hyperglycemia."
},
{
"drug": "Clonazepam",
"interacting_drug": "Opioids",
"description": "Clonazepam may enhance the respiratory depressant effects of Opioids.",
"extended_description": "The combination can lead to profound sedation and respiratory depression, requiring careful monitoring."
},
{
"drug": "Fluoxetine",
"interacting_drug": "NSAIDs",
"description": "Fluoxetine may increase the risk of gastrointestinal bleeding when taken with NSAIDs.",
"extended_description": "The combination can lead to an increased risk of serious bleeding complications due to additive effects on platelet function."
},
{
"drug": "Chloroquine",
"interacting_drug": "Beta-Blockers",
"description": "Chloroquine may increase the levels of Beta-Blockers.",
"extended_description": "This combination can lead to increased blood pressure control and potential bradycardia."
},
{
"drug": "Fexofenadine",
"interacting_drug": "Ketoconazole",
"description": "Ketoconazole may increase the levels of Fexofenadine.",
"extended_description": "The combination can enhance the effects of Fexofenadine, potentially increasing side effects like drowsiness."
},
{
"drug": "Metoclopramide",
"interacting_drug": "Levodopa",
"description": "Metoclopramide may reduce the effectiveness of Levodopa.",
"extended_description": "The combination can interfere with the central dopaminergic effects of Levodopa, worsening Parkinson's symptoms."
},
{
"drug": "Amiodarone",
"interacting_drug": "Warfarin",
"description": "Amiodarone may increase the effects of Warfarin.",
"extended_description": "The combination can lead to increased anticoagulant effects, necessitating monitoring of INR levels."
},
{
"drug": "Eplerenone",
"interacting_drug": "ACE Inhibitors",
"description": "ACE inhibitors may increase the risk of hyperkalemia when taken with Eplerenone.",
"extended_description": "The combination can lead to elevated potassium levels, requiring regular monitoring."
},
{
"drug": "Verapamil",
"interacting_drug": "Digoxin",
"description": "Verapamil may increase Digoxin levels.",
"extended_description": "The combination can lead to toxicity, necessitating monitoring of serum Digoxin concentrations."
},
{
"drug": "Nifedipine",
"interacting_drug": "CYP3A4 Inhibitors",
"description": "CYP3A4 inhibitors may increase the levels of Nifedipine.",
"extended_description": "The combination can lead to enhanced blood pressure lowering effects and side effects."
},
{
"drug": "Duloxetine",
"interacting_drug": "Warfarin",
"description": "Duloxetine may increase the effects of Warfarin.",
"extended_description": "The combination can increase the risk of bleeding, requiring careful monitoring of INR."
},
{
"drug": "Quetiapine",
"interacting_drug": "CYP3A4 Inhibitors",
"description": "CYP3A4 inhibitors may increase the levels of Quetiapine.",
"extended_description": "The combination can lead to increased sedation and potential side effects."
},
{
"drug": "Azithromycin",
"interacting_drug": "Statins",
"description": "Azithromycin may increase the levels of certain Statins.",
"extended_description": "The combination can enhance the risk of statin-related side effects, including muscle pain."
},
{
"drug": "Tramadol",
"interacting_drug": "Serotonergic Drugs",
"description": "Tramadol may enhance the effects of serotonergic drugs.",
"extended_description": "This combination can increase the risk of serotonin syndrome."
},
{
"drug": "Nitrofurantoin",
"interacting_drug": "Antacids",
"description": "Antacids may reduce the absorption of Nitrofurantoin.",
"extended_description": "The combination can lead to suboptimal therapeutic levels of Nitrofurantoin."
},
{
"drug": "Bupropion",
"interacting_drug": "Monoamine Oxidase Inhibitors (MAOIs)",
"description": "Bupropion may cause hypertensive crisis when taken with MAOIs.",
"extended_description": "The combination can lead to severe hypertension, necessitating caution."
},
{
"drug": "Isosorbide Mononitrate",
"interacting_drug": "Sildenafil",
"description": "Sildenafil may enhance the hypotensive effects of Isosorbide Mononitrate.",
"extended_description": "The combination can lead to significant drops in blood pressure, requiring careful monitoring."
},
{
"drug": "Acetaminophen",
"interacting_drug": "Warfarin",
"description": "Acetaminophen may enhance the anticoagulant effects of Warfarin.",
"extended_description": "Chronic use can increase INR levels, leading to increased risk of bleeding."
},
{
"drug": "Propranolol",
"interacting_drug": "Rifampin",
"description": "Rifampin may reduce the effectiveness of Propranolol.",
"extended_description": "This combination can lead to increased heart rate and potential cardiovascular issues."
},
{
"drug": "Lansoprazole",
"interacting_drug": "Methotrexate",
"description": "Lansoprazole may increase the levels of Methotrexate.",
"extended_description": "This combination can increase the risk of Methotrexate toxicity."
},
{
"drug": "Dexamethasone",
"interacting_drug": "Aspirin",
"description": "Aspirin may increase the risk of gastrointestinal bleeding when taken with Dexamethasone.",
"extended_description": "The combination can lead to an increased risk of serious bleeding complications."
},
{
"drug": "Fluconazole",
"interacting_drug": "Rifampin",
"description": "Rifampin may reduce the levels of Fluconazole.",
"extended_description": "This combination can lead to suboptimal antifungal therapy."
},
{
"drug": "Sodium Bicarbonate",
"interacting_drug": "Quinidine",
"description": "Sodium Bicarbonate may increase the levels of Quinidine.",
"extended_description": "The combination can lead to increased risk of toxicity, necessitating monitoring of serum levels."
},
{
"drug": "Albuterol",
"interacting_drug": "Beta-Blockers",
"description": "Beta-Blockers may reduce the effectiveness of Albuterol.",
"extended_description": "The combination can lead to decreased bronchodilation, requiring caution."
},
{
"drug": "Mirtazapine",
"interacting_drug": "Serotonergic Drugs",
"description": "Mirtazapine may enhance the effects of serotonergic drugs.",
"extended_description": "This combination can increase the risk of serotonin syndrome."
},
{
"drug": "Dapagliflozin",
"interacting_drug": "Diuretics",
"description": "Diuretics may increase the risk of dehydration when taken with Dapagliflozin.",
"extended_description": "The combination can lead to hypotension and kidney injury."
},
{
"drug": "Digoxin",
"interacting_drug": "Verapamil",
"description": "Verapamil may increase the levels of Digoxin.",
"extended_description": "The combination can lead to Digoxin toxicity, requiring monitoring of serum levels."
},
{
"drug": "Tamsulosin",
"interacting_drug": "CYP3A4 Inhibitors",
"description": "CYP3A4 inhibitors may increase the levels of Tamsulosin.",
"extended_description": "The combination can lead to enhanced side effects, such as dizziness and hypotension."
},
{
"drug": "Atenolol",
"interacting_drug": "Calcium Channel Blockers",
"description": "Calcium Channel Blockers may enhance the effects of Atenolol.",
"extended_description": "This combination can lead to increased bradycardia and hypotension."
},
{
"drug": "Salmeterol",
"interacting_drug": "Beta-Blockers",
"description": "Beta-Blockers may reduce the effectiveness of Salmeterol.",
"extended_description": "The combination can lead to decreased bronchodilation."
},
{
"drug": "Benazepril",
"interacting_drug": "Potassium-Sparing Diuretics",
"description": "Potassium-sparing diuretics may increase the risk of hyperkalemia when taken with Benazepril.",
"extended_description": "The combination can lead to elevated potassium levels, requiring regular monitoring."
},
{
"drug": "Ciprofloxacin",
"interacting_drug": "Theophylline",
"description": "Ciprofloxacin may increase the levels of Theophylline.",
"extended_description": "This combination can lead to toxicity, necessitating monitoring of Theophylline levels."
},
{
"drug": "Carbamazepine",
"interacting_drug": "CYP3A4 Inhibitors",
"description": "CYP3A4 inhibitors may increase the levels of Carbamazepine.",
"extended_description": "The combination can enhance the effects of Carbamazepine, leading to potential toxicity."
},
{
"drug": "Lamotrigine",
"interacting_drug": "Valproate",
"description": "Valproate may increase the levels of Lamotrigine.",
"extended_description": "This combination can lead to increased risk of Lamotrigine toxicity."
},
{
"drug": "Fenofibrate",
"interacting_drug": "Statins",
"description": "Fenofibrate may enhance the effects of Statins.",
"extended_description": "The combination can lead to increased risk of muscle-related side effects."
},
{
"drug": "Rivaroxaban",
"interacting_drug": "CYP3A4 Inducers",
"description": "CYP3A4 inducers may reduce the effectiveness of Rivaroxaban.",
"extended_description": "The combination can lead to suboptimal anticoagulation."
},
{
"drug": "Insulin",
"interacting_drug": "Thiazolidinediones",
"description": "Thiazolidinediones may enhance the effects of Insulin.",
"extended_description": "The combination can increase the risk of hypoglycemia and weight gain."
},
{
"drug": "Methotrexate",
"interacting_drug": "Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)",
"description": "NSAIDs may increase the toxicity of Methotrexate.",
"extended_description": "The combination can lead to increased risk of renal toxicity."
},
{
"drug": "Hydrochlorothiazide",
"interacting_drug": "Lithium",
"description": "Hydrochlorothiazide may increase the levels of Lithium.",
"extended_description": "This combination can lead to Lithium toxicity, necessitating monitoring of serum levels."
},
{
"drug": "Trazodone",
"interacting_drug": "CYP3A4 Inhibitors",
"description": "CYP3A4 inhibitors may increase the levels of Trazodone.",
"extended_description": "The combination can lead to increased sedation and risk of overdose."
},
{
"drug": "Clonazepam",
"interacting_drug": "Opioids",
"description": "Opioids may enhance the sedative effects of Clonazepam.",
"extended_description": "The combination can increase the risk of respiratory depression."
},
{
"drug": "Ranitidine",
"interacting_drug": "Warfarin",
"description": "Ranitidine may enhance the anticoagulant effects of Warfarin.",
"extended_description": "The combination can increase the risk of bleeding, requiring careful monitoring."
},
{
"drug": "Levothyroxine",
"interacting_drug": "Calcium Supplements",
"description": "Calcium supplements may interfere with the absorption of Levothyroxine.",
"extended_description": "The combination can lead to suboptimal thyroid hormone levels."
},
{
"drug": "Valproic Acid",
"interacting_drug": "Carbapenems",
"description": "Carbapenems may reduce the levels of Valproic Acid.",
"extended_description": "This combination can lead to loss of seizure control."
},
{
"drug": "Diltiazem",
"interacting_drug": "Beta-Blockers",
"description": "Beta-Blockers may enhance the effects of Diltiazem.",
"extended_description": "The combination can lead to increased bradycardia and hypotension."
},
{
"drug": "Prednisone",
"interacting_drug": "Aspirin",
"description": "Aspirin may increase the risk of gastrointestinal bleeding when taken with Prednisone.",
"extended_description": "The combination can lead to serious bleeding complications."
},
{
"drug": "Clopidogrel",
"interacting_drug": "Proton Pump Inhibitors",
"description": "Proton Pump Inhibitors may reduce the effectiveness of Clopidogrel.",
"extended_description": "This combination can lead to suboptimal antiplatelet effects."
},
{
"drug": "Phenobarbital",
"interacting_drug": "Warfarin",
"description": "Phenobarbital may reduce the anticoagulant effects of Warfarin.",
"extended_description": "This combination can lead to increased risk of thrombosis."
},
{
"drug": "Tetracycline",
"interacting_drug": "Calcium Supplements",
"description": "Calcium supplements may reduce the absorption of Tetracycline.",
"extended_description": "This combination can lead to suboptimal antibiotic levels."
},
{
"drug": "Amlodipine",
"interacting_drug": "Simvastatin",
"description": "Simvastatin may enhance the effects of Amlodipine.",
"extended_description": "The combination can lead to increased risk of side effects."
},
{
"drug": "Sildenafil",
"interacting_drug": "Nitrates",
"description": "Nitrates may enhance the hypotensive effects of Sildenafil.",
"extended_description": "The combination can lead to significant drops in blood pressure."
},
{
"drug": "Gabapentin",
"interacting_drug": "Opioids",
"description": "Opioids may enhance the sedative effects of Gabapentin.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Omeprazole",
"interacting_drug": "Clopidogrel",
"description": "Omeprazole may reduce the effectiveness of Clopidogrel.",
"extended_description": "The combination can lead to increased risk of cardiovascular events."
},
{
"drug": "Amiodarone",
"interacting_drug": "Warfarin",
"description": "Amiodarone may enhance the anticoagulant effects of Warfarin.",
"extended_description": "This combination can increase the risk of bleeding, requiring careful monitoring."
},
{
"drug": "Buspirone",
"interacting_drug": "MAOIs",
"description": "MAOIs may increase the effects of Buspirone.",
"extended_description": "This combination can lead to increased risk of serotonin syndrome."
},
{
"drug": "Spironolactone",
"interacting_drug": "ACE Inhibitors",
"description": "ACE inhibitors may increase the risk of hyperkalemia when taken with Spironolactone.",
"extended_description": "The combination can lead to elevated potassium levels."
},
{
"drug": "Escitalopram",
"interacting_drug": "CYP2C19 Inhibitors",
"description": "CYP2C19 inhibitors may increase the levels of Escitalopram.",
"extended_description": "This combination can lead to increased sedation and side effects."
},
{
"drug": "Citalopram",
"interacting_drug": "MAOIs",
"description": "MAOIs may increase the effects of Citalopram.",
"extended_description": "The combination can lead to increased risk of serotonin syndrome."
},
{
"drug": "Furosemide",
"interacting_drug": "Aminoglycosides",
"description": "Aminoglycosides may enhance the ototoxic effects of Furosemide.",
"extended_description": "This combination can lead to increased risk of hearing loss."
},
{
"drug": "Acarbose",
"interacting_drug": "Insulin",
"description": "Insulin may enhance the effects of Acarbose.",
"extended_description": "The combination can increase the risk of hypoglycemia."
},
{
"drug": "Colchicine",
"interacting_drug": "Statins",
"description": "Colchicine may enhance the effects of Statins.",
"extended_description": "The combination can lead to increased risk of muscle-related side effects."
},
{
"drug": "Doxazosin",
"interacting_drug": "Beta-Blockers",
"description": "Beta-Blockers may enhance the effects of Doxazosin.",
"extended_description": "This combination can lead to increased hypotension."
},
{
"drug": "Meloxicam",
"interacting_drug": "Lithium",
"description": "Lithium may increase the levels of Meloxicam.",
"extended_description": "This combination can lead to Lithium toxicity."
},
{
"drug": "Zolpidem",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the sedative effects of Zolpidem.",
"extended_description": "The combination can increase the risk of respiratory depression."
},
{
"drug": "Venlafaxine",
"interacting_drug": "MAOIs",
"description": "MAOIs may increase the effects of Venlafaxine.",
"extended_description": "The combination can lead to increased risk of serotonin syndrome."
},
{
"drug": "Clonidine",
"interacting_drug": "Beta-Blockers",
"description": "Beta-Blockers may enhance the effects of Clonidine.",
"extended_description": "This combination can lead to increased bradycardia."
},
{
"drug": "Propranolol",
"interacting_drug": "CYP2D6 Inhibitors",
"description": "CYP2D6 inhibitors may increase the levels of Propranolol.",
"extended_description": "The combination can lead to increased bradycardia and hypotension."
},
{
"drug": "Methylphenidate",
"interacting_drug": "MAOIs",
"description": "MAOIs may increase the effects of Methylphenidate.",
"extended_description": "This combination can lead to hypertensive crisis."
},
{
"drug": "Tizanidine",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the sedative effects of Tizanidine.",
"extended_description": "The combination can increase the risk of respiratory depression."
},
{
"drug": "Sodium Oxybate",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the sedative effects of Sodium Oxybate.",
"extended_description": "The combination can increase the risk of respiratory depression."
},
{
"drug": "Divalproex Sodium",
"interacting_drug": "Aspirin",
"description": "Aspirin may increase the risk of bleeding when taken with Divalproex Sodium.",
"extended_description": "The combination can lead to serious bleeding complications."
},
{
"drug": "Chlordiazepoxide",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the sedative effects of Chlordiazepoxide.",
"extended_description": "The combination can increase the risk of respiratory depression."
},
{
"drug": "Rifampin",
"interacting_drug": "Warfarin",
"description": "Rifampin may reduce the anticoagulant effects of Warfarin.",
"extended_description": "This combination can lead to increased risk of thrombosis."
},
{
"drug": "Terazosin",
"interacting_drug": "Beta-Blockers",
"description": "Beta-Blockers may enhance the effects of Terazosin.",
"extended_description": "The combination can lead to increased hypotension."
},
{
"drug": "Isosorbide Mononitrate",
"interacting_drug": "Sildenafil",
"description": "Sildenafil may enhance the hypotensive effects of Isosorbide Mononitrate.",
"extended_description": "The combination can lead to significant drops in blood pressure."
},
{
"drug": "Bupropion",
"interacting_drug": "MAOIs",
"description": "MAOIs may increase the risk of hypertensive crisis when taken with Bupropion.",
"extended_description": "This combination can lead to severe hypertension."
},
{
"drug": "Methotrexate",
"interacting_drug": "NSAIDs",
"description": "NSAIDs may increase the risk of methotrexate toxicity.",
"extended_description": "The combination can lead to increased risk of adverse effects."
},
{
"drug": "Ciprofloxacin",
"interacting_drug": "Theophylline",
"description": "Ciprofloxacin may increase the levels of Theophylline.",
"extended_description": "This combination can lead to toxicity and potential adverse effects."
},
{
"drug": "Fentanyl",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the effects of Fentanyl.",
"extended_description": "The combination can increase the risk of respiratory depression."
},
{
"drug": "Dexamethasone",
"interacting_drug": "Aspirin",
"description": "Aspirin may increase the risk of gastrointestinal bleeding when taken with Dexamethasone.",
"extended_description": "This combination can lead to serious bleeding complications."
},
{
"drug": "Carbamazepine",
"interacting_drug": "Oral Contraceptives",
"description": "Carbamazepine may reduce the effectiveness of oral contraceptives.",
"extended_description": "This combination can lead to unintended pregnancy."
},
{
"drug": "Probenecid",
"interacting_drug": "Penicillins",
"description": "Probenecid may enhance the effects of Penicillins.",
"extended_description": "This combination can lead to increased risk of side effects."
},
{
"drug": "Desipramine",
"interacting_drug": "CYP2D6 Inhibitors",
"description": "CYP2D6 inhibitors may increase the levels of Desipramine.",
"extended_description": "The combination can lead to increased sedation and side effects."
},
{
"drug": "Asenapine",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the effects of Asenapine.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Sitagliptin",
"interacting_drug": "Digoxin",
"description": "Digoxin levels may increase when taken with Sitagliptin.",
"extended_description": "This combination can lead to increased risk of Digoxin toxicity."
},
{
"drug": "Quetiapine",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the sedative effects of Quetiapine.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Amitriptyline",
"interacting_drug": "CYP2D6 Inhibitors",
"description": "CYP2D6 inhibitors may increase the levels of Amitriptyline.",
"extended_description": "The combination can lead to increased sedation and side effects."
},
{
"drug": "Lisinopril",
"interacting_drug": "Potassium-Sparing Diuretics",
"description": "Potassium-sparing diuretics may increase the risk of hyperkalemia when taken with Lisinopril.",
"extended_description": "The combination can lead to elevated potassium levels."
},
{
"drug": "Rosuvastatin",
"interacting_drug": "Antacids",
"description": "Antacids may reduce the absorption of Rosuvastatin.",
"extended_description": "This combination can lead to suboptimal cholesterol-lowering effects."
},
{
"drug": "Alendronate",
"interacting_drug": "Calcium Supplements",
"description": "Calcium supplements may interfere with the absorption of Alendronate.",
"extended_description": "This combination can lead to suboptimal treatment effects."
},
{
"drug": "Hydrocodone",
"interacting_drug": "Benzodiazepines",
"description": "Benzodiazepines may enhance the sedative effects of Hydrocodone.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Dabigatran",
"interacting_drug": "P-glycoprotein Inhibitors",
"description": "P-glycoprotein inhibitors may increase the levels of Dabigatran.",
"extended_description": "The combination can increase the risk of bleeding."
},
{
"drug": "Dronedarone",
"interacting_drug": "Digoxin",
"description": "Dronedarone may increase the levels of Digoxin.",
"extended_description": "This combination can lead to Digoxin toxicity."
},
{
"drug": "Etoricoxib",
"interacting_drug": "Warfarin",
"description": "Etoricoxib may enhance the anticoagulant effects of Warfarin.",
"extended_description": "This combination can increase the risk of bleeding, requiring careful monitoring."
},
{
"drug": "Fenofibrate",
"interacting_drug": "Statins",
"description": "Statins may increase the risk of muscle-related side effects when taken with Fenofibrate.",
"extended_description": "The combination can lead to increased risk of rhabdomyolysis."
},
{
"drug": "Azithromycin",
"interacting_drug": "Digoxin",
"description": "Azithromycin may increase the levels of Digoxin.",
"extended_description": "This combination can lead to Digoxin toxicity."
},
{
"drug": "Diltiazem",
"interacting_drug": "Grapefruit Juice",
"description": "Grapefruit juice may enhance the effects of Diltiazem.",
"extended_description": "The combination can lead to increased risk of hypotension."
},
{
"drug": "Benzodiazepines",
"interacting_drug": "Alcohol",
"description": "Alcohol may enhance the sedative effects of Benzodiazepines.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Tramadol",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the effects of Tramadol.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Dronabinol",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the effects of Dronabinol.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Buspirone",
"interacting_drug": "CYP3A4 Inhibitors",
"description": "CYP3A4 inhibitors may increase the effects of Buspirone.",
"extended_description": "This combination can lead to increased risk of serotonin syndrome."
},
{
"drug": "Ciprofloxacin",
"interacting_drug": "Warfarin",
"description": "Ciprofloxacin may enhance the anticoagulant effects of Warfarin.",
"extended_description": "This combination can increase the risk of bleeding, requiring careful monitoring."
},
{
"drug": "Alprazolam",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the sedative effects of Alprazolam.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Olanzapine",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the effects of Olanzapine.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Sertraline",
"interacting_drug": "MAOIs",
"description": "MAOIs may increase the risk of serotonin syndrome when taken with Sertraline.",
"extended_description": "This combination can lead to severe side effects."
},
{
"drug": "Clonazepam",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the sedative effects of Clonazepam.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Topiramate",
"interacting_drug": "Alcohol",
"description": "Alcohol may enhance the effects of Topiramate.",
"extended_description": "This combination can increase the risk of side effects."
},
{
"drug": "Risperidone",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the sedative effects of Risperidone.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Dexamethasone",
"interacting_drug": "NSAIDs",
"description": "NSAIDs may increase the risk of gastrointestinal bleeding when taken with Dexamethasone.",
"extended_description": "This combination can lead to serious bleeding complications."
},
{
"drug": "Clopidogrel",
"interacting_drug": "Proton Pump Inhibitors",
"description": "Proton Pump Inhibitors may reduce the effectiveness of Clopidogrel.",
"extended_description": "This combination can lead to an increased risk of cardiovascular events."
},
{
"drug": "Gabapentin",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the sedative effects of Gabapentin.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Meloxicam",
"interacting_drug": "Aspirin",
"description": "Aspirin may reduce the effectiveness of Meloxicam.",
"extended_description": "This combination can lead to increased pain and inflammation."
},
{
"drug": "Dopamine Agonists",
"interacting_drug": "Antipsychotics",
"description": "Antipsychotics may antagonize the effects of Dopamine Agonists.",
"extended_description": "This combination can lead to reduced effectiveness of treatment."
},
{
"drug": "Rivaroxaban",
"interacting_drug": "CYP3A4 Inhibitors",
"description": "CYP3A4 inhibitors may increase the levels of Rivaroxaban.",
"extended_description": "This combination can increase the risk of bleeding."
},
{
"drug": "Venlafaxine",
"interacting_drug": "MAOIs",
"description": "MAOIs may increase the risk of serotonin syndrome when taken with Venlafaxine.",
"extended_description": "This combination can lead to severe side effects."
},
{
"drug": "Amlodipine",
"interacting_drug": "Simvastatin",
"description": "Simvastatin may increase the risk of myopathy when taken with Amlodipine.",
"extended_description": "This combination can lead to muscle-related side effects."
},
{
"drug": "Metoprolol",
"interacting_drug": "CYP2D6 Inhibitors",
"description": "CYP2D6 inhibitors may increase the levels of Metoprolol.",
"extended_description": "This combination can lead to increased hypotension."
},
{
"drug": "Paroxetine",
"interacting_drug": "MAOIs",
"description": "MAOIs may increase the risk of serotonin syndrome when taken with Paroxetine.",
"extended_description": "This combination can lead to severe side effects."
},
{
"drug": "Duloxetine",
"interacting_drug": "MAOIs",
"description": "MAOIs may increase the risk of serotonin syndrome when taken with Duloxetine.",
"extended_description": "This combination can lead to severe side effects."
},
{
"drug": "Fluoxetine",
"interacting_drug": "MAOIs",
"description": "MAOIs may increase the risk of serotonin syndrome when taken with Fluoxetine.",
"extended_description": "This combination can lead to severe side effects."
},
{
"drug": "Pregabalin",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the sedative effects of Pregabalin.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Acarbose",
"interacting_drug": "Digoxin",
"description": "Acarbose may reduce the absorption of Digoxin.",
"extended_description": "This combination can lead to reduced effectiveness of Digoxin."
},
{
"drug": "Codeine",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the effects of Codeine.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Bupropion",
"interacting_drug": "Nicotine Replacement Therapy",
"description": "Nicotine replacement therapy may increase the risk of side effects when taken with Bupropion.",
"extended_description": "This combination can lead to increased risk of seizures."
},
{
"drug": "Escitalopram",
"interacting_drug": "MAOIs",
"description": "MAOIs may increase the risk of serotonin syndrome when taken with Escitalopram.",
"extended_description": "This combination can lead to severe side effects."
},
{
"drug": "Citalopram",
"interacting_drug": "MAOIs",
"description": "MAOIs may increase the risk of serotonin syndrome when taken with Citalopram.",
"extended_description": "This combination can lead to severe side effects."
},
{
"drug": "Clonidine",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the effects of Clonidine.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Mirtazapine",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the sedative effects of Mirtazapine.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Fluconazole",
"interacting_drug": "Warfarin",
"description": "Fluconazole may enhance the anticoagulant effects of Warfarin.",
"extended_description": "This combination can increase the risk of bleeding, requiring careful monitoring."
},
{
"drug": "Furosemide",
"interacting_drug": "NSAIDs",
"description": "NSAIDs may reduce the effectiveness of Furosemide.",
"extended_description": "This combination can lead to fluid retention and increased blood pressure."
},
{
"drug": "Azathioprine",
"interacting_drug": "Allopurinol",
"description": "Allopurinol may increase the risk of Azathioprine toxicity.",
"extended_description": "This combination can lead to increased adverse effects."
},
{
"drug": "Glyburide",
"interacting_drug": "Beta-Blockers",
"description": "Beta-blockers may mask the symptoms of hypoglycemia when taken with Glyburide.",
"extended_description": "This combination can lead to unawareness of low blood sugar."
},
{
"drug": "Benzodiazepines",
"interacting_drug": "Opioids",
"description": "Opioids may enhance the sedative effects of Benzodiazepines.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Buspirone",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the sedative effects of Buspirone.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Lamotrigine",
"interacting_drug": "Oral Contraceptives",
"description": "Oral contraceptives may reduce the effectiveness of Lamotrigine.",
"extended_description": "This combination can lead to increased seizure frequency."
},
{
"drug": "Quetiapine",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the sedative effects of Quetiapine.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Ritonavir",
"interacting_drug": "CYP3A4 Substrates",
"description": "CYP3A4 substrates may have increased levels when taken with Ritonavir.",
"extended_description": "This combination can lead to increased side effects."
},
{
"drug": "Carbamazepine",
"interacting_drug": "Oral Contraceptives",
"description": "Oral contraceptives may reduce the effectiveness of Carbamazepine.",
"extended_description": "This combination can lead to unplanned pregnancies."
},
{
"drug": "Sildenafil",
"interacting_drug": "Nitrates",
"description": "Nitrates may enhance the hypotensive effects of Sildenafil.",
"extended_description": "This combination can increase the risk of severe hypotension."
},
{
"drug": "Lithium",
"interacting_drug": "NSAIDs",
"description": "NSAIDs may increase the levels of Lithium.",
"extended_description": "This combination can lead to Lithium toxicity."
},
{
"drug": "Clobazam",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the sedative effects of Clobazam.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Paliperidone",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the sedative effects of Paliperidone.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Amiodarone",
"interacting_drug": "Warfarin",
"description": "Warfarin may enhance the anticoagulant effects of Amiodarone.",
"extended_description": "This combination can increase the risk of bleeding."
},
{
"drug": "Amitriptyline",
"interacting_drug": "MAOIs",
"description": "MAOIs may increase the risk of serotonin syndrome when taken with Amitriptyline.",
"extended_description": "This combination can lead to severe side effects."
},
{
"drug": "Oxycodone",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the effects of Oxycodone.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Methotrexate",
"interacting_drug": "NSAIDs",
"description": "NSAIDs may increase the risk of Methotrexate toxicity.",
"extended_description": "This combination can lead to serious adverse effects."
},
{
"drug": "Bupropion",
"interacting_drug": "CYP2D6 Inhibitors",
"description": "CYP2D6 inhibitors may increase the levels of Bupropion.",
"extended_description": "This combination can lead to increased risk of seizures."
},
{
"drug": "Tramadol",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the effects of Tramadol.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Digoxin",
"interacting_drug": "CYP3A4 Inhibitors",
"description": "CYP3A4 inhibitors may increase the levels of Digoxin.",
"extended_description": "This combination can increase the risk of toxicity."
},
{
"drug": "Naproxen",
"interacting_drug": "Warfarin",
"description": "Warfarin may enhance the anticoagulant effects of Naproxen.",
"extended_description": "This combination can increase the risk of bleeding."
},
{
"drug": "Fentanyl",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the effects of Fentanyl.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Oxycodone",
"interacting_drug": "Benzodiazepines",
"description": "Benzodiazepines may enhance the effects of Oxycodone.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Sodium Bicarbonate",
"interacting_drug": "Digoxin",
"description": "Sodium Bicarbonate may reduce the effectiveness of Digoxin.",
"extended_description": "This combination can lead to reduced therapeutic effects."
},
{
"drug": "Rifampin",
"interacting_drug": "Oral Contraceptives",
"description": "Oral contraceptives may have reduced effectiveness when taken with Rifampin.",
"extended_description": "This combination can lead to unplanned pregnancies."
},
{
"drug": "Hydrochlorothiazide",
"interacting_drug": "Lithium",
"description": "Lithium levels may increase when taken with Hydrochlorothiazide.",
"extended_description": "This combination can lead to Lithium toxicity."
},
{
"drug": "Methadone",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the effects of Methadone.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Isosorbide Mononitrate",
"interacting_drug": "Sildenafil",
"description": "Sildenafil may enhance the hypotensive effects of Isosorbide Mononitrate.",
"extended_description": "This combination can increase the risk of severe hypotension."
},
{
"drug": "Verapamil",
"interacting_drug": "Digoxin",
"description": "Digoxin levels may increase when taken with Verapamil.",
"extended_description": "This combination can lead to Digoxin toxicity."
},
{
"drug": "Esomeprazole",
"interacting_drug": "Clopidogrel",
"description": "Clopidogrel may have reduced effectiveness when taken with Esomeprazole.",
"extended_description": "This combination can lead to increased cardiovascular events."
},
{
"drug": "Citalopram",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the sedative effects of Citalopram.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Olaparib",
"interacting_drug": "CYP3A4 Inhibitors",
"description": "CYP3A4 inhibitors may increase the levels of Olaparib.",
"extended_description": "This combination can increase the risk of side effects."
},
{
"drug": "Diclofenac",
"interacting_drug": "Warfarin",
"description": "Warfarin may enhance the anticoagulant effects of Diclofenac.",
"extended_description": "This combination can increase the risk of bleeding."
},
{
"drug": "Olmesartan",
"interacting_drug": "NSAIDs",
"description": "NSAIDs may reduce the effectiveness of Olmesartan.",
"extended_description": "This combination can lead to increased blood pressure."
},
{
"drug": "Bupropion",
"interacting_drug": "Amitriptyline",
"description": "Amitriptyline may increase the risk of seizures when taken with Bupropion.",
"extended_description": "This combination can lead to increased risk of seizures."
},
{
"drug": "Clozapine",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the sedative effects of Clozapine.",
"extended_description": "This combination can increase the risk of respiratory depression."
},
{
"drug": "Aspirin",
"interacting_drug": "Warfarin",
"description": "Warfarin may enhance the anticoagulant effects of Aspirin.",
"extended_description": "This combination can increase the risk of bleeding."
},
{
"drug": "Chlordiazepoxide",
"interacting_drug": "CNS Depressants",
"description": "CNS depressants may enhance the sedative effects of Chlordiazepoxide.",
"extended_description": "This combination can increase the risk of respiratory depression."
},

{
"drug": "Acetaminophen",
"interacting_drug": "Alcohol",
"description": "Alcohol enhances the hepatotoxicity of Acetaminophen.",
"extended_description": "Chronic alcohol use induces liver enzymes that metabolize Acetaminophen, increasing the risk of liver damage when the drug is taken in therapeutic or overdose doses. The combination significantly increases the risk of acute liver failure, especially in individuals with pre-existing liver disease."
},
{
"drug": "Ibuprofen",
"interacting_drug": "Aspirin",
"description": "Ibuprofen can reduce the antiplatelet effect of low-dose Aspirin.",
"extended_description": "Ibuprofen inhibits cyclooxygenase (COX) enzymes, which can interfere with the antiplatelet effect of low-dose Aspirin used for cardiovascular protection. The concurrent use may increase the risk of cardiovascular events. It's recommended to space the administration of these medications by at least 8 hours."
},
{
"drug": "Tramadol",
"interacting_drug": "SSRIs (e.g., Fluoxetine)",
"description": "Tramadol and SSRIs increase the risk of serotonin syndrome.",
"extended_description": "Both Tramadol and SSRIs increase serotonin levels in the brain, and when combined, this can lead to serotonin syndrome. Symptoms include agitation, hyperreflexia, tremors, and autonomic instability. Discontinue one or both medications if serotonin syndrome is suspected."
},
{
"drug": "Morphine",
"interacting_drug": "Benzodiazepines (e.g., Lorazepam)",
"description": "Morphine and Benzodiazepines increase the risk of respiratory depression.",
"extended_description": "Both morphine (an opioid) and benzodiazepines act on the central nervous system and may cause significant sedation and respiratory depression. Concurrent use increases the risk of fatal overdose, and close monitoring of respiratory function is essential."
},
{
"drug": "Oxycodone",
"interacting_drug": "CYP3A4 inhibitors (e.g., Ketoconazole)",
"description": "CYP3A4 inhibitors can increase Oxycodone plasma levels, leading to toxicity.",
"extended_description": "CYP3A4 inhibitors, such as Ketoconazole, reduce the metabolism of Oxycodone, leading to elevated plasma levels and increased risk of opioid toxicity. Symptoms of toxicity include sedation, respiratory depression, and decreased alertness. Dose adjustments may be necessary."
},
{
"drug": "Aspirin",
"interacting_drug": "Methotrexate",
"description": "Aspirin can increase the plasma concentration of Methotrexate, enhancing its toxicity.",
"extended_description": "Aspirin inhibits renal clearance of Methotrexate, leading to elevated plasma concentrations. This increases the risk of Methotrexate toxicity, including bone marrow suppression, liver damage, and gastrointestinal toxicity. Monitoring Methotrexate levels is recommended."
},
{
"drug": "Codeine",
"interacting_drug": "CYP2D6 inhibitors (e.g., Paroxetine)",
"description": "CYP2D6 inhibitors can reduce the analgesic effect of Codeine.",
"extended_description": "Codeine is metabolized to its active form, morphine, by the CYP2D6 enzyme. Inhibitors of CYP2D6, such as Paroxetine, can reduce Codeine’s conversion to morphine, leading to reduced pain relief. Dose adjustments or alternative analgesics may be required."
},
{
"drug": "Fentanyl",
"interacting_drug": "MAO inhibitors (e.g., Phenelzine)",
"description": "Fentanyl and MAO inhibitors can lead to severe, life-threatening serotonin syndrome.",
"extended_description": "Fentanyl is a potent opioid that affects serotonin pathways. When combined with MAO inhibitors, this combination can lead to serotonin syndrome, characterized by agitation, confusion, autonomic instability, and hyperreflexia. MAO inhibitors should not be used within 14 days of Fentanyl administration."
},
{
"drug": "Acetaminophen",
"interacting_drug": "Warfarin",
"description": "Chronic use of Acetaminophen may increase the anticoagulant effect of Warfarin.",
"extended_description": "Acetaminophen has been shown to increase the anticoagulant effects of Warfarin by inhibiting certain enzymes involved in the clotting cascade. Monitoring INR is recommended when using both drugs, particularly with long-term Acetaminophen use."
},
{
"drug": "Ibuprofen",
"interacting_drug": "Angiotensin-converting enzyme inhibitors (ACE inhibitors)",
"description": "Ibuprofen and ACE inhibitors can reduce renal function.",
"extended_description": "Ibuprofen can inhibit renal prostaglandins, reducing the effectiveness of ACE inhibitors in managing blood pressure and causing potential renal impairment. Monitoring kidney function is recommended, especially in patients with pre-existing kidney disease."
},
{
"drug": "Hydrocodone",
"interacting_drug": "Alcohol",
"description": "Alcohol and Hydrocodone can cause severe CNS depression and respiratory failure.",
"extended_description": "Both Hydrocodone and alcohol are central nervous system depressants. When used together, they can result in profound sedation, respiratory depression, and even fatal overdose. Avoid alcohol consumption while on Hydrocodone therapy."
},
{
"drug": "Ketorolac",
"interacting_drug": "Lithium",
"description": "Ketorolac can increase Lithium levels, increasing the risk of toxicity.",
"extended_description": "Ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), can reduce renal clearance of Lithium, leading to elevated serum levels. Toxicity may result in tremor, confusion, and potential renal impairment. Monitor Lithium levels closely during co-administration."
},
{
"drug": "Tramadol",
"interacting_drug": "Alcohol",
"description": "Alcohol can enhance the CNS depressant effects of Tramadol.",
"extended_description": "Tramadol, a centrally acting analgesic, combined with alcohol can lead to increased sedation, dizziness, and respiratory depression. The risk of overdose is significant, and co-administration should be avoided."
},
{
"drug": "Diclofenac",
"interacting_drug": "Warfarin",
"description": "Diclofenac may increase the anticoagulant effect of Warfarin, leading to bleeding.",
"extended_description": "Diclofenac, like other NSAIDs, inhibits platelet aggregation, which can enhance the anticoagulant effect of Warfarin, increasing the risk of bleeding. Close monitoring of INR is recommended."
},
{
"drug": "Oxycodone",
"interacting_drug": "CNS depressants (e.g., Diazepam)",
"description": "Oxycodone and CNS depressants can lead to profound sedation and respiratory depression.",
"extended_description": "The combination of Oxycodone and CNS depressants like Diazepam increases the risk of severe sedation, respiratory depression, and fatal overdose. Dosage adjustments and close monitoring of respiratory function are essential."
},
{
"drug": "Morphine",
"interacting_drug": "MAO inhibitors",
"description": "Morphine and MAO inhibitors can cause severe hypotension and CNS depression.",
"extended_description": "Morphine and MAO inhibitors can cause extreme central nervous system depression and hypotension due to their synergistic effects on neurotransmitter pathways. This combination is contraindicated."
},
{
"drug": "Acetaminophen",
"interacting_drug": "Barbiturates",
"description": "Chronic use of Barbiturates can enhance the hepatotoxicity of Acetaminophen.",
"extended_description": "Barbiturates induce liver enzymes responsible for metabolizing Acetaminophen, which may lead to an increased production of toxic metabolites. This significantly raises the risk of liver damage and acute liver failure."
},
{
"drug": "Fentanyl",
"interacting_drug": "Benzodiazepines",
"description": "Fentanyl and Benzodiazepines together increase the risk of profound sedation and respiratory depression.",
"extended_description": "Fentanyl and Benzodiazepines both have central nervous system depressant effects. When used together, they can cause extreme sedation, respiratory depression, and possibly fatal overdose. Use with extreme caution and monitor closely."
},
{
"drug": "Acetaminophen",
"interacting_drug": "Isoniazid",
"description": "Isoniazid can increase the hepatotoxicity of Acetaminophen.",
"extended_description": "Isoniazid is a known hepatotoxic agent, and when taken with Acetaminophen, it can increase the risk of liver damage. This combination should be avoided, particularly in individuals with pre-existing liver disease."
},
{
"drug": "Ibuprofen",
"interacting_drug": "Diuretics",
"description": "Ibuprofen can reduce the effectiveness of Diuretics.",
"extended_description": "Ibuprofen can inhibit prostaglandins in the kidneys, leading to decreased renal blood flow and reduced effectiveness of diuretics. The combination may lead to fluid retention and increased blood pressure."
},
{
"drug": "Codeine",
"interacting_drug": "Alcohol",
"description": "Codeine and alcohol can cause profound sedation and respiratory depression.",
"extended_description": "Both Codeine and alcohol are central nervous system depressants. When combined, they can result in excessive sedation, respiratory depression, and risk of fatal overdose. This combination should be strictly avoided."
},
{
"drug": "Aspirin",
"interacting_drug": "Methotrexate",
"description": "Aspirin can increase the toxicity of Methotrexate.",
"extended_description": "Aspirin inhibits renal clearance of Methotrexate, potentially leading to increased serum levels and greater risk of toxicity, such as gastrointestinal ulceration, renal failure, and bone marrow suppression."
},
{
"drug": "Celecoxib",
"interacting_drug": "Warfarin",
"description": "Celecoxib may increase the anticoagulant effect of Warfarin.",
"extended_description": "Celecoxib, a selective COX-2 inhibitor, can enhance the anticoagulant effects of Warfarin, increasing the risk of bleeding. Patients using both medications should be monitored for signs of bleeding and have their INR levels regularly checked."
},
{
"drug": "Oxycodone",
"interacting_drug": "CYP3A4 inducers (e.g., Rifampin)",
"description": "CYP3A4 inducers can decrease Oxycodone plasma levels, reducing its analgesic effect.",
"extended_description": "CYP3A4 inducers, like Rifampin, accelerate the metabolism of Oxycodone, which can decrease its analgesic efficacy. This may necessitate increased dosages to achieve the desired pain control."
},
{
"drug": "Morphine",
"interacting_drug": "Antipsychotics",
"description": "Morphine and antipsychotics together can lead to increased sedation and risk of respiratory depression.",
"extended_description": "Both Morphine and antipsychotics have sedative effects. When combined, the risk of profound sedation, respiratory depression, and overdose increases. Patients on both medications should be closely monitored for respiratory function."
},
{
"drug": "Tramadol",
"interacting_drug": "Benzodiazepines",
"description": "Tramadol and Benzodiazepines together can cause severe CNS depression.",
"extended_description": "The combination of Tramadol and Benzodiazepines increases the sedative effects, raising the risk of respiratory depression, coma, and fatal overdose. Monitor patients carefully and consider dose reduction."
},
{
"drug": "Hydrocodone",
"interacting_drug": "CYP3A4 inhibitors (e.g., Erythromycin)",
"description": "CYP3A4 inhibitors can increase Hydrocodone levels and increase the risk of opioid toxicity.",
"extended_description": "CYP3A4 inhibitors, such as Erythromycin, reduce the metabolism of Hydrocodone, leading to increased serum levels and enhanced opioid effects. This combination can lead to sedation, respiratory depression, and potential overdose."
},
{
"drug": "Ketoprofen",
"interacting_drug": "SSRIs",
"description": "Ketoprofen and SSRIs together increase the risk of gastrointestinal bleeding.",
"extended_description": "Both Ketoprofen (a nonsteroidal anti-inflammatory drug) and SSRIs (e.g., Fluoxetine) can cause gastrointestinal irritation and bleeding. The combination significantly increases the risk of peptic ulcers and gastrointestinal bleeding. Caution is advised when using them together."
},

{
"drug": "Amoxicillin",
"interacting_drug": "Allopurinol",
"description": "Allopurinol can increase the risk of rash in patients taking Amoxicillin.",
"extended_description": "The combination of Amoxicillin and Allopurinol increases the likelihood of a maculopapular rash in susceptible individuals, especially in patients with hyperuricemia or gout. This is a non-allergic reaction, but it may be mistaken for a drug allergy. Discontinuation of either drug should be considered if the rash appears."
},
{
"drug": "Ciprofloxacin",
"interacting_drug": "Theophylline",
"description": "Ciprofloxacin can increase Theophylline levels, potentially leading to toxicity.",
"extended_description": "Ciprofloxacin inhibits the CYP1A2 enzyme, which is responsible for metabolizing Theophylline. As a result, Theophylline plasma levels can increase, leading to symptoms of toxicity such as nausea, arrhythmias, and seizures. Therapeutic drug monitoring of Theophylline levels is recommended when these drugs are used concomitantly."
},
{
"drug": "Erythromycin",
"interacting_drug": "Warfarin",
"description": "Erythromycin may enhance the anticoagulant effect of Warfarin.",
"extended_description": "Erythromycin inhibits the CYP450 enzyme system, particularly CYP3A4, which is involved in metabolizing Warfarin. This can increase Warfarin plasma concentrations, leading to an increased risk of bleeding. Regular monitoring of INR and possible Warfarin dose adjustments are necessary when combining these drugs."
},
{
"drug": "Doxycycline",
"interacting_drug": "Antacids",
"description": "Antacids containing calcium, magnesium, or aluminum can reduce the absorption of Doxycycline.",
"extended_description": "Doxycycline is a tetracycline antibiotic that can form insoluble complexes with cations like calcium, magnesium, and aluminum, which reduces its absorption from the gastrointestinal tract. This interaction may result in therapeutic failure of the antibiotic. Doxycycline should be taken at least 1-2 hours before or 4-6 hours after antacids."
},
{
"drug": "Clarithromycin",
"interacting_drug": "Statins (e.g., Atorvastatin)",
"description": "Clarithromycin can increase the plasma levels of Statins, increasing the risk of rhabdomyolysis.",
"extended_description": "Clarithromycin inhibits the CYP3A4 enzyme, which is responsible for metabolizing many statins. This inhibition can lead to elevated statin plasma levels, increasing the risk of statin-induced muscle toxicity, including rhabdomyolysis. Dose adjustments or an alternative statin may be considered during co-administration."
},
{
"drug": "Levofloxacin",
"interacting_drug": "Corticosteroids",
"description": "Levofloxacin and corticosteroids increase the risk of tendon rupture.",
"extended_description": "Fluoroquinolones, including Levofloxacin, have been associated with an increased risk of tendonitis and tendon rupture, especially when used concomitantly with corticosteroids. This interaction is more common in older adults and individuals with a history of organ transplantation. Patients should be monitored for signs of tendon pain, swelling, or inflammation."
},
{
"drug": "Metronidazole",
"interacting_drug": "Alcohol",
"description": "Metronidazole can cause a disulfiram-like reaction when combined with alcohol.",
"extended_description": "Metronidazole inhibits aldehyde dehydrogenase, an enzyme involved in alcohol metabolism. When taken with alcohol, this can lead to an accumulation of acetaldehyde, causing flushing, nausea, vomiting, and hypotension. Patients should avoid alcohol during treatment with Metronidazole and for at least 48 hours after the completion of therapy."
},
{
"drug": "Amoxicillin",
"interacting_drug": "Methotrexate",
"description": "Amoxicillin can increase the plasma concentration of Methotrexate, increasing the risk of toxicity.",
"extended_description": "Amoxicillin reduces renal clearance of Methotrexate, leading to elevated plasma levels and an increased risk of toxicity, such as bone marrow suppression, mucositis, and hepatotoxicity. Careful monitoring of Methotrexate levels is required, and dose adjustment may be necessary."
},
{
"drug": "Azithromycin",
"interacting_drug": "CYP3A4 inhibitors (e.g., Ketoconazole)",
"description": "CYP3A4 inhibitors may increase the plasma levels of Azithromycin.",
"extended_description": "Although Azithromycin is not significantly metabolized by CYP3A4, concurrent use with potent CYP3A4 inhibitors, such as Ketoconazole, may still increase the risk of QT interval prolongation. Patients should be monitored for signs of arrhythmias, and the combination should be used with caution in patients with cardiovascular risk factors."
},
{
"drug": "Rifampin",
"interacting_drug": "Oral Contraceptives",
"description": "Rifampin may reduce the efficacy of oral contraceptives.",
"extended_description": "Rifampin is a potent inducer of the cytochrome P450 enzyme system, particularly CYP3A4, which is involved in metabolizing contraceptive hormones. This can reduce the plasma concentration of oral contraceptives, increasing the risk of unintended pregnancy. Additional or alternative contraceptive methods should be used during Rifampin therapy."
},
{
"drug": "Trimethoprim-Sulfamethoxazole",
"interacting_drug": "Warfarin",
"description": "Trimethoprim-Sulfamethoxazole can enhance the anticoagulant effect of Warfarin.",
"extended_description": "Trimethoprim-Sulfamethoxazole inhibits the metabolism of Warfarin, which can lead to increased Warfarin levels and a heightened risk of bleeding. Patients on Warfarin therapy should be monitored closely for signs of bleeding, and Warfarin dose adjustments may be necessary."
},
{
"drug": "Tetracycline",
"interacting_drug": "Dairy products",
"description": "Dairy products can decrease the absorption of Tetracycline.",
"extended_description": "Tetracycline forms complexes with calcium in dairy products, which significantly reduces its absorption. As a result, the efficacy of the antibiotic is reduced. Patients should avoid dairy products for 1-2 hours before or after taking Tetracycline to ensure optimal absorption."
},
{
"drug": "Penicillin",
"interacting_drug": "Probenecid",
"description": "Probenecid can increase the plasma concentration of Penicillin.",
"extended_description": "Probenecid inhibits the renal tubular secretion of Penicillin, resulting in higher blood concentrations of the drug. While this may be useful in certain therapeutic settings, such as in the treatment of severe infections, it may also increase the risk of Penicillin toxicity, especially in patients with renal impairment."
},
{
"drug": "Clindamycin",
"interacting_drug": "Neuromuscular blocking agents",
"description": "Clindamycin can enhance the effects of neuromuscular blocking agents.",
"extended_description": "Clindamycin may potentiate the effects of neuromuscular blocking agents, leading to prolonged paralysis and respiratory depression. Close monitoring of neuromuscular function is recommended in patients receiving both Clindamycin and such agents."
},
{
"drug": "Cephalexin",
"interacting_drug": "Metformin",
"description": "Cephalexin may increase blood glucose levels in patients taking Metformin.",
"extended_description": "Cephalexin can interfere with the renal clearance of Metformin, potentially leading to hyperglycemia. Patients with diabetes should monitor their blood glucose levels more frequently when taking this combination. Dose adjustments to Metformin may be required."
},
{
"drug": "Levofloxacin",
"interacting_drug": "Antacids",
"description": "Antacids containing aluminum, magnesium, or calcium can reduce the absorption of Levofloxacin.",
"extended_description": "Levofloxacin can form chelates with cations such as calcium, magnesium, and aluminum, reducing its absorption and therapeutic effect. Antacids should be taken at least 2 hours before or 2 hours after Levofloxacin to avoid this interaction."
},
{
"drug": "Gentamicin",
"interacting_drug": "Loop diuretics (e.g., Furosemide)",
"description": "Loop diuretics can increase the risk of ototoxicity when used with Gentamicin.",
"extended_description": "Both Gentamicin and Loop diuretics, such as Furosemide, can cause damage to the inner ear, leading to hearing loss. The risk of ototoxicity is increased when these drugs are used together, particularly in high doses or with prolonged treatment. Audiometric monitoring is recommended in patients receiving this combination."
},
{
"drug": "Aztreonam",
"interacting_drug": "Cimetidine",
"description": "Cimetidine can increase Aztreonam levels by inhibiting renal excretion.",
"extended_description": "Cimetidine inhibits renal tubular secretion, which can increase the plasma concentration of Aztreonam. This interaction may necessitate a dose adjustment of Aztreonam, especially in patients with renal impairment. Monitoring for signs of Aztreonam toxicity is advised."
},
{
"drug": "Moxifloxacin",
"interacting_drug": "Antacids",
"description": "Antacids containing magnesium or aluminum can decrease the absorption of Moxifloxacin.",
"extended_description": "Moxifloxacin is a fluoroquinolone antibiotic, and its absorption can be reduced by antacids containing magnesium, aluminum, or calcium. This interaction may lead to suboptimal therapeutic effects. Patients should avoid antacids for at least 4 hours before or 2 hours after taking Moxifloxacin."
},
{
"drug": "Ceftriaxone",
"interacting_drug": "Calcium-containing intravenous solutions",
"description": "Ceftriaxone and calcium-containing intravenous solutions can form precipitates.",
"extended_description": "Ceftriaxone and calcium-containing intravenous solutions can form potentially harmful precipitates when co-administered, particularly in neonates. This can result in serious complications, such as pulmonary and renal embolism. Ceftriaxone should not be mixed or infused simultaneously with calcium-containing solutions."
},
{
"drug": "Nitrofurantoin",
"interacting_drug": "Probenecid",
"description": "Probenecid can increase Nitrofurantoin levels, potentially leading to toxicity.",
"extended_description": "Probenecid inhibits the renal excretion of Nitrofurantoin, leading to higher plasma levels and an increased risk of adverse effects, such as pulmonary toxicity. Close monitoring and dose adjustments are recommended when these drugs are used together."
}, 


{
"drug": "Cefazolin",
"interacting_drug": "Warfarin",
"description": "Cefazolin can enhance the anticoagulant effect of Warfarin.",
"extended_description": "Cefazolin may increase the anticoagulant effect of Warfarin, raising the risk of bleeding. The mechanism is not completely understood, but it may involve altered vitamin K production in the gut or inhibition of Warfarin metabolism. Regular monitoring of INR and possible dose adjustments for Warfarin are recommended."
},
{
"drug": "Vancomycin",
"interacting_drug": "Aminoglycosides (e.g., Gentamicin)",
"description": "The combination of Vancomycin and Aminoglycosides increases the risk of nephrotoxicity.",
"extended_description": "Both Vancomycin and Aminoglycosides, such as Gentamicin, can independently cause nephrotoxicity. When used together, the risk of renal damage is potentiated. Renal function should be closely monitored, and dose adjustments may be necessary."
},
{
"drug": "Penicillin",
"interacting_drug": "Methotrexate",
"description": "Penicillin can increase the plasma concentration of Methotrexate.",
"extended_description": "Penicillin reduces the renal clearance of Methotrexate, leading to increased plasma levels and a heightened risk of toxicity, such as bone marrow suppression and mucositis. Close monitoring of Methotrexate levels is required, especially in patients with renal impairment."
},
{
"drug": "Tobramycin",
"interacting_drug": "Furosemide",
"description": "Furosemide can increase the risk of ototoxicity when combined with Tobramycin.",
"extended_description": "Both Tobramycin and Furosemide have ototoxic properties. When administered together, they can increase the risk of hearing loss and balance issues. Audiometric monitoring is recommended during concomitant use, particularly in elderly patients or those with renal impairment."
},
{
"drug": "Levofloxacin",
"interacting_drug": "Corticosteroids",
"description": "Levofloxacin and corticosteroids increase the risk of tendon rupture.",
"extended_description": "Fluoroquinolones, including Levofloxacin, are associated with an increased risk of tendonitis and tendon rupture, especially when used with corticosteroids. This risk is higher in older adults and those with a history of organ transplantation. Discontinue therapy if tendon pain or inflammation occurs."
},
{
"drug": "Clindamycin",
"interacting_drug": "Neuromuscular blocking agents",
"description": "Clindamycin can potentiate the effects of neuromuscular blocking agents.",
"extended_description": "Clindamycin may enhance the effects of neuromuscular blocking agents, leading to prolonged paralysis and respiratory depression. Careful monitoring of neuromuscular function is recommended when these drugs are used together."
},
{
"drug": "Ciprofloxacin",
"interacting_drug": "Theophylline",
"description": "Ciprofloxacin increases Theophylline levels, potentially leading to toxicity.",
"extended_description": "Ciprofloxacin inhibits the CYP1A2 enzyme, which metabolizes Theophylline, increasing its plasma levels. Symptoms of Theophylline toxicity, such as nausea, seizures, and arrhythmias, may occur. Monitoring Theophylline levels is recommended when these drugs are used together."
},
{
"drug": "Azithromycin",
"interacting_drug": "CYP3A4 inhibitors (e.g., Ketoconazole)",
"description": "CYP3A4 inhibitors can increase Azithromycin plasma levels.",
"extended_description": "While Azithromycin is not primarily metabolized by CYP3A4, the use of CYP3A4 inhibitors, such as Ketoconazole, can still increase Azithromycin plasma levels. This may increase the risk of QT interval prolongation and arrhythmias. Close monitoring is recommended, especially in high-risk patients."
},
{
"drug": "Cephalexin",
"interacting_drug": "Metformin",
"description": "Cephalexin can increase blood glucose levels in patients taking Metformin.",
"extended_description": "Cephalexin can impair renal clearance of Metformin, potentially leading to elevated blood glucose levels. Diabetic patients should closely monitor their blood glucose while on this combination. Adjustments to the Metformin dose may be needed."
},
{
"drug": "Moxifloxacin",
"interacting_drug": "Antacids",
"description": "Antacids can decrease the absorption of Moxifloxacin.",
"extended_description": "Moxifloxacin's absorption is significantly reduced when taken with antacids containing magnesium, aluminum, or calcium. This can lead to therapeutic failure. Patients should take Moxifloxacin at least 2 hours before or 4 hours after antacids."
},
{
"drug": "Rifampin",
"interacting_drug": "Oral Contraceptives",
"description": "Rifampin can reduce the efficacy of oral contraceptives.",
"extended_description": "Rifampin is a potent enzyme inducer that accelerates the metabolism of oral contraceptives, decreasing their effectiveness. Patients using oral contraceptives should be advised to use additional or alternative forms of contraception during Rifampin therapy and for at least 4 weeks after its completion."
},
{
"drug": "Doxycycline",
"interacting_drug": "Antacids",
"description": "Antacids containing calcium, magnesium, or aluminum can reduce the absorption of Doxycycline.",
"extended_description": "Doxycycline forms complexes with cations found in antacids, reducing its absorption and therapeutic efficacy. Patients should avoid taking antacids within 1-2 hours of taking Doxycycline to ensure optimal absorption."
},
{
"drug": "Erythromycin",
"interacting_drug": "Warfarin",
"description": "Erythromycin can increase the anticoagulant effect of Warfarin.",
"extended_description": "Erythromycin inhibits CYP3A4, which is involved in metabolizing Warfarin. This can increase Warfarin plasma levels, raising the risk of bleeding. Regular INR monitoring is necessary, and Warfarin dose adjustments may be required."
},
{
"drug": "Gentamicin",
"interacting_drug": "Loop diuretics",
"description": "Loop diuretics increase the risk of nephrotoxicity when used with Gentamicin.",
"extended_description": "Both Gentamicin and Loop diuretics can independently cause nephrotoxicity. When used together, the risk is heightened. Renal function should be closely monitored, and dose adjustments for Gentamicin may be required in patients on Loop diuretics."
},
{
"drug": "Ceftriaxone",
"interacting_drug": "Calcium-containing intravenous solutions",
"description": "Ceftriaxone should not be mixed with calcium-containing solutions.",
"extended_description": "Ceftriaxone and calcium-containing intravenous solutions can form dangerous precipitates, especially in neonates. This can lead to serious complications, such as pulmonary and renal embolism. Ceftriaxone should never be mixed or infused with calcium-containing solutions, particularly in neonates."
},
{
"drug": "Clarithromycin",
"interacting_drug": "Statins",
"description": "Clarithromycin can increase the plasma concentration of Statins, increasing the risk of rhabdomyolysis.",
"extended_description": "Clarithromycin inhibits CYP3A4, which metabolizes many statins. As a result, statin levels can increase, leading to a higher risk of rhabdomyolysis. Monitoring for muscle toxicity is recommended, and dose adjustments or alternative statins may be necessary."
},
{
"drug": "Vancomycin",
"interacting_drug": "Corticosteroids",
"description": "Corticosteroids may enhance the nephrotoxic effects of Vancomycin.",
"extended_description": "Both Vancomycin and corticosteroids can independently cause nephrotoxicity. When combined, the risk of renal damage is increased. Renal function should be closely monitored, and adjustments to dosing or duration of Vancomycin therapy may be necessary."
},
{
"drug": "Amoxicillin",
"interacting_drug": "Allopurinol",
"description": "Allopurinol can increase the risk of rash in patients taking Amoxicillin.",
"extended_description": "The combination of Amoxicillin and Allopurinol increases the risk of a maculopapular rash, particularly in patients with hyperuricemia or gout. This is not an allergic reaction but can be mistaken for one. Discontinuation of either drug is recommended if a rash develops."
},
{
"drug": "Metronidazole",
"interacting_drug": "Alcohol",
"description": "Metronidazole causes a disulfiram-like reaction when taken with alcohol.",
"extended_description": "Metronidazole inhibits aldehyde dehydrogenase, causing the accumulation of acetaldehyde when alcohol is consumed. This results in symptoms such as flushing, nausea, vomiting, and hypotension. Patients should avoid alcohol during treatment with Metronidazole and for 48 hours after completion of therapy."
},
{
"drug": "Linezolid",
"interacting_drug": "SSRIs (e.g., Sertraline)",
"description": "Linezolid and SSRIs together can precipitate serotonin syndrome.",
"extended_description": "Linezolid is a weak monoamine oxidase inhibitor (MAOI), which, when combined with serotonergic agents like SSRIs, can cause excessive serotonergic activity. Clinical features include hyperreflexia, agitation, tremor, and autonomic instability. Discontinue SSRIs before initiating Linezolid if feasible."
},
{
"drug": "Cefepime",
"interacting_drug": "Probenecid",
"description": "Probenecid can increase the plasma concentration of Cefepime.",
"extended_description": "Probenecid inhibits the renal tubular secretion of Cefepime, leading to increased plasma levels. While this may enhance the therapeutic effect, it also increases the risk of neurotoxicity, especially in patients with impaired renal function. Monitoring for signs of toxicity is advised."
},
{
"drug": "Benzylpenicillin",
"interacting_drug": "Probenecid",
"description": "Probenecid reduces the renal clearance of Benzylpenicillin.",
"extended_description": "Probenecid inhibits the renal excretion of Benzylpenicillin, leading to higher blood levels and prolonged antibacterial effects. This interaction can be used therapeutically in some cases, but careful monitoring is necessary to avoid potential toxicity, especially in patients with renal impairment."
},
{
"drug": "Tetracycline",
"interacting_drug": "Antacids",
"description": "Antacids containing aluminum or magnesium can reduce the absorption of Tetracycline.",
"extended_description": "Tetracycline forms insoluble complexes with the cations in antacids, which significantly reduces its absorption. This can result in suboptimal therapeutic effects. Tetracycline should be taken at least 1-2 hours before or after antacids."
},
{
"drug": "Aztreonam",
"interacting_drug": "Cisplatin",
"description": "Aztreonam and Cisplatin can increase the risk of nephrotoxicity.",
"extended_description": "Both Aztreonam and Cisplatin can independently cause nephrotoxicity. When used together, the risk is increased. Renal function should be closely monitored, and dose adjustments for both drugs may be necessary."
},

{
"drug": "Tigecycline",
"interacting_drug": "Warfarin",
"description": "Tigecycline may enhance the anticoagulant effect of Warfarin.",
"extended_description": "Tigecycline can increase the anticoagulant effect of Warfarin by inhibiting hepatic CYP enzymes. This may lead to an increased risk of bleeding. Close monitoring of INR levels and possible adjustment of Warfarin dosage is advised."
},
{
"drug": "Daptomycin",
"interacting_drug": "Statins",
"description": "Daptomycin increases the risk of myopathy when combined with Statins.",
"extended_description": "Both Daptomycin and statins can independently cause muscle toxicity, and their combination increases the risk of myopathy or rhabdomyolysis. Creatine kinase (CK) levels should be monitored, and statins should be discontinued if myopathy occurs."
},
{
"drug": "Colistin",
"interacting_drug": "Aminoglycosides",
"description": "Colistin and Aminoglycosides together increase the risk of nephrotoxicity.",
"extended_description": "Both Colistin and Aminoglycosides can cause nephrotoxicity. When used concurrently, the risk of renal impairment is amplified. Renal function should be closely monitored, and the duration of therapy should be minimized."
},
{
"drug": "Fidaxomicin",
"interacting_drug": "CYP3A4 inhibitors",
"description": "CYP3A4 inhibitors may increase the plasma concentration of Fidaxomicin.",
"extended_description": "Fidaxomicin is partially metabolized by CYP3A4, and inhibitors of this enzyme can increase its plasma concentration. This could lead to an increased risk of adverse effects, including gastrointestinal disturbances. Dose adjustments may be necessary."
},
{
"drug": "Mupirocin",
"interacting_drug": "Other topical antibiotics",
"description": "Concurrent use of Mupirocin with other topical antibiotics may lead to an increased risk of local skin reactions.",
"extended_description": "Mupirocin can cause local skin irritation. When combined with other topical antibiotics, the risk of skin reactions may increase. If severe irritation or allergic reactions occur, the combined use should be discontinued."
},
{
"drug": "Ceftaroline",
"interacting_drug": "Probenecid",
"description": "Probenecid may increase the plasma levels of Ceftaroline.",
"extended_description": "Probenecid inhibits renal tubular secretion, increasing the plasma concentration of Ceftaroline. This may enhance its therapeutic effect but also increase the risk of side effects, such as diarrhea or rash. Dosage adjustments and renal monitoring may be necessary."
},
{
"drug": "Meropenem",
"interacting_drug": "Valproic acid",
"description": "Meropenem may reduce the serum levels of Valproic acid.",
"extended_description": "Meropenem can decrease the serum concentration of Valproic acid by increasing its renal clearance, potentially precipitating seizures in patients on Valproic acid therapy. Serum levels of Valproic acid should be monitored, and dose adjustments may be required."
},
{
"drug": "Clindamycin",
"interacting_drug": "Erythromycin",
"description": "Clindamycin and Erythromycin can antagonize each other's antibacterial effects.",
"extended_description": "Clindamycin and Erythromycin both inhibit protein synthesis but via different mechanisms. When used together, their effects may antagonize each other, reducing efficacy. This combination should be avoided, especially in the treatment of serious infections."
},
{
"drug": "Quinupristin/Dalfopristin",
"interacting_drug": "CYP3A4 inhibitors",
"description": "CYP3A4 inhibitors can increase plasma concentrations of Quinupristin/Dalfopristin.",
"extended_description": "Both Quinupristin and Dalfopristin are metabolized by CYP3A4. Inhibitors of this enzyme, such as Ketoconazole, can increase the plasma levels of Quinupristin/Dalfopristin, potentially leading to increased side effects. Dose adjustments should be considered in patients taking these inhibitors."
},
{
"drug": "Tigecycline",
"interacting_drug": "Oral Contraceptives",
"description": "Tigecycline may reduce the efficacy of oral contraceptives.",
"extended_description": "Tigecycline has been shown to potentially reduce the effectiveness of oral contraceptives, increasing the risk of unintended pregnancy. Additional or alternative contraception should be used during treatment and for at least 28 days after therapy."
},
{
"drug": "Fosfomycin",
"interacting_drug": "Methotrexate",
"description": "Fosfomycin may increase the plasma concentration of Methotrexate.",
"extended_description": "Fosfomycin can inhibit the renal excretion of Methotrexate, resulting in elevated serum levels and an increased risk of Methotrexate toxicity. Close monitoring of Methotrexate levels and renal function is recommended."
},
{
"drug": "Chloramphenicol",
"interacting_drug": "Cyclosporine",
"description": "Chloramphenicol can increase Cyclosporine levels, increasing the risk of nephrotoxicity.",
"extended_description": "Chloramphenicol inhibits the metabolism of Cyclosporine, leading to elevated plasma levels. This increases the risk of nephrotoxicity. Monitoring of Cyclosporine levels and renal function is essential, and dose adjustments may be necessary."
},
{
"drug": "Rifaximin",
"interacting_drug": "CYP3A4 inhibitors",
"description": "CYP3A4 inhibitors may increase the plasma concentration of Rifaximin.",
"extended_description": "Rifaximin is minimally metabolized by CYP3A4, but the use of CYP3A4 inhibitors may still increase its plasma concentration. This could enhance the drug's gastrointestinal side effects. Close monitoring for adverse effects is recommended."
},
{
"drug": "Nitrofurantoin",
"interacting_drug": "Probenecid",
"description": "Probenecid can reduce the renal clearance of Nitrofurantoin.",
"extended_description": "Probenecid inhibits the renal excretion of Nitrofurantoin, leading to increased plasma levels. This may increase the risk of toxicity, especially in patients with impaired renal function. Monitoring renal function and adjusting the Nitrofurantoin dose may be necessary."
},
{
"drug": "Doxycycline",
"interacting_drug": "Oral Contraceptives",
"description": "Doxycycline may reduce the efficacy of oral contraceptives.",
"extended_description": "Doxycycline may reduce the effectiveness of oral contraceptives, increasing the risk of pregnancy. Additional or alternative contraception methods should be used during treatment and for a short period after discontinuation."
},
{
"drug": "Tetracycline",
"interacting_drug": "Barbiturates",
"description": "Barbiturates may reduce the plasma concentration of Tetracycline.",
"extended_description": "Barbiturates are enzyme inducers that can increase the metabolism of Tetracycline, leading to decreased plasma levels and reduced effectiveness. Higher doses of Tetracycline or alternative antibiotics may be required."
},
{
"drug": "Ciprofloxacin",
"interacting_drug": "Corticosteroids",
"description": "Ciprofloxacin increases the risk of tendon rupture when used with corticosteroids.",
"extended_description": "Fluoroquinolones, including Ciprofloxacin, are associated with an increased risk of tendonitis and tendon rupture, particularly when used with corticosteroids. This risk is elevated in older adults and patients with organ transplants."
},
{
"drug": "Cefixime",
"interacting_drug": "Live vaccines",
"description": "Cefixime may reduce the effectiveness of live vaccines.",
"extended_description": "Cefixime may interfere with the immune response to live bacterial vaccines, such as Typhoid vaccine. It is recommended to complete vaccination before starting antibiotic therapy or to delay the vaccine until therapy is completed."
},
{
"drug": "Cefpodoxime",
"interacting_drug": "Antacids",
"description": "Antacids containing magnesium or aluminum can decrease the absorption of Cefpodoxime.",
"extended_description": "Cefpodoxime absorption is reduced by antacids containing magnesium or aluminum. This decreases the therapeutic effect of Cefpodoxime. Patients should avoid taking antacids within 2 hours of Cefpodoxime."
},
{
"drug": "Imipenem/Cilastatin",
"interacting_drug": "Valproic acid",
"description": "Imipenem/Cilastatin reduces the plasma levels of Valproic acid.",
"extended_description": "Imipenem/Cilastatin can reduce the serum concentration of Valproic acid, potentially increasing the risk of seizures. Serum levels of Valproic acid should be closely monitored, and dose adjustments may be necessary."
},
{
"drug": "Aztreonam",
"interacting_drug": "Probenecid",
"description": "Probenecid can increase the plasma concentration of Aztreonam.",
"extended_description": "Probenecid inhibits the renal excretion of Aztreonam, leading to elevated plasma concentrations. This may increase the risk of side effects, such as rash or gastrointestinal disturbances. Renal function and Aztreonam levels should be monitored."
},


{
"drug": "Clindamycin",
"interacting_drug": "Neuromuscular blocking agents",
"description": "Clindamycin may potentiate the effects of neuromuscular blocking agents.",
"extended_description": "Clindamycin can inhibit the release of acetylcholine, which may enhance the effects of neuromuscular blocking agents used during surgery. The patient’s neuromuscular function should be closely monitored, and the use of these agents should be carefully managed."
},
{
"drug": "Moxifloxacin",
"interacting_drug": "Antacids containing magnesium or aluminum",
"description": "Antacids containing magnesium or aluminum can reduce the absorption of Moxifloxacin.",
"extended_description": "The absorption of Moxifloxacin is decreased when taken with antacids containing magnesium or aluminum. Patients should avoid taking these antacids within 4 hours of Moxifloxacin administration to prevent reduced drug efficacy."
},
{
"drug": "Cefuroxime",
"interacting_drug": "Warfarin",
"description": "Cefuroxime may enhance the anticoagulant effect of Warfarin.",
"extended_description": "Cefuroxime can potentiate the effects of Warfarin, increasing the risk of bleeding. Regular monitoring of INR and dose adjustments of Warfarin may be necessary to maintain therapeutic levels."
},
{
"drug": "Tigecycline",
"interacting_drug": "Cyclosporine",
"description": "Tigecycline may increase the plasma concentration of Cyclosporine.",
"extended_description": "Tigecycline can inhibit the metabolism of Cyclosporine, leading to elevated levels and an increased risk of nephrotoxicity and other side effects. Cyclosporine levels should be monitored, and dose adjustments may be required."
},
{
"drug": "Meropenem",
"interacting_drug": "Valproic acid",
"description": "Meropenem can lower the plasma concentration of Valproic acid.",
"extended_description": "Meropenem accelerates the renal clearance of Valproic acid, which may lead to subtherapeutic levels and an increased risk of seizures. Monitoring of Valproic acid levels and potential dose adjustments are recommended."
},
{
"drug": "Colistin",
"interacting_drug": "Nephrotoxic drugs (e.g., Aminoglycosides)",
"description": "Colistin increases the risk of nephrotoxicity when used with nephrotoxic drugs.",
"extended_description": "Colistin itself has nephrotoxic potential, and its use with other nephrotoxic agents, such as Aminoglycosides, can exacerbate renal damage. Renal function should be carefully monitored, and the combined use should be minimized or avoided."
},
{
"drug": "Linezolid",
"interacting_drug": "Tyramine-containing foods",
"description": "Linezolid can interact with tyramine-containing foods to cause hypertensive crises.",
"extended_description": "Linezolid is a weak monoamine oxidase inhibitor (MAOI). Consuming tyramine-rich foods (such as aged cheese, cured meats) while on Linezolid can precipitate a hypertensive crisis due to excessive release of norepinephrine. Patients should avoid these foods during therapy."
},
{
"drug": "Rifaximin",
"interacting_drug": "CYP3A4 inducers",
"description": "CYP3A4 inducers may reduce the efficacy of Rifaximin.",
"extended_description": "Rifaximin is minimally metabolized by CYP3A4, but inducers of this enzyme (e.g., Rifampin) may lower its plasma concentration and reduce its therapeutic effect. Monitoring and dose adjustments may be necessary if CYP3A4 inducers are used concurrently."
},
{
"drug": "Clindamycin",
"interacting_drug": "Benzodiazepines",
"description": "Clindamycin may enhance the sedative effects of benzodiazepines.",
"extended_description": "Clindamycin can increase the sedative effects of benzodiazepines, which may lead to excessive drowsiness or respiratory depression. Close monitoring of sedation levels is recommended, and dose reduction of benzodiazepines may be necessary."
},
{
"drug": "Tetracycline",
"interacting_drug": "Antacids containing calcium, magnesium, or aluminum",
"description": "Antacids containing calcium, magnesium, or aluminum can decrease the absorption of Tetracycline.",
"extended_description": "Antacids containing calcium, magnesium, or aluminum can bind to Tetracycline, reducing its absorption and therapeutic efficacy. Tetracycline should be taken at least 2 hours before or after antacids."
},
{
"drug": "Fosfomycin",
"interacting_drug": "Methotrexate",
"description": "Fosfomycin may increase the plasma concentration of Methotrexate.",
"extended_description": "Fosfomycin inhibits the renal clearance of Methotrexate, leading to increased serum levels and a higher risk of toxicity. Methotrexate levels should be closely monitored, and dose adjustments may be required."
},
{
"drug": "Daptomycin",
"interacting_drug": "HMG-CoA reductase inhibitors (e.g., Statins)",
"description": "Daptomycin may increase the risk of muscle toxicity when used with statins.",
"extended_description": "Both Daptomycin and statins can cause muscle-related side effects. Their combination increases the risk of myopathy and rhabdomyolysis. Creatine kinase levels should be monitored, and statins should be discontinued if muscle symptoms occur."
},
{
"drug": "Mupirocin",
"interacting_drug": "Other topical antibiotics",
"description": "Concurrent use of Mupirocin with other topical antibiotics can increase the risk of local irritation.",
"extended_description": "Mupirocin is a potent topical antibiotic that can cause skin irritation. When combined with other topical antibiotics, the risk of irritation or allergic reactions may be higher. Monitor for signs of skin reactions, and discontinue use if necessary."
},
{
"drug": "Aztreonam",
"interacting_drug": "Probenecid",
"description": "Probenecid can increase the plasma concentration of Aztreonam.",
"extended_description": "Probenecid inhibits the renal excretion of Aztreonam, leading to higher plasma concentrations. This can increase the risk of side effects such as rash, gastrointestinal upset, and fever. Monitoring renal function and Aztreonam levels is advised."
},
{
"drug": "Cefdinir",
"interacting_drug": "Iron supplements",
"description": "Iron supplements may reduce the absorption of Cefdinir.",
"extended_description": "Cefdinir's absorption is reduced when taken with iron supplements, potentially lowering its effectiveness. To avoid this interaction, Cefdinir should be taken at least 2 hours before or after iron-containing supplements."
},
{
"drug": "Vancomycin",
"interacting_drug": "Aminoglycosides",
"description": "Vancomycin and Aminoglycosides may increase the risk of nephrotoxicity and ototoxicity.",
"extended_description": "Both Vancomycin and Aminoglycosides have nephrotoxic and ototoxic potential. When used together, the risk of renal damage and hearing loss is increased. Monitoring of renal function and auditory function is essential."
},
{
"drug": "Tigecycline",
"interacting_drug": "Oral contraceptives",
"description": "Tigecycline may reduce the effectiveness of oral contraceptives.",
"extended_description": "Tigecycline may interfere with the pharmacokinetics of oral contraceptives, reducing their effectiveness. Patients should be advised to use additional or alternative contraceptive methods during and after Tigecycline therapy."
},
{
"drug": "Rifampin",
"interacting_drug": "Corticosteroids",
"description": "Rifampin may reduce the effectiveness of corticosteroids.",
"extended_description": "Rifampin is a potent inducer of hepatic enzymes, which can increase the metabolism of corticosteroids, leading to reduced plasma concentrations. Dose adjustments of corticosteroids may be necessary when used with Rifampin."
},
{
"drug": "Ceftriaxone",
"interacting_drug": "Calcium-containing intravenous solutions",
"description": "Ceftriaxone should not be administered with calcium-containing intravenous solutions in neonates.",
"extended_description": "Ceftriaxone and calcium-containing solutions can precipitate in neonates, leading to fatal outcomes. Ceftriaxone should be administered separately from calcium-containing solutions in this population."
},
{
"drug": "Fidaxomicin",
"interacting_drug": "CYP3A4 inhibitors",
"description": "CYP3A4 inhibitors may increase the plasma concentration of Fidaxomicin.",
"extended_description": "Fidaxomicin is primarily metabolized by CYP3A4. Inhibition of this enzyme by drugs such as Ketoconazole can increase the plasma levels of Fidaxomicin, potentially increasing the risk of adverse effects. Dose adjustments may be needed."
},
{
"drug": "Chloramphenicol",
"interacting_drug": "Phenytoin",
"description": "Chloramphenicol may inhibit the metabolism of Phenytoin.",
"extended_description": "Chloramphenicol inhibits the hepatic enzymes that metabolize Phenytoin, leading to elevated serum levels of Phenytoin. This increases the risk of Phenytoin toxicity, including ataxia and nystagmus. Monitoring of serum Phenytoin levels is recommended."
},
{
"drug": "Tetracycline",
"interacting_drug": "Digoxin",
"description": "Tetracycline may increase the absorption of Digoxin.",
"extended_description": "Tetracycline may increase the gastrointestinal absorption of Digoxin, potentially leading to Digoxin toxicity. Patients should be monitored for symptoms of Digoxin overdose, such as nausea, vomiting, and visual disturbances."
},

{
"drug": "Amikacin",
"interacting_drug": "Vancomycin",
"description": "The combination of Amikacin and Vancomycin may increase the risk of nephrotoxicity.",
"extended_description": "Both Amikacin and Vancomycin have nephrotoxic potential. When used together, they can increase the risk of renal injury. Renal function should be closely monitored, and the combination should be avoided if possible."
},
{
"drug": "Tigecycline",
"interacting_drug": "Warfarin",
"description": "Tigecycline may enhance the anticoagulant effect of Warfarin.",
"extended_description": "Tigecycline may increase the anticoagulant effects of Warfarin, leading to a higher risk of bleeding. Monitoring of INR is recommended, and Warfarin dose adjustments may be required."
},
{
"drug": "Cefazolin",
"interacting_drug": "Probenecid",
"description": "Probenecid can increase the plasma concentration of Cefazolin.",
"extended_description": "Probenecid inhibits the renal excretion of Cefazolin, leading to higher plasma concentrations. This may increase the risk of adverse effects, such as rash or gastrointestinal disturbances. Monitoring of Cefazolin levels is recommended."
},
{
"drug": "Meropenem",
"interacting_drug": "Valproic acid",
"description": "Meropenem can reduce the plasma concentration of Valproic acid.",
"extended_description": "Meropenem increases the renal clearance of Valproic acid, leading to decreased serum levels and reduced efficacy. This interaction may increase the risk of seizures. Valproic acid levels should be monitored and dose adjustments considered."
},
{
"drug": "Levofloxacin",
"interacting_drug": "Corticosteroids",
"description": "Levofloxacin may increase the risk of tendon rupture when used with corticosteroids.",
"extended_description": "Levofloxacin, a fluoroquinolone, when used with corticosteroids, can increase the risk of tendonitis and tendon rupture. This is particularly concerning in elderly patients or those with underlying conditions. Patients should be monitored for signs of tendon pain or swelling."
},
{
"drug": "Daptomycin",
"interacting_drug": "Statins",
"description": "Daptomycin increases the risk of myopathy and rhabdomyolysis when used with statins.",
"extended_description": "Daptomycin, when used with HMG-CoA reductase inhibitors (statins), increases the risk of muscle toxicity, including myopathy and rhabdomyolysis. Creatine kinase levels should be closely monitored, and statins should be discontinued if muscle symptoms develop."
},
{
"drug": "Clindamycin",
"interacting_drug": "Cyclosporine",
"description": "Clindamycin can increase the plasma concentration of Cyclosporine.",
"extended_description": "Clindamycin may inhibit the metabolism of Cyclosporine, leading to elevated serum concentrations. This may increase the risk of Cyclosporine-related toxicity, including nephrotoxicity. Cyclosporine levels should be monitored and dose adjustments may be necessary."
},
{
"drug": "Nitrofurantoin",
"interacting_drug": "Probenecid",
"description": "Probenecid can decrease the renal clearance of Nitrofurantoin.",
"extended_description": "Probenecid inhibits the renal clearance of Nitrofurantoin, leading to increased plasma concentrations. This can increase the risk of Nitrofurantoin-related toxicity, such as pulmonary fibrosis or hepatotoxicity. Renal function should be monitored, and dose adjustments may be required."
},
{
"drug": "Ceftriaxone",
"interacting_drug": "Calcium-containing intravenous solutions",
"description": "Ceftriaxone should not be administered with calcium-containing intravenous solutions in neonates.",
"extended_description": "Ceftriaxone and calcium-containing solutions can precipitate in neonates, leading to fatal outcomes. Ceftriaxone should be administered separately from calcium-containing solutions in this population, and careful monitoring is necessary."
},
{
"drug": "Moxifloxacin",
"interacting_drug": "Antacids containing aluminum, calcium, or magnesium",
"description": "Antacids can reduce the absorption of Moxifloxacin.",
"extended_description": "The absorption of Moxifloxacin is decreased when taken with antacids containing aluminum, calcium, or magnesium. Patients should avoid taking these antacids within 4 hours of Moxifloxacin administration to maintain its therapeutic effect."
},
{
"drug": "Vancomycin",
"interacting_drug": "Aminoglycosides",
"description": "Vancomycin and Aminoglycosides may increase the risk of nephrotoxicity and ototoxicity.",
"extended_description": "Both Vancomycin and Aminoglycosides have nephrotoxic and ototoxic potential. Their combined use increases the risk of renal injury and hearing loss. Renal and auditory function should be closely monitored."
},
{
"drug": "Ciprofloxacin",
"interacting_drug": "Theophylline",
"description": "Ciprofloxacin can increase the serum concentration of Theophylline.",
"extended_description": "Ciprofloxacin inhibits CYP1A2, the enzyme responsible for metabolizing Theophylline, leading to elevated Theophylline levels. This can increase the risk of Theophylline toxicity, including nausea, seizures, and arrhythmias. Monitoring serum Theophylline levels is recommended."
},
{
"drug": "Metronidazole",
"interacting_drug": "Alcohol",
"description": "Metronidazole can cause a disulfiram-like reaction when taken with alcohol.",
"extended_description": "Metronidazole inhibits aldehyde dehydrogenase, leading to the accumulation of acetaldehyde when alcohol is consumed. This results in a disulfiram-like reaction, characterized by flushing, nausea, vomiting, and headache. Patients should avoid alcohol during and for at least 48 hours after completing Metronidazole therapy."
},
{
"drug": "Azithromycin",
"interacting_drug": "Antacids containing aluminum or magnesium",
"description": "Antacids can reduce the absorption of Azithromycin.",
"extended_description": "Azithromycin's absorption is reduced when taken with antacids containing aluminum or magnesium. To avoid decreased efficacy, patients should separate the administration of Azithromycin and antacids by at least 2 hours."
},
{
"drug": "Amoxicillin",
"interacting_drug": "Allopurinol",
"description": "Amoxicillin increases the risk of rash when used with Allopurinol.",
"extended_description": "The combination of Amoxicillin and Allopurinol increases the risk of developing a rash, particularly in patients with gout. Patients should be monitored for signs of allergic reactions, and the combination should be used with caution."
},
{
"drug": "Chloramphenicol",
"interacting_drug": "Phenytoin",
"description": "Chloramphenicol may inhibit the metabolism of Phenytoin.",
"extended_description": "Chloramphenicol inhibits the hepatic enzymes responsible for metabolizing Phenytoin, leading to elevated serum levels of Phenytoin. This increases the risk of toxicity, including nystagmus and ataxia. Monitoring of Phenytoin levels is recommended."
},
{
"drug": "Cefepime",
"interacting_drug": "Probenecid",
"description": "Probenecid can increase the plasma concentration of Cefepime.",
"extended_description": "Probenecid inhibits the renal excretion of Cefepime, resulting in higher plasma concentrations. This may increase the risk of Cefepime-related adverse effects, such as neurotoxicity. Renal function and Cefepime levels should be monitored during concomitant use."
},
{
"drug": "Rifampin",
"interacting_drug": "Oral contraceptives",
"description": "Rifampin may reduce the effectiveness of oral contraceptives.",
"extended_description": "Rifampin induces hepatic enzymes that metabolize oral contraceptives, reducing their effectiveness. Women should be advised to use additional or alternative forms of contraception while taking Rifampin."
},
{
"drug": "Doxycycline",
"interacting_drug": "Antacids containing calcium, magnesium, or aluminum",
"description": "Antacids can decrease the absorption of Doxycycline.",
"extended_description": "Antacids containing calcium, magnesium, or aluminum can bind to Doxycycline, reducing its absorption and therapeutic effect. Doxycycline should be taken at least 2 hours before or after antacids to avoid this interaction."
},
{
"drug": "Cefpodoxime",
"interacting_drug": "H2 antagonists",
"description": "H2 antagonists may reduce the absorption of Cefpodoxime.",
"extended_description": "Cefpodoxime is affected by reduced gastric acidity caused by H2 antagonists, leading to decreased absorption. To maintain efficacy, Cefpodoxime should be taken 2 hours before or after H2 antagonists."
},

{
"drug": "Tedizolid",
"interacting_drug": "SSRIs",
"description": "Tedizolid can increase the risk of serotonin syndrome when used with SSRIs.",
"extended_description": "Tedizolid, a selective oxazolidinone antibiotic, weakly inhibits monoamine oxidase. When used with SSRIs, this can result in an excess of serotonin, leading to serotonin syndrome. Symptoms include hyperreflexia, agitation, and autonomic instability. Discontinuing the serotonergic drug or adjusting the Tedizolid dose may be necessary."
},
{
"drug": "Fosfomycin",
"interacting_drug": "Metoclopramide",
"description": "Metoclopramide may reduce the absorption of Fosfomycin.",
"extended_description": "Metoclopramide increases gastric motility and can decrease the absorption of Fosfomycin by accelerating gastric emptying. This interaction may reduce the effectiveness of Fosfomycin, especially in treating urinary tract infections. Fosfomycin should be taken at least 2 hours before or after Metoclopramide."
},
{
"drug": "Quinupristin/Dalfopristin",
"interacting_drug": "Cytochrome P450 inhibitors (e.g., Ketoconazole)",
"description": "Quinupristin/Dalfopristin levels can increase with concurrent use of Cytochrome P450 inhibitors.",
"extended_description": "Cytochrome P450 inhibitors, such as Ketoconazole, can decrease the metabolism of Quinupristin/Dalfopristin, leading to increased drug levels. This interaction may increase the risk of adverse effects, such as arthralgia, myalgia, and hepatotoxicity. Monitoring of liver function and dose adjustments may be necessary."
},
{
"drug": "Polymyxin B",
"interacting_drug": "Cisplatin",
"description": "Polymyxin B can potentiate the nephrotoxic effects of Cisplatin.",
"extended_description": "Both Polymyxin B and Cisplatin have nephrotoxic potential. When used together, they can increase the risk of renal damage, potentially leading to acute renal failure. Renal function should be closely monitored, and the use of both drugs should be limited to cases where the benefit outweighs the risk."
},
{
"drug": "Chloramphenicol",
"interacting_drug": "Chlorpromazine",
"description": "Chloramphenicol may potentiate the sedative effects of Chlorpromazine.",
"extended_description": "Chloramphenicol can inhibit the metabolism of Chlorpromazine, a typical antipsychotic, leading to increased serum levels and enhanced sedative effects. This combination may result in excessive sedation, hypotension, and respiratory depression. Monitoring and dose adjustment of Chlorpromazine may be necessary."
},
{
"drug": "Rifaximin",
"interacting_drug": "Cyclosporine",
"description": "Rifaximin can increase the serum concentration of Cyclosporine.",
"extended_description": "Rifaximin is a mild inhibitor of CYP3A4 and may increase the plasma concentration of Cyclosporine, a calcineurin inhibitor. Elevated Cyclosporine levels can increase the risk of nephrotoxicity and other side effects. Close monitoring of Cyclosporine levels is advised when both drugs are used together."
},
{
"drug": "Linezolid",
"interacting_drug": "Tyramine-containing foods",
"description": "Linezolid can cause hypertensive crisis when taken with foods high in Tyramine.",
"extended_description": "Linezolid is a weak monoamine oxidase inhibitor (MAOI). When consumed with foods high in Tyramine (such as aged cheese, cured meats, and fermented products), it can lead to a hypertensive crisis due to the accumulation of norepinephrine. Patients on Linezolid should avoid such foods during therapy."
},
{
"drug": "Daptomycin",
"interacting_drug": "Warfarin",
"description": "Daptomycin may increase the anticoagulant effect of Warfarin.",
"extended_description": "Daptomycin can enhance the anticoagulant effect of Warfarin by inhibiting platelet aggregation. This interaction may increase the risk of bleeding. Monitoring of INR is recommended, and Warfarin dosage may need to be adjusted."
},
{
"drug": "Tigecycline",
"interacting_drug": "Warfarin",
"description": "Tigecycline can potentiate the anticoagulant effect of Warfarin.",
"extended_description": "Tigecycline has been shown to increase the anticoagulant effect of Warfarin, leading to an increased risk of bleeding. This interaction is thought to be due to a decrease in Vitamin K metabolism. Patients taking both drugs should have their INR levels closely monitored and Warfarin dosage adjusted as needed."
},
{
"drug": "Cefotaxime",
"interacting_drug": "Calcium",
"description": "Cefotaxime should not be mixed with calcium-containing solutions in neonates.",
"extended_description": "Cefotaxime and calcium can form precipitates when administered together, particularly in neonates, potentially leading to fatal outcomes. Cefotaxime should not be mixed with calcium-containing solutions in this population, and careful monitoring of IV drug compatibility is necessary."
},
{
"drug": "Colistin",
"interacting_drug": "Rifampin",
"description": "Colistin may enhance the nephrotoxic effect of Rifampin.",
"extended_description": "Colistin and Rifampin both have nephrotoxic potential, and their combination can increase the risk of renal impairment. Renal function should be closely monitored, and the combination should be used with caution, particularly in patients with pre-existing kidney conditions."
},
{
"drug": "Ciprofloxacin",
"interacting_drug": "Sodium bicarbonate",
"description": "Sodium bicarbonate may decrease the effectiveness of Ciprofloxacin.",
"extended_description": "Sodium bicarbonate can increase the pH of urine, which can affect the absorption and efficacy of Ciprofloxacin, especially in the treatment of urinary tract infections. Ciprofloxacin should be taken separately from Sodium bicarbonate for optimal effectiveness."
},
{
"drug": "Meropenem",
"interacting_drug": "Valproic acid",
"description": "Meropenem can lower the serum concentration of Valproic acid.",
"extended_description": "Meropenem can increase the renal clearance of Valproic acid, decreasing its serum concentration and reducing its anticonvulsant effects. This interaction may lead to breakthrough seizures in patients taking Valproic acid for seizure management. Valproic acid levels should be monitored, and dose adjustments may be necessary."
},
{
"drug": "Ertapenem",
"interacting_drug": "Probenecid",
"description": "Probenecid can increase the plasma concentration of Ertapenem.",
"extended_description": "Probenecid inhibits the renal excretion of Ertapenem, leading to higher plasma concentrations. This may increase the risk of Ertapenem-related side effects, including seizures or gastrointestinal disturbances. Renal function should be monitored, and dosage adjustments may be necessary."
},
{
"drug": "Vancomycin",
"interacting_drug": "Aminoglycosides",
"description": "Vancomycin may increase the risk of ototoxicity when used with Aminoglycosides.",
"extended_description": "Both Vancomycin and Aminoglycosides are associated with ototoxicity, and their concurrent use may increase the risk of hearing loss. Audiometric monitoring is recommended, and the combination should be used only when absolutely necessary."
},
{
"drug": "Clindamycin",
"interacting_drug": "Lithium",
"description": "Clindamycin may increase the plasma concentration of Lithium.",
"extended_description": "Clindamycin may inhibit the renal clearance of Lithium, leading to elevated serum Lithium levels. This can increase the risk of Lithium toxicity, including tremor, confusion, and seizures. Lithium levels should be closely monitored, and dose adjustments may be needed."
},
{
"drug": "Teicoplanin",
"interacting_drug": "Vancomycin",
"description": "Teicoplanin and Vancomycin may increase the risk of nephrotoxicity when used together.",
"extended_description": "Both Teicoplanin and Vancomycin are glycopeptide antibiotics with nephrotoxic potential. Their combined use increases the risk of renal damage. Renal function should be carefully monitored during co-administration."
},

{
"drug": "Ritonavir",
"interacting_drug": "Midazolam",
"description": "Ritonavir can increase the sedative effect of Midazolam.",
"extended_description": "Ritonavir is a potent inhibitor of CYP3A4, the enzyme responsible for metabolizing Midazolam. When used together, Ritonavir can significantly increase Midazolam levels, leading to excessive sedation, respiratory depression, and hypotension. Dose reduction of Midazolam or alternative sedatives may be required, and monitoring of sedation levels is advised."
},
{
"drug": "Acyclovir",
"interacting_drug": "Zidovudine",
"description": "Acyclovir can increase Zidovudine levels, potentially enhancing side effects.",
"extended_description": "Acyclovir inhibits renal tubular secretion of Zidovudine, increasing its plasma concentration. This can enhance the risk of Zidovudine-related side effects, including bone marrow suppression and lactic acidosis. Dose adjustments of Zidovudine may be required, and blood counts should be monitored regularly."
},
{
"drug": "Valacyclovir",
"interacting_drug": "Cimetidine",
"description": "Cimetidine can increase the serum concentration of Valacyclovir.",
"extended_description": "Cimetidine inhibits renal tubular secretion of Valacyclovir, resulting in higher plasma levels. This may increase the risk of Valacyclovir-related adverse effects, including neurotoxicity (e.g., confusion, seizures), especially in patients with impaired renal function. Valacyclovir dosing should be adjusted, and renal function monitored closely."
},
{
"drug": "Efavirenz",
"interacting_drug": "Methadone",
"description": "Efavirenz can reduce the effectiveness of Methadone.",
"extended_description": "Efavirenz is a CYP3A4 inducer, which can increase the metabolism of Methadone, reducing its therapeutic effect. This may lead to withdrawal symptoms in patients using Methadone for opioid substitution therapy. Methadone dosage adjustments may be required, and careful monitoring for withdrawal symptoms is necessary."
},
{
"drug": "Lamivudine",
"interacting_drug": "Trimethoprim/Sulfamethoxazole",
"description": "Trimethoprim/Sulfamethoxazole can increase Lamivudine levels, enhancing the risk of toxicity.",
"extended_description": "Trimethoprim/Sulfamethoxazole inhibits renal clearance of Lamivudine, increasing its plasma levels. This may increase the risk of Lamivudine-related side effects, including lactic acidosis and hepatotoxicity. Close monitoring of renal function and periodic liver enzyme tests should be performed during co-administration."
},
{
"drug": "Oseltamivir",
"interacting_drug": "Probenecid",
"description": "Probenecid can increase the plasma concentration of Oseltamivir.",
"extended_description": "Probenecid inhibits renal tubular secretion, which can reduce the renal clearance of Oseltamivir. This may result in higher plasma concentrations of Oseltamivir, potentially increasing the risk of adverse effects such as nausea and vomiting. Dosage adjustments may be needed in patients with renal impairment."
},
{
"drug": "Sofosbuvir",
"interacting_drug": "Rifampin",
"description": "Rifampin can decrease the effectiveness of Sofosbuvir.",
"extended_description": "Rifampin is a potent inducer of CYP450 enzymes, particularly CYP3A4, which is responsible for metabolizing Sofosbuvir. This interaction may reduce the plasma concentration of Sofosbuvir, diminishing its antiviral effectiveness. Sofosbuvir should not be used with Rifampin due to the potential for suboptimal therapeutic outcomes."
},
{
"drug": "Darunavir",
"interacting_drug": "Atorvastatin",
"description": "Darunavir can increase the serum concentration of Atorvastatin.",
"extended_description": "Darunavir inhibits CYP3A4, the enzyme responsible for metabolizing Atorvastatin. This interaction can lead to increased serum levels of Atorvastatin, raising the risk of statin-related side effects, such as myopathy and rhabdomyolysis. Monitoring of creatine kinase levels is recommended, and a reduction in Atorvastatin dose may be necessary."
},
{
"drug": "Abacavir",
"interacting_drug": "Alcohol",
"description": "Alcohol may increase the risk of side effects when used with Abacavir.",
"extended_description": "Alcohol may increase the plasma concentration of Abacavir by affecting hepatic metabolism, raising the risk of Abacavir-associated side effects, such as liver toxicity, hypersensitivity reactions, and gastrointestinal disturbances. Caution is advised, and patients should be advised to limit alcohol intake while on Abacavir therapy."
},
{
"drug": "Raltegravir",
"interacting_drug": "Antacids",
"description": "Antacids can reduce the absorption of Raltegravir.",
"extended_description": "Antacids, especially those containing calcium, aluminum, or magnesium, can decrease the absorption of Raltegravir, potentially reducing its efficacy. Raltegravir should be taken at least 2 hours before or 6 hours after antacids to avoid this interaction and ensure optimal absorption."
},
{
"drug": "Tenofovir",
"interacting_drug": "Didanosine",
"description": "Tenofovir and Didanosine together can increase the risk of lactic acidosis and hepatotoxicity.",
"extended_description": "Both Tenofovir and Didanosine can cause mitochondrial toxicity, which may lead to lactic acidosis and hepatotoxicity. The combination of these drugs should be avoided, especially in patients with existing liver disease, and liver function should be closely monitored in those who must use both drugs."
},
{
"drug": "Emtricitabine",
"interacting_drug": "Lamivudine",
"description": "Emtricitabine and Lamivudine have similar mechanisms of action and should not be used together.",
"extended_description": "Both Emtricitabine and Lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) with similar mechanisms of action against HIV. Using both drugs together offers no additional benefit and increases the risk of side effects such as bone marrow suppression and lactic acidosis. Dual therapy with these drugs should be avoided."
},
{
"drug": "Fosamprenavir",
"interacting_drug": "Rifampin",
"description": "Rifampin can reduce the effectiveness of Fosamprenavir.",
"extended_description": "Rifampin is a potent CYP450 inducer that accelerates the metabolism of Fosamprenavir, reducing its plasma concentration and antiviral activity. This interaction can lead to treatment failure. When Rifampin is necessary, an alternative antiretroviral regimen should be considered."
},
{
"drug": "Indinavir",
"interacting_drug": "Cimetidine",
"description": "Cimetidine can increase Indinavir levels, raising the risk of toxicity.",
"extended_description": "Cimetidine inhibits the CYP3A4 enzyme, which metabolizes Indinavir, leading to elevated plasma levels of the protease inhibitor. This can increase the risk of side effects such as nephrolithiasis, hyperbilirubinemia, and gastrointestinal disturbances. Renal function should be monitored, and dose adjustments may be necessary."
},
{
"drug": "Maraviroc",
"interacting_drug": "Ketoconazole",
"description": "Ketoconazole can increase Maraviroc levels, potentially enhancing side effects.",
"extended_description": "Ketoconazole, a potent CYP3A4 inhibitor, can increase Maraviroc plasma levels, leading to a higher risk of adverse effects such as dizziness, orthostatic hypotension, and liver toxicity. Maraviroc dose reduction should be considered, and close monitoring of liver function is advised."
},
{
"drug": "Zanamivir",
"interacting_drug": "Live attenuated influenza vaccine",
"description": "Zanamivir can interfere with the efficacy of the live attenuated influenza vaccine.",
"extended_description": "Zanamivir, an antiviral medication, can reduce the immune response to the live attenuated influenza vaccine by inhibiting the replication of the influenza virus. Patients receiving Zanamivir should avoid the live vaccine, and inactivated vaccines should be preferred."
},
{
"drug": "Oseltamivir",
"interacting_drug": "Warfarin",
"description": "Oseltamivir can potentiate the anticoagulant effect of Warfarin.",
"extended_description": "Oseltamivir may increase the anticoagulant effect of Warfarin by enhancing its clearance, leading to an increased risk of bleeding. Regular monitoring of INR is recommended, and dose adjustments to Warfarin may be required."
},
{
"drug": "Lamivudine",
"interacting_drug": "Ganciclovir",
"description": "Ganciclovir can increase Lamivudine levels, increasing the risk of toxicity.",
"extended_description": "Ganciclovir inhibits renal clearance of Lamivudine, resulting in elevated plasma concentrations. This can increase the risk of Lamivudine-associated side effects, such as lactic acidosis, liver toxicity, and bone marrow suppression. Monitoring of renal function and blood counts is advised."
},
{
"drug": "Telbivudine",
"interacting_drug": "Ribavirin",
"description": "Telbivudine and Ribavirin together can increase the risk of lactic acidosis.",
"extended_description": "Both Telbivudine and Ribavirin are associated with mitochondrial toxicity and can increase the risk of lactic acidosis when used together. This combination should be avoided, particularly in patients with liver dysfunction, and regular monitoring of liver enzymes and lactate levels is recommended."
},
{
"drug": "Dolutegravir",
"interacting_drug": "Dofetilide",
"description": "Dolutegravir can increase the risk of QT prolongation when used with Dofetilide.",
"extended_description": "Dolutegravir can increase the plasma levels of Dofetilide, a drug associated with QT prolongation. This interaction can increase the risk of life-threatening arrhythmias. The combination should be avoided, and if co-administration is necessary, ECG monitoring is essential."
},
{
"drug": "TDF (Tenofovir disoproxil fumarate)",
"interacting_drug": "Acid-reducing agents (e.g., Omeprazole)",
"description": "Acid-reducing agents can reduce the absorption of Tenofovir.",
"extended_description": "Acid-reducing agents, such as proton pump inhibitors, can increase the pH in the stomach and reduce the absorption of Tenofovir, thereby decreasing its efficacy in treating HIV. Tenofovir should be taken with food and away from acid-reducing agents to ensure optimal absorption."
},


{
"drug": "Ritonavir",
"interacting_drug": "Clarithromycin",
"description": "Ritonavir can increase Clarithromycin levels, enhancing the risk of toxicity.",
"extended_description": "Ritonavir inhibits CYP3A4, which is responsible for metabolizing Clarithromycin. This interaction leads to increased plasma concentrations of Clarithromycin, increasing the risk of adverse effects such as QT prolongation, hepatotoxicity, and gastrointestinal symptoms. Close monitoring of liver enzymes and ECG is advised."
},
{
"drug": "Acyclovir",
"interacting_drug": "Cyclosporine",
"description": "Cyclosporine can increase Acyclovir levels, raising the risk of nephrotoxicity.",
"extended_description": "Cyclosporine inhibits renal excretion of Acyclovir, leading to increased serum concentrations. This may increase the risk of nephrotoxicity, particularly in patients with pre-existing renal impairment. Renal function should be monitored closely, and dose adjustments may be necessary for both drugs."
},
{
"drug": "Efavirenz",
"interacting_drug": "Voriconazole",
"description": "Voriconazole can reduce the plasma concentration of Efavirenz.",
"extended_description": "Voriconazole is a potent inhibitor of CYP2C9 and CYP3A4, enzymes involved in the metabolism of Efavirenz. This interaction may result in subtherapeutic levels of Efavirenz, reducing its efficacy in treating HIV. Dose adjustments of Efavirenz may be required when co-administered with Voriconazole."
},
{
"drug": "Abacavir",
"interacting_drug": "Alcohol",
"description": "Alcohol may increase the risk of Abacavir-associated side effects.",
"extended_description": "Alcohol can increase plasma concentrations of Abacavir, raising the risk of side effects such as liver toxicity, hypersensitivity reactions, and gastrointestinal discomfort. It is advisable for patients taking Abacavir to limit alcohol consumption and undergo regular liver function testing."
},
{
"drug": "Lamivudine",
"interacting_drug": "Fluconazole",
"description": "Fluconazole can increase Lamivudine levels, potentially enhancing side effects.",
"extended_description": "Fluconazole inhibits CYP3A4 and can reduce the clearance of Lamivudine, resulting in higher plasma levels. This may increase the risk of adverse effects such as lactic acidosis and hepatotoxicity. Patients should be monitored for these side effects, and dose adjustments may be required."
},
{
"drug": "Valacyclovir",
"interacting_drug": "Cimetidine",
"description": "Cimetidine can increase the plasma concentration of Valacyclovir.",
"extended_description": "Cimetidine inhibits renal tubular secretion, decreasing the renal clearance of Valacyclovir. This can lead to elevated plasma concentrations and increased risk of neurotoxicity, especially in elderly patients or those with renal impairment. Renal function should be monitored, and dose adjustments may be necessary."
},
{
"drug": "Sofosbuvir",
"interacting_drug": "Antacids",
"description": "Antacids can reduce the absorption of Sofosbuvir.",
"extended_description": "Antacids, particularly those containing magnesium or aluminum, can alter the pH of the stomach and reduce the absorption of Sofosbuvir, leading to suboptimal therapeutic levels. Sofosbuvir should be administered at least 4 hours before or 4 hours after antacids to avoid this interaction."
},
{
"drug": "Darunavir",
"interacting_drug": "Amiodarone",
"description": "Darunavir can increase the plasma levels of Amiodarone, enhancing the risk of arrhythmias.",
"extended_description": "Darunavir inhibits CYP3A4, which is involved in the metabolism of Amiodarone. Increased Amiodarone levels can potentiate its proarrhythmic effects, leading to serious cardiac events such as torsades de pointes. ECG monitoring and dose adjustments of Amiodarone are recommended during co-administration."
},
{
"drug": "Ritonavir",
"interacting_drug": "Simvastatin",
"description": "Ritonavir can increase Simvastatin levels, increasing the risk of myopathy and rhabdomyolysis.",
"extended_description": "Ritonavir inhibits CYP3A4, the enzyme responsible for metabolizing Simvastatin. This interaction leads to elevated Simvastatin concentrations, raising the risk of muscle-related side effects, including myopathy and rhabdomyolysis. Patients should be monitored for muscle pain, weakness, and creatine kinase levels."
},
{
"drug": "Lamivudine",
"interacting_drug": "Didanosine",
"description": "The combination of Lamivudine and Didanosine increases the risk of lactic acidosis.",
"extended_description": "Both Lamivudine and Didanosine are nucleoside reverse transcriptase inhibitors (NRTIs) that can cause mitochondrial toxicity. When used together, the risk of lactic acidosis and hepatotoxicity is heightened. This combination should be avoided, and patients should be closely monitored for signs of lactic acidosis and liver dysfunction."
},
{
"drug": "Zidovudine",
"interacting_drug": "St. John's Wort",
"description": "St. John's Wort can reduce the plasma concentration of Zidovudine.",
"extended_description": "St. John's Wort induces CYP3A4 and P-glycoprotein, leading to reduced absorption and increased clearance of Zidovudine. This interaction may result in subtherapeutic levels of Zidovudine, potentially leading to treatment failure. The use of St. John's Wort with Zidovudine should be avoided."
},
{
"drug": "Indinavir",
"interacting_drug": "Rifampin",
"description": "Rifampin reduces the effectiveness of Indinavir.",
"extended_description": "Rifampin is a potent inducer of CYP450 enzymes, particularly CYP3A4, which is responsible for metabolizing Indinavir. This interaction may reduce the plasma concentration of Indinavir, resulting in suboptimal antiviral effects. Rifampin should not be co-administered with Indinavir, and alternative treatments should be considered."
},
{
"drug": "Abacavir",
"interacting_drug": "Methadone",
"description": "Abacavir can increase Methadone levels, potentially leading to enhanced side effects.",
"extended_description": "Abacavir may inhibit the metabolism of Methadone, increasing its plasma concentration. This could potentiate Methadone-related side effects, such as sedation, respiratory depression, and QT prolongation. Methadone levels should be closely monitored, and dose adjustments may be necessary."
},
{
"drug": "Rifabutin",
"interacting_drug": "Atazanavir",
"description": "Rifabutin can reduce the effectiveness of Atazanavir.",
"extended_description": "Rifabutin induces CYP3A4, which increases the metabolism of Atazanavir, leading to reduced plasma concentrations and potential treatment failure. To maintain efficacy, Atazanavir dosing may need to be adjusted when co-administered with Rifabutin, and careful monitoring of HIV viral load is recommended."
},
{
"drug": "Efavirenz",
"interacting_drug": "Clarithromycin",
"description": "Clarithromycin can increase the levels of Efavirenz, increasing the risk of side effects.",
"extended_description": "Clarithromycin inhibits CYP3A4, which metabolizes Efavirenz. This interaction can lead to higher plasma concentrations of Efavirenz, increasing the risk of side effects such as dizziness, CNS toxicity, and hepatotoxicity. Monitoring for side effects is essential, and dose adjustments may be required."
},
{
"drug": "Sofosbuvir",
"interacting_drug": "Carbamazepine",
"description": "Carbamazepine can reduce the effectiveness of Sofosbuvir.",
"extended_description": "Carbamazepine is an enzyme inducer and can decrease the plasma concentration of Sofosbuvir, reducing its antiviral efficacy. This may lead to treatment failure in hepatitis C patients. Carbamazepine should be avoided with Sofosbuvir, and alternative anticonvulsant therapies should be considered."
},
{
"drug": "Dolutegravir",
"interacting_drug": "Rifampin",
"description": "Rifampin can reduce Dolutegravir levels, potentially diminishing its efficacy.",
"extended_description": "Rifampin is a strong CYP3A4 inducer that accelerates the metabolism of Dolutegravir, leading to reduced plasma concentrations. This may compromise its antiviral activity. If Rifampin is necessary, a higher dose of Dolutegravir may be required, and viral load should be closely monitored."
},
{
"drug": "Tenofovir",
"interacting_drug": "Aminoglycosides",
"description": "Aminoglycosides can increase the nephrotoxic potential of Tenofovir.",
"extended_description": "Both Tenofovir and aminoglycosides are associated with nephrotoxicity. When used together, they may have a synergistic effect, increasing the risk of acute kidney injury. Renal function should be closely monitored, and dose adjustments may be necessary."
},
{
"drug": "Emtricitabine",
"interacting_drug": "Dapsone",
"description": "Dapsone can reduce the effectiveness of Emtricitabine.",
"extended_description": "Dapsone is an inhibitor of folate metabolism and can interfere with the antiviral activity of Emtricitabine. This interaction may lead to reduced efficacy in treating HIV or hepatitis B. Emtricitabine should not be used in combination with Dapsone unless closely monitored for therapeutic failure."
},
{
"drug": "Maraviroc",
"interacting_drug": "Ketoconazole",
"description": "Ketoconazole increases Maraviroc levels, enhancing the risk of side effects.",
"extended_description": "Ketoconazole is a strong inhibitor of CYP3A4 and can increase the plasma concentration of Maraviroc. This may heighten the risk of adverse effects, including dizziness, orthostatic hypotension, and liver toxicity. Maraviroc dose reductions should be considered when co-administered with Ketoconazole."
},
{
"drug": "Ribavirin",
"interacting_drug": "Didanosine",
"description": "The combination of Ribavirin and Didanosine increases the risk of lactic acidosis and pancreatitis.",
"extended_description": "Both Ribavirin and Didanosine have been associated with mitochondrial toxicity, and their combined use increases the risk of lactic acidosis and pancreatitis. This combination should be avoided in most patients, particularly those with pre-existing liver or pancreatic conditions."
},

{
"drug": "Acyclovir",
"interacting_drug": "Probenecid",
"description": "Probenecid can increase Acyclovir levels, increasing the risk of nephrotoxicity.",
"extended_description": "Probenecid inhibits renal tubular secretion of Acyclovir, resulting in higher plasma concentrations. This may increase the risk of nephrotoxicity, particularly in patients with pre-existing renal impairment. Renal function should be closely monitored, and dose adjustments may be necessary."
},
{
"drug": "Valacyclovir",
"interacting_drug": "Tacroliumus",
"description": "Tacrolimus may increase Valacyclovir levels, enhancing the risk of nephrotoxicity.",
"extended_description": "Tacrolimus is a potent immunosuppressant that can impair renal function. When co-administered with Valacyclovir, there is an increased risk of renal toxicity, including acute kidney injury. Renal function should be monitored closely, and dose modifications may be necessary."
},
{
"drug": "Ritonavir",
"interacting_drug": "Fluconazole",
"description": "Fluconazole can increase Ritonavir levels, increasing the risk of toxicity.",
"extended_description": "Fluconazole inhibits CYP3A4, which is responsible for metabolizing Ritonavir. This interaction can lead to elevated plasma levels of Ritonavir, increasing the risk of side effects such as hepatotoxicity, gastrointestinal distress, and cardiovascular issues. Regular liver function tests should be conducted."
},
{
"drug": "Efavirenz",
"interacting_drug": "Ketoconazole",
"description": "Ketoconazole can increase Efavirenz levels, increasing the risk of central nervous system side effects.",
"extended_description": "Ketoconazole inhibits CYP3A4, which metabolizes Efavirenz. This interaction may result in increased plasma levels of Efavirenz, leading to a higher likelihood of CNS side effects such as dizziness, confusion, and insomnia. Patients should be closely monitored for these effects."
},
{
"drug": "Sofosbuvir",
"interacting_drug": "Carbamazepine",
"description": "Carbamazepine reduces the efficacy of Sofosbuvir.",
"extended_description": "Carbamazepine is a CYP3A4 inducer and accelerates the metabolism of Sofosbuvir, leading to reduced plasma concentrations and potential treatment failure in patients with hepatitis C. Co-administration of these drugs should be avoided, and alternative anticonvulsants should be considered."
},
{
"drug": "Lamivudine",
"interacting_drug": "Trimethoprim-Sulfamethoxazole",
"description": "Trimethoprim-Sulfamethoxazole can increase Lamivudine levels, increasing the risk of adverse effects.",
"extended_description": "Trimethoprim-Sulfamethoxazole inhibits renal tubular secretion and can increase the plasma concentration of Lamivudine. This may lead to an elevated risk of adverse effects such as gastrointestinal disturbances and hepatotoxicity. Monitoring of renal function and liver enzymes is recommended."
},
{
"drug": "Ritonavir",
"interacting_drug": "Atorvastatin",
"description": "Ritonavir increases Atorvastatin levels, heightening the risk of myopathy and rhabdomyolysis.",
"extended_description": "Ritonavir inhibits CYP3A4, the enzyme responsible for metabolizing Atorvastatin. This interaction results in elevated plasma levels of Atorvastatin, which increases the risk of muscle-related adverse effects, including myopathy and rhabdomyolysis. Patients should be monitored for muscle pain and creatine kinase levels."
},
{
"drug": "Abacavir",
"interacting_drug": "Lopinavir",
"description": "Lopinavir can increase Abacavir levels, increasing the risk of side effects.",
"extended_description": "Lopinavir inhibits the metabolism of Abacavir through CYP3A4. This results in increased plasma concentrations of Abacavir, heightening the risk of hypersensitivity reactions, liver toxicity, and gastrointestinal distress. Monitoring of liver function and signs of hypersensitivity is essential."
},
{
"drug": "Tenofovir",
"interacting_drug": "Didanosine",
"description": "Didanosine can increase Tenofovir levels, raising the risk of kidney toxicity.",
"extended_description": "Didanosine inhibits the renal tubular secretion of Tenofovir, resulting in elevated plasma concentrations. This may increase the risk of nephrotoxicity, particularly in patients with pre-existing renal conditions. Renal function should be monitored regularly, and dose adjustments may be necessary."
},
{
"drug": "Indinavir",
"interacting_drug": "Rifampin",
"description": "Rifampin reduces the effectiveness of Indinavir, potentially leading to HIV treatment failure.",
"extended_description": "Rifampin is a potent inducer of CYP3A4, the enzyme responsible for metabolizing Indinavir. This interaction leads to decreased plasma levels of Indinavir, reducing its effectiveness in controlling HIV. Alternative treatments should be considered when co-administering Rifampin with Indinavir."
},
{
"drug": "Darunavir",
"interacting_drug": "Amiodarone",
"description": "Darunavir can increase Amiodarone levels, potentially leading to arrhythmias.",
"extended_description": "Darunavir inhibits CYP3A4, the enzyme responsible for metabolizing Amiodarone. This interaction can result in elevated Amiodarone plasma levels, increasing the risk of proarrhythmic effects such as torsades de pointes. ECG monitoring and dose adjustments are recommended when these drugs are co-administered."
},
{
"drug": "Efavirenz",
"interacting_drug": "Cimetidine",
"description": "Cimetidine may increase the plasma concentration of Efavirenz.",
"extended_description": "Cimetidine inhibits CYP2C19, which is involved in the metabolism of Efavirenz. This can lead to higher plasma levels of Efavirenz, potentially increasing the risk of CNS side effects such as dizziness, insomnia, and depression. Monitoring for side effects and dose adjustments may be necessary."
},
{
"drug": "Ritonavir",
"interacting_drug": "Tacrolimus",
"description": "Ritonavir increases Tacrolimus levels, raising the risk of nephrotoxicity.",
"extended_description": "Ritonavir inhibits the metabolism of Tacrolimus via CYP3A4, leading to higher plasma concentrations of Tacrolimus. This increases the risk of nephrotoxicity and other adverse effects, such as neurotoxicity and hypertension. Kidney function should be closely monitored, and Tacrolimus dose adjustments may be necessary."
},
{
"drug": "Valacyclovir",
"interacting_drug": "Phenytoin",
"description": "Phenytoin can reduce Valacyclovir levels, potentially decreasing its antiviral efficacy.",
"extended_description": "Phenytoin induces hepatic enzymes such as CYP3A4, which can lead to reduced plasma concentrations of Valacyclovir. This interaction may reduce the antiviral effect of Valacyclovir, particularly in herpes simplex virus infections. Alternative antiviral treatments or dose adjustments may be needed."
},
{
"drug": "Ritonavir",
"interacting_drug": "Alprazolam",
"description": "Ritonavir increases the plasma concentration of Alprazolam, enhancing sedative effects.",
"extended_description": "Ritonavir inhibits the metabolism of Alprazolam via CYP3A4, leading to increased plasma levels. This may enhance the sedative effects of Alprazolam, increasing the risk of CNS depression, dizziness, and respiratory depression. Close monitoring of sedation and respiratory status is necessary."
},
{
"drug": "Lamivudine",
"interacting_drug": "Zidovudine",
"description": "Lamivudine and Zidovudine co-administration can increase the risk of lactic acidosis.",
"extended_description": "Both Lamivudine and Zidovudine are nucleoside reverse transcriptase inhibitors (NRTIs), which have been associated with mitochondrial toxicity. Their combined use increases the risk of lactic acidosis, especially in patients with pre-existing renal or hepatic dysfunction. Monitoring for symptoms of lactic acidosis is recommended."
},
{
"drug": "Acyclovir",
"interacting_drug": "Methotrexate",
"description": "Methotrexate can increase the nephrotoxic effects of Acyclovir.",
"extended_description": "Methotrexate can impair renal function, which, when combined with Acyclovir, can lead to an increased risk of renal toxicity. Patients should be monitored for signs of nephrotoxicity, and renal function should be regularly assessed during co-administration."
},
{
"drug": "Valacyclovir",
"interacting_drug": "Ciclosporin",
"description": "Ciclosporin increases the plasma concentration of Valacyclovir, enhancing the risk of nephrotoxicity.",
"extended_description": "Ciclosporin inhibits renal excretion and can elevate plasma levels of Valacyclovir, increasing the risk of nephrotoxicity. Patients receiving both drugs should be closely monitored for signs of kidney damage, and dose adjustments may be necessary."
},
{
"drug": "Abacavir",
"interacting_drug": "Methadone",
"description": "Abacavir can increase Methadone levels, enhancing the sedative effects.",
"extended_description": "Abacavir inhibits the metabolism of Methadone, leading to higher plasma concentrations. This increases the risk of sedation, respiratory depression, and potential overdose, particularly in patients on chronic Methadone therapy. Monitoring of sedation and respiratory status is advised."
},
{
"drug": "Rifabutin",
"interacting_drug": "Ciprofloxacin",
"description": "Ciprofloxacin may reduce the efficacy of Rifabutin.",
"extended_description": "Ciprofloxacin inhibits CYP1A2 and may alter the metabolism of Rifabutin, reducing its plasma concentrations. This can decrease the antibacterial and antiviral efficacy of Rifabutin, especially in tuberculosis and HIV co-infected patients. Close monitoring and possible dose adjustments are recommended."
},

{
"drug": "Oseltamivir",
"interacting_drug": "Probenecid",
"description": "Probenecid may increase Oseltamivir levels, enhancing the risk of neuropsychiatric side effects.",
"extended_description": "Probenecid inhibits the renal excretion of Oseltamivir, leading to increased plasma concentrations. This can elevate the risk of neuropsychiatric events such as confusion, hallucinations, and agitation, especially in pediatric patients. Renal function should be closely monitored, and dose adjustments may be necessary."
},
{
"drug": "Darunavir",
"interacting_drug": "Cobicistat",
"description": "Cobicistat can increase Darunavir levels, leading to an increased risk of adverse reactions.",
"extended_description": "Cobicistat is a CYP3A4 inhibitor and is often co-administered with Darunavir to boost its plasma levels. This combination can lead to an increased risk of hepatotoxicity, gastrointestinal side effects, and cardiovascular complications. Liver function tests should be monitored regularly."
},
{
"drug": "Ganciclovir",
"interacting_drug": "Valproic acid",
"description": "Valproic acid can increase Ganciclovir levels, increasing the risk of hematologic toxicity.",
"extended_description": "Valproic acid inhibits renal clearance of Ganciclovir, which may lead to elevated plasma levels of Ganciclovir. This increases the risk of hematologic toxicity, including neutropenia, thrombocytopenia, and anemia. Regular blood counts and renal function monitoring are recommended."
},
{
"drug": "Lamivudine",
"interacting_drug": "Pegylated Interferon alfa",
"description": "Co-administration of Lamivudine with Pegylated Interferon alfa may increase the risk of liver toxicity.",
"extended_description": "Both Lamivudine and Pegylated Interferon alfa can have hepatotoxic effects. When used together in patients with hepatitis B or C, they can elevate liver enzymes, leading to liver injury. Liver function should be closely monitored, and dose adjustments may be necessary for patients with pre-existing liver disease."
},
{
"drug": "Entecavir",
"interacting_drug": "Rifampin",
"description": "Rifampin reduces Entecavir effectiveness, potentially leading to treatment failure.",
"extended_description": "Rifampin is a potent CYP3A4 inducer, which accelerates the metabolism of Entecavir, leading to decreased plasma levels and reduced antiviral efficacy. This interaction can lead to treatment failure in chronic hepatitis B patients. Alternative antimicrobial agents should be considered in such cases."
},
{
"drug": "Acyclovir",
"interacting_drug": "Cimetidine",
"description": "Cimetidine may increase Acyclovir levels, enhancing the risk of neurotoxicity.",
"extended_description": "Cimetidine inhibits renal tubular secretion of Acyclovir, which may increase its plasma levels, especially in patients with renal impairment. This may increase the risk of neurotoxicity, including seizures, confusion, and hallucinations. Dose adjustments may be needed, and renal function should be monitored."
},
{
"drug": "Sofosbuvir",
"interacting_drug": "Antacids",
"description": "Antacids may reduce Sofosbuvir absorption, decreasing its efficacy.",
"extended_description": "Antacids containing aluminum, magnesium, or calcium may decrease the absorption of Sofosbuvir, leading to suboptimal plasma concentrations and reduced efficacy in treating hepatitis C. To avoid this interaction, antacids should be taken at least 4 hours apart from Sofosbuvir."
},
{
"drug": "Valganciclovir",
"interacting_drug": "Didanosine",
"description": "Didanosine can increase Valganciclovir levels, heightening the risk of mitochondrial toxicity.",
"extended_description": "Didanosine inhibits the renal elimination of Valganciclovir, leading to higher plasma concentrations. This can increase the risk of mitochondrial toxicity, manifesting as pancreatitis, peripheral neuropathy, and lactic acidosis. Regular monitoring of renal function and for signs of toxicity is recommended."
},
{
"drug": "Ritonavir",
"interacting_drug": "Atazanavir",
"description": "Ritonavir can increase Atazanavir levels, increasing the risk of jaundice and other adverse effects.",
"extended_description": "Ritonavir is used to boost Atazanavir levels by inhibiting its metabolism. However, this can lead to elevated bilirubin levels, resulting in jaundice, as well as other side effects like gastrointestinal disturbances and hepatotoxicity. Monitoring liver function and bilirubin levels is advised."
},
{
"drug": "Telbivudine",
"interacting_drug": "Ribavirin",
"description": "Ribavirin can decrease the effectiveness of Telbivudine, increasing the risk of viral resistance.",
"extended_description": "Ribavirin is known to cause mutagenesis and can interfere with the antiviral activity of Telbivudine. When used together in hepatitis B or C patients, there is an increased risk of viral resistance and treatment failure. These drugs should be used cautiously in combination, and alternative therapies may be needed."
},
{
"drug": "Cobicistat",
"interacting_drug": "Etravirine",
"description": "Cobicistat may increase Etravirine levels, increasing the risk of side effects.",
"extended_description": "Cobicistat inhibits CYP3A4, which is responsible for metabolizing Etravirine. This can lead to increased plasma levels of Etravirine, which may heighten the risk of skin reactions, hepatotoxicity, and gastrointestinal disturbances. Patients should be monitored for these adverse effects, and dose adjustments may be necessary."
},
{
"drug": "Darunavir",
"interacting_drug": "Rifabutin",
"description": "Rifabutin can decrease Darunavir plasma levels, reducing its efficacy.",
"extended_description": "Rifabutin induces CYP3A4, the enzyme responsible for metabolizing Darunavir, leading to reduced plasma levels of Darunavir. This can result in suboptimal viral suppression in HIV patients. To mitigate this interaction, dose adjustments of Darunavir may be necessary when co-administering with Rifabutin."
},
{
"drug": "Abacavir",
"interacting_drug": "Methadone",
"description": "Methadone can increase Abacavir levels, raising the risk of side effects.",
"extended_description": "Methadone inhibits the glucuronidation of Abacavir, resulting in higher plasma concentrations of Abacavir. This may increase the risk of hypersensitivity reactions, including fever, rash, and respiratory symptoms. Close monitoring for these adverse effects is necessary when co-administering these drugs."
},
{
"drug": "Sofosbuvir",
"interacting_drug": "Amiodarone",
"description": "Amiodarone can increase the risk of bradycardia when used with Sofosbuvir.",
"extended_description": "The co-administration of Sofosbuvir with Amiodarone may increase the risk of severe bradycardia and other cardiovascular complications. This interaction is particularly concerning for patients with pre-existing cardiac conditions. Close monitoring of heart rate and rhythm is necessary, and the combination should be avoided if possible."
},
{
"drug": "Ritonavir",
"interacting_drug": "Warfarin",
"description": "Ritonavir may increase Warfarin levels, enhancing the risk of bleeding.",
"extended_description": "Ritonavir inhibits CYP2C9, which is responsible for metabolizing Warfarin. This can result in elevated Warfarin levels, increasing the risk of bleeding. Frequent monitoring of INR (International Normalized Ratio) and dose adjustments of Warfarin are essential during co-administration."
},
{
"drug": "Zidovudine",
"interacting_drug": "Methadone",
"description": "Methadone may reduce Zidovudine plasma levels, potentially decreasing its efficacy.",
"extended_description": "Methadone induces certain cytochrome P450 enzymes that metabolize Zidovudine, leading to lower plasma concentrations. This interaction may decrease the antiviral efficacy of Zidovudine, particularly in HIV treatment. Dose adjustments of Zidovudine may be required to maintain therapeutic efficacy."
},
{
"drug": "Valacyclovir",
"interacting_drug": "Warfarin",
"description": "Valacyclovir may increase Warfarin levels, enhancing the risk of bleeding.",
"extended_description": "Valacyclovir can increase plasma concentrations of Warfarin by inhibiting its metabolism via CYP2C9. This can result in an elevated INR and an increased risk of bleeding. Monitoring of INR and adjustment of Warfarin dose is recommended when co-administering with Valacyclovir."
},
{
"drug": "Ritonavir",
"interacting_drug": "Clarithromycin",
"description": "Clarithromycin may increase Ritonavir levels, enhancing the risk of side effects.",
"extended_description": "Clarithromycin is a CYP3A4 inhibitor and can increase the plasma concentration of Ritonavir. This interaction may enhance the risk of Ritonavir-related side effects such as gastrointestinal disturbances, hepatotoxicity, and cardiovascular complications. Regular monitoring of liver function and electrolytes is necessary."
},
{
"drug": "Valganciclovir",
"interacting_drug": "Trimethoprim-Sulfamethoxazole",
"description": "Trimethoprim-Sulfamethoxazole can increase Valganciclovir levels, heightening the risk of bone marrow suppression.",
"extended_description": "Trimethoprim-Sulfamethoxazole inhibits renal elimination of Valganciclovir, which can lead to increased plasma levels and an enhanced risk of bone marrow suppression, including neutropenia and thrombocytopenia. Regular blood counts should be monitored during co-administration."
},
{
"drug": "Acyclovir",
"interacting_drug": "Theophylline",
"description": "Acyclovir may increase Theophylline levels, increasing the risk of toxicity.",
"extended_description": "Acyclovir inhibits renal tubular secretion, which can increase plasma levels of Theophylline. This can lead to toxicity, manifesting as nausea, vomiting, seizures, and arrhythmias. Monitoring of Theophylline levels and renal function is recommended."
},
{
"drug": "Abacavir",
"interacting_drug": "Rifampin",
"description": "Rifampin can reduce Abacavir levels, potentially decreasing its efficacy.",
"extended_description": "Rifampin induces CYP enzymes that metabolize Abacavir, leading to decreased plasma concentrations of Abacavir. This can reduce the efficacy of the drug in treating HIV. Regular viral load monitoring and alternative treatment options may be necessary."
},

{
"drug": "Sofosbuvir",
"interacting_drug": "Amlodipine",
"description": "Amlodipine can increase Sofosbuvir levels, which may heighten the risk of bradycardia.",
"extended_description": "Amlodipine, a calcium channel blocker, can inhibit the metabolism of Sofosbuvir, leading to increased plasma concentrations. Elevated levels of Sofosbuvir may enhance the risk of bradycardia, especially in patients with underlying cardiac conditions. ECG monitoring is recommended during co-administration."
},
{
"drug": "Ritonavir",
"interacting_drug": "Dabigatran",
"description": "Ritonavir can increase Dabigatran levels, increasing the risk of bleeding.",
"extended_description": "Ritonavir inhibits P-glycoprotein, which is involved in the renal clearance of Dabigatran. Increased Dabigatran levels can elevate the risk of bleeding complications, including gastrointestinal and intracranial hemorrhage. Monitoring of renal function and coagulation parameters, including activated partial thromboplastin time (aPTT), is advised."
},
{
"drug": "Lamivudine",
"interacting_drug": "Cimetidine",
"description": "Cimetidine can increase Lamivudine plasma concentrations, increasing the risk of adverse effects.",
"extended_description": "Cimetidine inhibits renal tubular secretion of Lamivudine, leading to higher plasma concentrations. This interaction may increase the risk of side effects, such as nausea, dizziness, and lactic acidosis. Renal function should be closely monitored when co-administering these drugs."
},
{
"drug": "Valacyclovir",
"interacting_drug": "Metoclopramide",
"description": "Metoclopramide may increase Valacyclovir absorption, leading to elevated plasma levels.",
"extended_description": "Metoclopramide accelerates gastric emptying, which may increase the absorption of Valacyclovir. This could result in higher plasma concentrations and a greater risk of toxicity, including renal impairment. Renal function and drug plasma levels should be monitored during co-administration."
},
{
"drug": "Darunavir",
"interacting_drug": "Rifampin",
"description": "Rifampin reduces Darunavir levels, potentially leading to therapeutic failure.",
"extended_description": "Rifampin is a potent CYP3A4 inducer that accelerates the metabolism of Darunavir, reducing its plasma concentrations. This interaction may compromise the antiviral efficacy of Darunavir, increasing the risk of HIV treatment failure. Alternative antibiotics should be considered for patients on Darunavir therapy."
},
{
"drug": "Efavirenz",
"interacting_drug": "Methadone",
"description": "Methadone can decrease Efavirenz plasma levels, which may reduce its effectiveness.",
"extended_description": "Methadone induces CYP3A4, which increases the metabolism of Efavirenz, potentially reducing its plasma concentrations. This may lead to suboptimal treatment for HIV patients. Dose adjustments of Efavirenz may be required, and regular monitoring of HIV viral load is recommended."
},
{
"drug": "Zidovudine",
"interacting_drug": "St. John’s Wort",
"description": "St. John’s Wort may decrease Zidovudine levels, potentially leading to treatment failure.",
"extended_description": "St. John’s Wort is a potent inducer of CYP3A4 and P-glycoprotein, which accelerates the metabolism of Zidovudine. This may lead to reduced plasma concentrations of Zidovudine, potentially resulting in treatment failure and the development of drug resistance. Monitoring of viral load and potential dose adjustments are recommended."
},
{
"drug": "Acyclovir",
"interacting_drug": "Probenecid",
"description": "Probenecid can increase Acyclovir levels, enhancing the risk of nephrotoxicity.",
"extended_description": "Probenecid inhibits the renal tubular secretion of Acyclovir, leading to increased plasma concentrations. This can increase the risk of nephrotoxicity, especially in patients with pre-existing renal impairment. Renal function should be monitored regularly, and dose adjustments may be necessary."
},
{
"drug": "Sofosbuvir",
"interacting_drug": "Carbamazepine",
"description": "Carbamazepine can reduce Sofosbuvir plasma concentrations, potentially decreasing its efficacy.",
"extended_description": "Carbamazepine is a CYP3A4 inducer that increases the metabolism of Sofosbuvir, reducing its plasma concentrations. This can reduce the antiviral efficacy of Sofosbuvir in treating hepatitis C. Alternative anticonvulsants should be considered in patients on Sofosbuvir therapy."
},
{
"drug": "Ritonavir",
"interacting_drug": "Atorvastatin",
"description": "Ritonavir can increase Atorvastatin levels, increasing the risk of statin-related side effects.",
"extended_description": "Ritonavir inhibits CYP3A4, which metabolizes Atorvastatin. This can lead to increased Atorvastatin plasma concentrations, heightening the risk of statin-related side effects such as myopathy and rhabdomyolysis. Dose adjustments of Atorvastatin may be required, and patients should be monitored for muscle pain and weakness."
},
{
"drug": "Lamivudine",
"interacting_drug": "Trimethoprim-Sulfamethoxazole",
"description": "Trimethoprim-Sulfamethoxazole can increase Lamivudine levels, potentially leading to toxicity.",
"extended_description": "Trimethoprim-Sulfamethoxazole inhibits renal clearance of Lamivudine, which can lead to increased plasma concentrations. This may elevate the risk of side effects such as lactic acidosis, fatigue, and hepatotoxicity. Renal function should be monitored, and dose adjustments may be necessary."
},
{
"drug": "Abacavir",
"interacting_drug": "Amitriptyline",
"description": "Amitriptyline can increase Abacavir levels, potentially leading to adverse effects.",
"extended_description": "Amitriptyline inhibits the glucuronidation of Abacavir, which can result in increased plasma concentrations. This may heighten the risk of hypersensitivity reactions, including fever, rash, and difficulty breathing. Close monitoring for these adverse effects is essential, particularly in patients with a history of hypersensitivity to Abacavir."
},
{
"drug": "Oseltamivir",
"interacting_drug": "Sodium bicarbonate",
"description": "Sodium bicarbonate can reduce the absorption of Oseltamivir, decreasing its efficacy.",
"extended_description": "Sodium bicarbonate can increase gastric pH, which may reduce the absorption of Oseltamivir, leading to suboptimal plasma concentrations and reduced antiviral activity. To avoid this interaction, sodium bicarbonate and Oseltamivir should be taken several hours apart."
},
{
"drug": "Acyclovir",
"interacting_drug": "Cisplatin",
"description": "Cisplatin can increase the nephrotoxic potential of Acyclovir.",
"extended_description": "Cisplatin is a nephrotoxic chemotherapeutic agent, and when combined with Acyclovir, the risk of renal impairment is heightened. This interaction is particularly concerning for patients with pre-existing kidney dysfunction. Adequate hydration and renal monitoring are essential during co-administration."
},
{
"drug": "Darunavir",
"interacting_drug": "Ketoconazole",
"description": "Ketoconazole may increase Darunavir levels, raising the risk of adverse events.",
"extended_description": "Ketoconazole inhibits CYP3A4, which is responsible for metabolizing Darunavir. This interaction can increase the plasma concentration of Darunavir, potentially enhancing the risk of hepatotoxicity, gastrointestinal disturbances, and cardiovascular events. Liver function and electrolyte levels should be monitored."
},
{
"drug": "Sofosbuvir",
"interacting_drug": "Omeprazole",
"description": "Omeprazole may reduce Sofosbuvir efficacy by decreasing its absorption.",
"extended_description": "Omeprazole, a proton pump inhibitor, can reduce the acidity of the stomach, potentially decreasing the absorption of Sofosbuvir. This interaction can lower plasma concentrations of Sofosbuvir, reducing its antiviral activity. Sofosbuvir should be taken with food, and proton pump inhibitors should be used cautiously."
},
{
"drug": "Efavirenz",
"interacting_drug": "Methadone",
"description": "Methadone can increase Efavirenz levels, raising the risk of central nervous system side effects.",
"extended_description": "Methadone is a CYP3A4 substrate and may inhibit the metabolism of Efavirenz, leading to elevated plasma concentrations. This can increase the risk of neuropsychiatric side effects, including dizziness, insomnia, and mood disturbances. Patients should be monitored for these symptoms, and dose adjustments may be necessary."
},
{
"drug": "Tenofovir",
"interacting_drug": "Didanosine",
"description": "Didanosine can increase Tenofovir levels, increasing the risk of renal toxicity.",
"extended_description": "Didanosine inhibits renal tubular secretion of Tenofovir, which can increase its plasma concentration. This can enhance the risk of renal toxicity, particularly in patients with pre-existing renal dysfunction. Renal function should be closely monitored during co-administration."
},
{
"drug": "Valacyclovir",
"interacting_drug": "Cimetidine",
"description": "Cimetidine can increase Valacyclovir plasma levels, leading to increased toxicity.",
"extended_description": "Cimetidine inhibits the renal clearance of Valacyclovir, leading to higher plasma concentrations. This may increase the risk of toxicity, including renal impairment and central nervous system side effects such as confusion and hallucinations, especially in elderly patients."
}, 

{
"drug": "Raltegravir",
"interacting_drug": "Mylanta",
"description": "Mylanta can decrease Raltegravir absorption, reducing its effectiveness.",
"extended_description": "Mylanta, an antacid, can increase gastric pH, which may reduce the absorption of Raltegravir. This can lead to suboptimal plasma concentrations and decreased antiviral activity. To avoid this interaction, Raltegravir and Mylanta should be taken at least two hours apart."
},
{
"drug": "Lamivudine",
"interacting_drug": "Probenecid",
"description": "Probenecid may increase Lamivudine levels, leading to an increased risk of side effects.",
"extended_description": "Probenecid inhibits the renal tubular secretion of Lamivudine, causing an increase in its plasma concentration. Elevated Lamivudine levels may increase the risk of adverse effects such as lactic acidosis and hepatotoxicity. Close monitoring of renal function and drug levels is recommended."
},
{
"drug": "Acyclovir",
"interacting_drug": "Tacrolimus",
"description": "Tacrolimus can increase Acyclovir levels, raising the risk of nephrotoxicity.",
"extended_description": "Tacrolimus inhibits renal clearance of Acyclovir, which can lead to elevated plasma levels of Acyclovir. This increases the risk of nephrotoxicity, particularly in patients with pre-existing renal dysfunction. Renal function should be carefully monitored, and dose adjustments may be required."
},
{
"drug": "Sofosbuvir",
"interacting_drug": "Carbamazepine",
"description": "Carbamazepine can decrease Sofosbuvir plasma concentrations, leading to reduced effectiveness.",
"extended_description": "Carbamazepine is a CYP3A4 inducer, which can accelerate the metabolism of Sofosbuvir, reducing its plasma concentrations. This may compromise the efficacy of Sofosbuvir in treating hepatitis C. Alternative anticonvulsants should be considered for patients on Sofosbuvir therapy."
},
{
"drug": "Valacyclovir",
"interacting_drug": "Ciclosporin",
"description": "Ciclosporin can increase Valacyclovir levels, increasing the risk of renal toxicity.",
"extended_description": "Ciclosporin inhibits renal clearance of Valacyclovir, leading to higher plasma concentrations. This may increase the risk of nephrotoxicity, particularly in patients with pre-existing renal impairment. Renal function should be monitored, and dose adjustments may be needed."
},
{
"drug": "Efavirenz",
"interacting_drug": "Antacids",
"description": "Antacids may reduce Efavirenz absorption, decreasing its efficacy.",
"extended_description": "Antacids can increase gastric pH and reduce the absorption of Efavirenz. This can result in lower plasma concentrations of Efavirenz and reduced antiviral activity. To avoid this interaction, antacids should be taken at least two hours before or after Efavirenz."
},
{
"drug": "Darunavir",
"interacting_drug": "Voriconazole",
"description": "Voriconazole may increase Darunavir levels, raising the risk of side effects.",
"extended_description": "Voriconazole is a potent CYP3A4 inhibitor and can increase Darunavir plasma concentrations. This increases the risk of hepatotoxicity, gastrointestinal disturbances, and other adverse effects. Liver function should be monitored, and dose adjustments of Darunavir may be necessary."
},
{
"drug": "Tenofovir",
"interacting_drug": "Aspirin",
"description": "Aspirin can reduce Tenofovir renal clearance, increasing the risk of nephrotoxicity.",
"extended_description": "Aspirin may reduce renal clearance of Tenofovir, resulting in elevated plasma levels. This increases the risk of nephrotoxicity, particularly in patients with pre-existing renal dysfunction. Renal function should be closely monitored when co-administering these drugs."
},
{
"drug": "Zidovudine",
"interacting_drug": "Acetaminophen",
"description": "Acetaminophen may increase the risk of hepatotoxicity when used with Zidovudine.",
"extended_description": "Both Zidovudine and Acetaminophen can potentially cause liver toxicity. When used together, the risk of hepatotoxicity may increase, especially in patients with pre-existing liver disease or those receiving high doses of Acetaminophen. Liver function should be monitored closely."
},
{
"drug": "Sofosbuvir",
"interacting_drug": "Cimetidine",
"description": "Cimetidine may reduce Sofosbuvir absorption, decreasing its antiviral efficacy.",
"extended_description": "Cimetidine, a histamine H2 receptor antagonist, may increase gastric pH and reduce the absorption of Sofosbuvir. Lower plasma concentrations may compromise the efficacy of Sofosbuvir in treating hepatitis C. These medications should be taken at different times to prevent interaction."
},
{
"drug": "Ritonavir",
"interacting_drug": "Amiodarone",
"description": "Amiodarone can increase Ritonavir levels, raising the risk of cardiac arrhythmias.",
"extended_description": "Amiodarone inhibits the metabolism of Ritonavir, which can increase its plasma concentrations. Elevated Ritonavir levels may enhance the risk of QT prolongation and other cardiac arrhythmias, especially in patients with pre-existing cardiac conditions. ECG monitoring is recommended."
},
{
"drug": "Abacavir",
"interacting_drug": "Ranitidine",
"description": "Ranitidine can reduce Abacavir absorption, leading to reduced therapeutic efficacy.",
"extended_description": "Ranitidine may increase gastric pH, which could impair the absorption of Abacavir. This interaction can result in lower plasma concentrations of Abacavir and reduced antiviral effectiveness. The drugs should be administered several hours apart to avoid this interaction."
},
{
"drug": "Acyclovir",
"interacting_drug": "Angiotensin-converting enzyme (ACE) inhibitors",
"description": "ACE inhibitors may increase Acyclovir plasma levels, leading to renal toxicity.",
"extended_description": "ACE inhibitors may decrease renal perfusion, potentially increasing Acyclovir plasma concentrations. This interaction can enhance the risk of nephrotoxicity, especially in patients with compromised renal function. Renal function should be monitored, and dose adjustments may be needed."
},
{
"drug": "Lamivudine",
"interacting_drug": "Sulfamethoxazole-Trimethoprim",
"description": "Sulfamethoxazole-Trimethoprim can increase Lamivudine plasma levels, enhancing the risk of toxicity.",
"extended_description": "Sulfamethoxazole-Trimethoprim inhibits the renal clearance of Lamivudine, leading to higher plasma concentrations. This may increase the risk of side effects such as lactic acidosis and hepatotoxicity. Renal function should be monitored, and dose adjustments may be required."
},
{
"drug": "Darunavir",
"interacting_drug": "Dexamethasone",
"description": "Dexamethasone can reduce Darunavir levels, potentially reducing its antiviral efficacy.",
"extended_description": "Dexamethasone is a CYP3A4 inducer and may accelerate the metabolism of Darunavir, reducing its plasma concentrations. This can result in a diminished antiviral response. Alternative corticosteroids should be considered for patients receiving Darunavir."
},
{
"drug": "Sofosbuvir",
"interacting_drug": "Amiodarone",
"description": "Amiodarone may increase the risk of bradycardia when used with Sofosbuvir.",
"extended_description": "Amiodarone can increase the plasma concentration of Sofosbuvir, which may enhance its bradycardic effects. In some cases, severe bradycardia has been reported. Continuous cardiac monitoring is recommended when these drugs are co-administered."
},
{
"drug": "Zidovudine",
"interacting_drug": "Ganciclovir",
"description": "Ganciclovir can increase Zidovudine levels, leading to a heightened risk of hematologic toxicity.",
"extended_description": "Ganciclovir can inhibit the renal clearance of Zidovudine, resulting in increased plasma levels of Zidovudine. This can increase the risk of hematologic toxicity, such as anemia, neutropenia, and thrombocytopenia. Blood counts should be closely monitored."
},
{
"drug": "Tenofovir",
"interacting_drug": "Cobicistat",
"description": "Cobicistat can increase Tenofovir levels, enhancing the risk of nephrotoxicity.",
"extended_description": "Cobicistat inhibits the renal elimination of Tenofovir, leading to higher plasma concentrations. This increases the risk of nephrotoxicity, particularly in patients with pre-existing kidney impairment. Renal function should be monitored during co-administration of these drugs."
},
{
"drug": "Efavirenz",
"interacting_drug": "Ethanol",
"description": "Ethanol may enhance the central nervous system side effects of Efavirenz.",
"extended_description": "Ethanol can exacerbate the neuropsychiatric side effects of Efavirenz, such as dizziness, insomnia, and mood changes. Co-consumption of alcohol and Efavirenz should be avoided, and patients should be monitored for neuropsychiatric symptoms."
},
{
"drug": "Fluconazole",
"interacting_drug": "Warfarin",
"description": "Fluconazole can increase Warfarin levels, increasing the risk of bleeding.",
"extended_description": "Fluconazole inhibits CYP2C9, an enzyme responsible for metabolizing Warfarin. This can lead to elevated INR and an increased risk of bleeding. Close monitoring of INR is recommended during co-administration."
},
{
"drug": "Itraconazole",
"interacting_drug": "Digoxin",
"description": "Itraconazole can increase Digoxin levels, increasing the risk of toxicity.",
"extended_description": "Itraconazole inhibits the P-glycoprotein transporter and CYP3A4, leading to higher plasma concentrations of Digoxin. Elevated Digoxin levels may cause nausea, vomiting, and life-threatening arrhythmias. Therapeutic drug monitoring is advised."
},
{
"drug": "Ketoconazole",
"interacting_drug": "Midazolam",
"description": "Ketoconazole can increase Midazolam levels, leading to prolonged sedation.",
"extended_description": "Ketoconazole is a potent CYP3A4 inhibitor, which can slow the metabolism of Midazolam. This results in increased sedative effects and may cause excessive sedation, respiratory depression, or hypotension. Careful monitoring of sedation levels is advised."
},
{
"drug": "Posaconazole",
"interacting_drug": "Rifampin",
"description": "Rifampin can reduce Posaconazole levels, diminishing its antifungal effectiveness.",
"extended_description": "Rifampin is a CYP3A4 inducer and accelerates the metabolism of Posaconazole, leading to decreased plasma concentrations. This can result in therapeutic failure. Alternative antifungal therapy should be considered."
},
{
"drug": "Voriconazole",
"interacting_drug": "Phenytoin",
"description": "Phenytoin can decrease Voriconazole levels, leading to treatment failure.",
"extended_description": "Phenytoin is a potent CYP3A4 inducer that increases the metabolism of Voriconazole, reducing its plasma concentration. This interaction may compromise the efficacy of Voriconazole in treating invasive fungal infections. Adjusting the dose of Voriconazole is often necessary."
},
{
"drug": "Fluconazole",
"interacting_drug": "Cyclosporine",
"description": "Fluconazole can increase Cyclosporine levels, leading to nephrotoxicity.",
"extended_description": "Fluconazole inhibits the CYP3A4 enzyme, which is responsible for metabolizing Cyclosporine. This can result in elevated Cyclosporine levels and increase the risk of nephrotoxicity. Renal function and Cyclosporine levels should be monitored closely."
},
{
"drug": "Itraconazole",
"interacting_drug": "Tacrolimus",
"description": "Itraconazole can increase Tacrolimus levels, raising the risk of nephrotoxicity.",
"extended_description": "Itraconazole inhibits CYP3A4, which is involved in the metabolism of Tacrolimus. Increased Tacrolimus levels can lead to nephrotoxicity, particularly in patients with pre-existing kidney disease. Monitoring Tacrolimus levels and renal function is necessary."
},
{
"drug": "Fluconazole",
"interacting_drug": "Statins (e.g., Atorvastatin)",
"description": "Fluconazole can increase Statin levels, leading to an increased risk of myopathy.",
"extended_description": "Fluconazole inhibits CYP3A4, which metabolizes statins. Elevated statin levels can increase the risk of adverse effects, including myopathy and rhabdomyolysis. Monitoring of creatine kinase (CK) levels and adjusting statin dosage may be required."
},
{
"drug": "Itraconazole",
"interacting_drug": "Alprazolam",
"description": "Itraconazole can increase Alprazolam levels, enhancing sedative effects.",
"extended_description": "Itraconazole inhibits CYP3A4, slowing the metabolism of Alprazolam and increasing plasma concentrations. This interaction can lead to excessive sedation, respiratory depression, and impaired coordination. Dosing adjustments for Alprazolam may be necessary."
},
{
"drug": "Fluconazole",
"interacting_drug": "Sulfonylureas (e.g., Glipizide)",
"description": "Fluconazole can increase the hypoglycemic effects of Sulfonylureas.",
"extended_description": "Fluconazole inhibits CYP2C9, which is involved in the metabolism of sulfonylureas like Glipizide. This can lead to increased sulfonylurea levels and enhance the risk of hypoglycemia. Blood glucose levels should be closely monitored."
},
{
"drug": "Posaconazole",
"interacting_drug": "Carbamazepine",
"description": "Carbamazepine can decrease Posaconazole levels, reducing its antifungal effectiveness.",
"extended_description": "Carbamazepine is a CYP3A4 inducer and increases the metabolism of Posaconazole, leading to decreased plasma concentrations. This interaction may result in suboptimal antifungal therapy. The use of alternative antifungals may be necessary."
},
{
"drug": "Ketoconazole",
"interacting_drug": "Benzodiazepines (e.g., Diazepam)",
"description": "Ketoconazole can increase the sedative effects of Benzodiazepines.",
"extended_description": "Ketoconazole inhibits CYP3A4, which is responsible for metabolizing Benzodiazepines like Diazepam. Increased Benzodiazepine levels can result in excessive sedation, respiratory depression, and impaired cognitive function. Monitoring of sedation levels is essential."
},
{
"drug": "Voriconazole",
"interacting_drug": "Cimetidine",
"description": "Cimetidine can increase Voriconazole levels, enhancing the risk of hepatotoxicity.",
"extended_description": "Cimetidine inhibits CYP2C19 and CYP3A4, enzymes involved in the metabolism of Voriconazole. This can lead to elevated plasma concentrations, increasing the risk of hepatotoxicity and other side effects. Monitoring liver function is essential during co-administration."
},
{
"drug": "Fluconazole",
"interacting_drug": "Clopidogrel",
"description": "Fluconazole can increase Clopidogrel plasma levels, potentially enhancing bleeding risk.",
"extended_description": "Fluconazole inhibits CYP2C19, which plays a role in metabolizing Clopidogrel. Increased plasma concentrations of Clopidogrel can enhance its antiplatelet effects and increase bleeding risk. Close monitoring of platelet function and bleeding tendencies is recommended."
},
{
"drug": "Itraconazole",
"interacting_drug": "Verapamil",
"description": "Itraconazole can increase Verapamil levels, raising the risk of hypotension and bradycardia.",
"extended_description": "Itraconazole inhibits CYP3A4, which metabolizes Verapamil. Elevated Verapamil levels can lead to severe bradycardia, hypotension, and atrioventricular block. Monitoring of blood pressure and heart rate is necessary during co-administration."
},
{
"drug": "Posaconazole",
"interacting_drug": "Simvastatin",
"description": "Posaconazole can increase Simvastatin levels, raising the risk of myopathy.",
"extended_description": "Posaconazole inhibits CYP3A4, which is responsible for metabolizing Simvastatin. Elevated Simvastatin levels can lead to an increased risk of muscle toxicity, including myopathy and rhabdomyolysis. Monitoring creatine kinase (CK) levels and adjusting Simvastatin dosage may be needed."
},
{
"drug": "Fluconazole",
"interacting_drug": "Phenytoin",
"description": "Fluconazole can increase Phenytoin levels, enhancing the risk of toxicity.",
"extended_description": "Fluconazole inhibits CYP2C9, which metabolizes Phenytoin. Increased Phenytoin levels can lead to side effects such as nystagmus, ataxia, and gingival hyperplasia. Close monitoring of Phenytoin levels and dose adjustments are recommended."
},
{
"drug": "Voriconazole",
"interacting_drug": "Tacrolimus",
"description": "Voriconazole can increase Tacrolimus levels, leading to nephrotoxicity.",
"extended_description": "Voriconazole inhibits CYP3A4, which is responsible for the metabolism of Tacrolimus. Elevated Tacrolimus levels can increase the risk of nephrotoxicity. Renal function and Tacrolimus levels should be closely monitored, and dose adjustments may be necessary."
},
{
"drug": "Itraconazole",
"interacting_drug": "Erythromycin",
"description": "Erythromycin can increase Itraconazole levels, raising the risk of hepatotoxicity.",
"extended_description": "Erythromycin inhibits CYP3A4, which metabolizes Itraconazole. Elevated plasma concentrations of Itraconazole can lead to hepatotoxicity and QT prolongation. Liver function tests should be monitored during co-administration."
},
{
"drug": "Fluconazole",
"interacting_drug": "Methadone",
"description": "Fluconazole can increase Methadone levels, leading to sedation and respiratory depression.",
"extended_description": "Fluconazole inhibits CYP3A4, which is involved in the metabolism of Methadone. Elevated Methadone levels can result in excessive sedation, respiratory depression, and an increased risk of overdose. Monitoring of sedation levels and respiratory function is essential."
},
{
"drug": "Ketoconazole",
"interacting_drug": "Rifampin",
"description": "Rifampin can decrease Ketoconazole levels, reducing its antifungal effectiveness.",
"extended_description": "Rifampin is a potent CYP3A4 inducer and accelerates the metabolism of Ketoconazole, leading to decreased plasma concentrations. This may reduce the therapeutic efficacy of Ketoconazole. Adjustments to therapy or alternative antifungal agents may be necessary."
},
{
"drug": "Fluconazole",
"interacting_drug": "Chlorpropamide",
"description": "Fluconazole can increase Chlorpropamide levels, raising the risk of hypoglycemia.",
"extended_description": "Fluconazole inhibits CYP2C9, an enzyme responsible for the metabolism of Chlorpropamide, a sulfonylurea. Elevated Chlorpropamide levels can enhance its hypoglycemic effects, leading to a risk of severe hypoglycemia. Close monitoring of blood glucose is necessary."
},
{
"drug": "Itraconazole",
"interacting_drug": "Cisapride",
"description": "Itraconazole can increase Cisapride levels, leading to an increased risk of arrhythmias.",
"extended_description": "Itraconazole inhibits CYP3A4, which metabolizes Cisapride. Elevated Cisapride levels can result in QT interval prolongation, potentially leading to life-threatening arrhythmias such as torsades de pointes. This combination should be avoided, and ECG monitoring is essential if co-administration is unavoidable."
},
{
"drug": "Voriconazole",
"interacting_drug": "Phenytoin",
"description": "Voriconazole can decrease Phenytoin levels, leading to seizures.",
"extended_description": "Voriconazole induces CYP2C9 and inhibits CYP2C19, both of which metabolize Phenytoin. The altered metabolism may decrease Phenytoin levels, leading to suboptimal seizure control. Adjusting the Phenytoin dose and close monitoring of therapeutic drug levels is necessary."
},
{
"drug": "Fluconazole",
"interacting_drug": "Immunosuppressive agents (e.g., Azathioprine)",
"description": "Fluconazole can increase the levels of Azathioprine, raising the risk of bone marrow suppression.",
"extended_description": "Fluconazole inhibits the CYP1A2 and CYP3A4 enzymes, which metabolize Azathioprine. Elevated Azathioprine levels may result in increased immunosuppression and bone marrow suppression. Monitoring complete blood count (CBC) and adjusting Azathioprine dosage may be required."
},
{
"drug": "Itraconazole",
"interacting_drug": "Cyclosporine",
"description": "Itraconazole can increase Cyclosporine levels, increasing the risk of nephrotoxicity.",
"extended_description": "Itraconazole inhibits CYP3A4, which is involved in the metabolism of Cyclosporine. Elevated Cyclosporine levels can lead to nephrotoxicity, particularly in patients with pre-existing kidney conditions. Regular monitoring of renal function and Cyclosporine levels is recommended."
},
{
"drug": "Posaconazole",
"interacting_drug": "Warfarin",
"description": "Posaconazole can increase Warfarin levels, increasing the risk of bleeding.",
"extended_description": "Posaconazole inhibits CYP2C9, an enzyme responsible for metabolizing Warfarin. Increased Warfarin concentrations can elevate INR, leading to an increased bleeding risk. Careful monitoring of INR and potential Warfarin dose adjustments are advised."
},
{
"drug": "Ketoconazole",
"interacting_drug": "Tacrolimus",
"description": "Ketoconazole can increase Tacrolimus levels, enhancing the risk of nephrotoxicity.",
"extended_description": "Ketoconazole inhibits CYP3A4, which metabolizes Tacrolimus. Elevated Tacrolimus levels can increase the risk of nephrotoxicity, requiring regular monitoring of renal function and Tacrolimus levels, with dose adjustments as necessary."
},
{
"drug": "Fluconazole",
"interacting_drug": "Clopidogrel",
"description": "Fluconazole can increase Clopidogrel plasma levels, potentiating bleeding risk.",
"extended_description": "Fluconazole inhibits CYP2C19, an enzyme involved in the metabolism of Clopidogrel. This can result in elevated Clopidogrel levels and enhanced platelet inhibition, increasing the risk of bleeding. Close monitoring of platelet function is recommended."
},
{
"drug": "Voriconazole",
"interacting_drug": "Cimetidine",
"description": "Cimetidine can increase Voriconazole levels, leading to hepatotoxicity.",
"extended_description": "Cimetidine inhibits several cytochrome P450 enzymes, including CYP2C19 and CYP3A4, responsible for metabolizing Voriconazole. Elevated Voriconazole levels may increase the risk of hepatotoxicity. Liver function tests should be closely monitored during co-administration."
},
{
"drug": "Itraconazole",
"interacting_drug": "Benzodiazepines (e.g., Lorazepam)",
"description": "Itraconazole can increase Lorazepam levels, leading to excessive sedation.",
"extended_description": "Itraconazole inhibits CYP3A4, which is responsible for metabolizing Lorazepam. Increased Lorazepam levels can cause prolonged sedation, respiratory depression, and cognitive impairment. Dose reduction of Lorazepam and close monitoring of sedation is advised."
},
{
"drug": "Fluconazole",
"interacting_drug": "Tacrolimus",
"description": "Fluconazole can increase Tacrolimus levels, leading to nephrotoxicity.",
"extended_description": "Fluconazole inhibits CYP3A4, which metabolizes Tacrolimus. Elevated Tacrolimus levels can increase the risk of nephrotoxicity and require close monitoring of renal function and Tacrolimus levels."
},
{
"drug": "Voriconazole",
"interacting_drug": "Rifampin",
"description": "Rifampin can decrease Voriconazole levels, reducing its efficacy.",
"extended_description": "Rifampin is a potent CYP3A4 inducer, which accelerates the metabolism of Voriconazole, reducing its plasma concentration. This may compromise its antifungal effectiveness. Alternative therapy should be considered, or the Voriconazole dose may need adjustment."
},
{
"drug": "Fluconazole",
"interacting_drug": "Amiodarone",
"description": "Fluconazole can increase Amiodarone levels, increasing the risk of arrhythmias.",
"extended_description": "Fluconazole inhibits CYP2C9, CYP3A4, and CYP1A2, which metabolize Amiodarone. Elevated Amiodarone levels can lead to QT prolongation and increase the risk of life-threatening arrhythmias. ECG monitoring and dose adjustments may be required."
},
{
"drug": "Ketoconazole",
"interacting_drug": "Lopinavir/Ritonavir",
"description": "Ketoconazole can increase Lopinavir levels, increasing the risk of toxicity.",
"extended_description": "Ketoconazole inhibits CYP3A4, which is responsible for metabolizing Lopinavir. Elevated Lopinavir levels may lead to increased adverse effects, including gastrointestinal disturbances and hepatotoxicity. Monitoring liver function is important, and dose reduction may be necessary."
},
{
"drug": "Posaconazole",
"interacting_drug": "Dexamethasone",
"description": "Dexamethasone can decrease Posaconazole levels, reducing its antifungal efficacy.",
"extended_description": "Dexamethasone is a CYP3A4 inducer and can increase the metabolism of Posaconazole, reducing its plasma concentration and therapeutic effect. If co-administration is necessary, an increase in the Posaconazole dose may be required."
},
{
"drug": "Itraconazole",
"interacting_drug": "Ciclosporin",
"description": "Itraconazole can increase Ciclosporin levels, enhancing the risk of nephrotoxicity.",
"extended_description": "Itraconazole inhibits CYP3A4, which metabolizes Ciclosporin. Elevated Ciclosporin levels may increase the risk of nephrotoxicity, and close monitoring of renal function and Ciclosporin levels is essential during co-administration."
},
{
"drug": "Voriconazole",
"interacting_drug": "Erythromycin",
"description": "Erythromycin can increase Voriconazole levels, enhancing the risk of hepatotoxicity.",
"extended_description": "Erythromycin inhibits CYP3A4, which is responsible for metabolizing Voriconazole. Elevated Voriconazole levels can increase the risk of hepatotoxicity, requiring careful liver function monitoring during treatment."
},
{
"drug": "Fluconazole",
"interacting_drug": "Clarithromycin",
"description": "Clarithromycin can increase Fluconazole levels, increasing the risk of hepatotoxicity.",
"extended_description": "Clarithromycin inhibits CYP3A4 and CYP2C9, both of which metabolize Fluconazole. Elevated Fluconazole levels can lead to hepatotoxicity. Monitoring of liver function and adjusting the Fluconazole dose may be necessary."
},
{
"drug": "Ketoconazole",
"interacting_drug": "Ergotamine",
"description": "Ketoconazole can increase Ergotamine levels, leading to ergot toxicity.",
"extended_description": "Ketoconazole inhibits CYP3A4, which metabolizes Ergotamine. Elevated Ergotamine levels can lead to severe toxicity, including vasoconstriction, peripheral ischemia, and gangrene. This combination should generally be avoided."
},
{
"drug": "Posaconazole",
"interacting_drug": "St. John's Wort",
"description": "St. John's Wort can decrease Posaconazole levels, reducing its antifungal efficacy.",
"extended_description": "St. John's Wort is a CYP3A4 inducer and accelerates the metabolism of Posaconazole, reducing its plasma concentrations and potentially resulting in treatment failure. Avoid concomitant use or consider increasing the Posaconazole dose."
},
{
"drug": "Voriconazole",
"interacting_drug": "Phenobarbital",
"description": "Phenobarbital can decrease Voriconazole levels, leading to reduced efficacy.",
"extended_description": "Phenobarbital is a CYP3A4 inducer, and its co-administration with Voriconazole can reduce the plasma concentration of Voriconazole, impairing its antifungal action. Dose adjustment of Voriconazole or alternative therapy may be required."
},
{
"drug": "Itraconazole",
"interacting_drug": "Rifabutin",
"description": "Rifabutin can increase Itraconazole levels, increasing the risk of hepatotoxicity.",
"extended_description": "Rifabutin inhibits CYP3A4, which is responsible for metabolizing Itraconazole. Elevated Itraconazole levels can increase the risk of hepatotoxicity and other side effects. Monitoring liver function and adjusting Itraconazole dosage may be necessary."
},

{
"drug": "Diphenhydramine",
"interacting_drug": "Monoamine oxidase inhibitors (MAOIs)",
"description": "Diphenhydramine can increase the risk of hypertensive crisis when taken with MAOIs.",
"extended_description": "Diphenhydramine has anticholinergic properties, and when combined with MAOIs, it may enhance the risk of severe hypertensive episodes. This occurs due to the combined effects on neurotransmitter reuptake and sympathetic stimulation, leading to elevated blood pressure and hypertensive crisis. Avoid co-administration whenever possible."
},
{
"drug": "Cetirizine",
"interacting_drug": "CNS depressants (e.g., alcohol, benzodiazepines)",
"description": "Cetirizine may enhance the sedative effects of CNS depressants.",
"extended_description": "Cetirizine, though a second-generation antihistamine with minimal sedative effects, can still enhance the CNS depressant properties of alcohol and benzodiazepines, increasing the risk of drowsiness, impaired coordination, and respiratory depression. Caution should be exercised when using these drugs together."
},
{
"drug": "Loratadine",
"interacting_drug": "Erythromycin",
"description": "Erythromycin can increase Loratadine plasma levels, leading to QT prolongation.",
"extended_description": "Erythromycin inhibits the CYP3A4 enzyme, which is responsible for metabolizing Loratadine. Elevated Loratadine levels can increase the risk of QT interval prolongation and torsades de pointes. Electrocardiogram (ECG) monitoring is recommended for patients on this combination."
},
{
"drug": "Fexofenadine",
"interacting_drug": "Grapefruit juice",
"description": "Grapefruit juice can decrease the bioavailability of Fexofenadine.",
"extended_description": "Grapefruit juice inhibits OATP1A2, a transporter responsible for the absorption of Fexofenadine in the intestine. Reduced absorption can lead to suboptimal therapeutic effects. Patients should avoid consuming grapefruit juice while taking Fexofenadine to ensure full efficacy."
},
{
"drug": "Chlorpheniramine",
"interacting_drug": "CNS depressants (e.g., alcohol, opioids)",
"description": "Chlorpheniramine can enhance CNS depressant effects, leading to sedation and respiratory depression.",
"extended_description": "Chlorpheniramine is a first-generation antihistamine with significant sedative properties, and when taken with other CNS depressants such as alcohol or opioids, it can potentiate drowsiness, sedation, and respiratory depression. Caution is required when co-administering these drugs."
},
{
"drug": "Desloratadine",
"interacting_drug": "Ritonavir",
"description": "Ritonavir can increase Desloratadine levels, enhancing the risk of side effects.",
"extended_description": "Ritonavir is a potent CYP3A4 inhibitor, which can slow the metabolism of Desloratadine, leading to elevated plasma concentrations. This may increase the likelihood of adverse effects, including dry mouth, headache, and drowsiness. Monitoring for adverse reactions and adjusting doses may be necessary."
},
{
"drug": "Levocetirizine",
"interacting_drug": "Theophylline",
"description": "Theophylline can increase the clearance of Levocetirizine, reducing its efficacy.",
"extended_description": "Theophylline may induce certain hepatic enzymes (CYP1A2) that accelerate the metabolism of Levocetirizine. This interaction can lower the plasma concentrations of Levocetirizine, reducing its therapeutic effect in managing allergic symptoms. Dose adjustments may be required."
},
{
"drug": "Diphenhydramine",
"interacting_drug": "Tricyclic antidepressants (TCAs)",
"description": "Diphenhydramine can increase the sedative effects of TCAs, raising the risk of drowsiness and delirium.",
"extended_description": "Both Diphenhydramine and TCAs have anticholinergic properties that can cause excessive sedation, dry mouth, and confusion. When used together, the combined anticholinergic load increases the risk of delirium, especially in elderly patients. Avoid concomitant use or closely monitor for CNS effects."
},
{
"drug": "Fexofenadine",
"interacting_drug": "Antacids (e.g., aluminum hydroxide, magnesium hydroxide)",
"description": "Antacids can decrease the absorption of Fexofenadine.",
"extended_description": "Antacids containing aluminum and magnesium can reduce the absorption of Fexofenadine, leading to decreased therapeutic effectiveness. It is recommended to separate the administration of Fexofenadine and antacids by at least two hours."
},
{
"drug": "Clemastine",
"interacting_drug": "MAOIs (e.g., Phenelzine)",
"description": "Clemastine can enhance the hypertensive effects of MAOIs.",
"extended_description": "Clemastine is a first-generation antihistamine with mild sympathomimetic properties. When combined with MAOIs, it may exacerbate the hypertensive effects due to increased catecholamine release. Patients should be monitored for signs of hypertensive crisis, and this combination should generally be avoided."
},
{
"drug": "Loratadine",
"interacting_drug": "Cimetidine",
"description": "Cimetidine can increase Loratadine levels, leading to potential sedation.",
"extended_description": "Cimetidine inhibits the metabolism of Loratadine by inhibiting CYP3A4. Elevated Loratadine levels can cause excessive sedation, drowsiness, and impaired cognitive function. If co-administration is necessary, close monitoring for adverse effects is recommended."
},
{
"drug": "Desloratadine",
"interacting_drug": "Fluconazole",
"description": "Fluconazole can increase Desloratadine levels, leading to an increased risk of adverse effects.",
"extended_description": "Fluconazole is a CYP3A4 inhibitor that can slow the metabolism of Desloratadine, leading to elevated plasma concentrations. This increases the risk of sedation, dry mouth, and headache. Monitoring for side effects is advised, and dose adjustments may be necessary."
},
{
"drug": "Diphenhydramine",
"interacting_drug": "Barbiturates",
"description": "Diphenhydramine can potentiate the sedative effects of Barbiturates.",
"extended_description": "Both Diphenhydramine and Barbiturates have sedative properties, and when taken together, they can enhance CNS depression, leading to profound drowsiness, respiratory depression, and impaired motor coordination. Caution is required when co-administering these drugs."
},
{
"drug": "Cetirizine",
"interacting_drug": "Alcohol",
"description": "Cetirizine can potentiate the sedative effects of alcohol.",
"extended_description": "Although Cetirizine is a second-generation antihistamine with minimal sedative properties, it can still increase the sedative effects of alcohol, leading to increased drowsiness and impaired cognitive function. Patients should avoid alcohol consumption while taking Cetirizine."
},
{
"drug": "Levocetirizine",
"interacting_drug": "Digoxin",
"description": "Levocetirizine may increase the plasma levels of Digoxin, increasing the risk of toxicity.",
"extended_description": "Levocetirizine can reduce renal clearance, which may increase Digoxin levels in the plasma. Elevated Digoxin levels can lead to symptoms of toxicity, including nausea, vomiting, arrhythmias, and confusion. Digoxin levels should be monitored in patients on this combination."
},
{
"drug": "Chlorpheniramine",
"interacting_drug": "Anticholinergic agents",
"description": "Chlorpheniramine can enhance the anticholinergic effects of other agents.",
"extended_description": "Both Chlorpheniramine and anticholinergic agents (e.g., atropine, scopolamine) have anticholinergic effects. When taken together, they can exacerbate dry mouth, urinary retention, constipation, and cognitive impairment. Caution is advised when using this combination, especially in elderly patients."
},
{
"drug": "Cetirizine",
"interacting_drug": "Theophylline",
"description": "Theophylline can reduce the clearance of Cetirizine, increasing its sedative effects.",
"extended_description": "Theophylline inhibits the metabolism of Cetirizine, leading to increased Cetirizine concentrations. This can result in increased sedation, drowsiness, and impaired cognitive function. Adjusting the dose of Cetirizine may be necessary in patients who require both drugs."
},
{
"drug": "Diphenhydramine",
"interacting_drug": "Thiazide diuretics",
"description": "Diphenhydramine can enhance the anticholinergic effects of Thiazide diuretics.",
"extended_description": "Thiazide diuretics can cause dry mouth and other anticholinergic effects. When combined with Diphenhydramine, which also has anticholinergic properties, these effects can be intensified, leading to urinary retention, constipation, and dry mouth. Caution is necessary when co-administering these agents."
},
{
"drug": "Desloratadine",
"interacting_drug": "Carbamazepine",
"description": "Carbamazepine can reduce the effectiveness of Desloratadine.",
"extended_description": "Carbamazepine induces hepatic enzymes, including CYP3A4, which metabolizes Desloratadine. This induction can reduce the plasma concentration of Desloratadine, reducing its efficacy in controlling allergic symptoms. Dose adjustments may be necessary when these drugs are co-administered."
},
{
"drug": "Loratadine",
"interacting_drug": "Diltiazem",
"description": "Diltiazem can increase Loratadine levels, leading to potential side effects.",
"extended_description": "Diltiazem inhibits CYP3A4, which is responsible for the metabolism of Loratadine. This can result in elevated Loratadine levels, increasing the risk of side effects such as sedation, headache, and dry mouth. Monitoring is recommended for patients on this combination."
},
{
"drug": "Cetirizine",
"interacting_drug": "Fluvoxamine",
"description": "Fluvoxamine can increase Cetirizine levels, enhancing the risk of sedation.",
"extended_description": "Fluvoxamine inhibits CYP1A2, the enzyme involved in the metabolism of Cetirizine. Increased Cetirizine levels can lead to enhanced sedative effects, resulting in drowsiness, dizziness, and impaired motor skills. Dose reduction and monitoring for side effects are recommended."
},

{
"drug": "Diphenhydramine",
"interacting_drug": "Benzodiazepines (e.g., Diazepam)",
"description": "Diphenhydramine can increase the sedative effects of benzodiazepines.",
"extended_description": "Both Diphenhydramine and benzodiazepines have CNS depressant effects. When taken together, they can lead to increased drowsiness, sedation, confusion, and impaired motor coordination. This combination should be used with caution, particularly in elderly patients."
},
{
"drug": "Chlorpheniramine",
"interacting_drug": "MAOIs (e.g., Phenelzine)",
"description": "Chlorpheniramine can enhance the hypertensive effects of MAOIs.",
"extended_description": "Chlorpheniramine is a first-generation antihistamine with mild sympathomimetic properties. When used with MAOIs, the combination can increase the risk of hypertensive crisis, with symptoms such as severe headache, elevated blood pressure, and risk of stroke. Avoid co-administration."
},
{
"drug": "Loratadine",
"interacting_drug": "Antacids (e.g., Magnesium Hydroxide)",
"description": "Antacids can reduce the absorption of Loratadine, lowering its effectiveness.",
"extended_description": "Antacids containing magnesium or aluminum can impair the absorption of Loratadine, reducing its bioavailability. This may result in reduced therapeutic efficacy for managing allergic symptoms. Patients should avoid taking Loratadine and antacids together, or space them by at least two hours."
},
{
"drug": "Fexofenadine",
"interacting_drug": "Ketoconazole",
"description": "Ketoconazole can increase Fexofenadine levels, increasing the risk of side effects.",
"extended_description": "Ketoconazole inhibits the CYP3A4 enzyme, which metabolizes Fexofenadine. This can result in elevated Fexofenadine levels, increasing the likelihood of side effects such as headache, dizziness, and drowsiness. Close monitoring is recommended when these drugs are used together."
},
{
"drug": "Desloratadine",
"interacting_drug": "Fluconazole",
"description": "Fluconazole can increase Desloratadine levels, leading to a greater risk of sedation.",
"extended_description": "Fluconazole inhibits CYP3A4 and CYP2D6 enzymes, which are involved in the metabolism of Desloratadine. This inhibition can elevate plasma concentrations of Desloratadine, potentially enhancing sedative effects such as drowsiness and dry mouth. Close monitoring of sedative effects is advised."
},
{
"drug": "Diphenhydramine",
"interacting_drug": "Opioids (e.g., Morphine)",
"description": "Diphenhydramine can potentiate the sedative effects of opioids.",
"extended_description": "Diphenhydramine and opioids both depress the central nervous system. When used together, there is an increased risk of profound sedation, respiratory depression, and even coma. This combination should be used with extreme caution and only under medical supervision."
},
{
"drug": "Cetirizine",
"interacting_drug": "Ritonavir",
"description": "Ritonavir can increase Cetirizine levels, raising the risk of adverse effects.",
"extended_description": "Ritonavir inhibits CYP3A4, which metabolizes Cetirizine. Elevated Cetirizine levels may lead to an increased risk of side effects such as drowsiness, dizziness, and dry mouth. Monitoring for side effects and possible dose adjustments are recommended."
},
{
"drug": "Levocetirizine",
"interacting_drug": "Cimetidine",
"description": "Cimetidine can increase Levocetirizine plasma concentrations, leading to increased sedative effects.",
"extended_description": "Cimetidine inhibits the metabolism of Levocetirizine, resulting in higher plasma concentrations. This can enhance the sedative effects of Levocetirizine, potentially causing drowsiness, fatigue, and impaired concentration. Monitoring for CNS effects is advised."
},
{
"drug": "Chlorpheniramine",
"interacting_drug": "Alcohol",
"description": "Chlorpheniramine can enhance the sedative effects of alcohol.",
"extended_description": "Chlorpheniramine is a first-generation antihistamine with sedative properties. When used with alcohol, these sedative effects can be intensified, leading to increased drowsiness, impaired coordination, and respiratory depression. This combination should be avoided, especially during activities that require mental alertness."
},
{
"drug": "Desloratadine",
"interacting_drug": "Grapefruit Juice",
"description": "Grapefruit juice can increase Desloratadine plasma concentrations.",
"extended_description": "Grapefruit juice inhibits the CYP3A4 enzyme, which metabolizes Desloratadine. This interaction can increase Desloratadine levels, enhancing the sedative effects and potentially causing drowsiness and dry mouth. Patients should avoid consuming grapefruit juice while taking Desloratadine."
},
{
"drug": "Diphenhydramine",
"interacting_drug": "Tricyclic Antidepressants (TCAs)",
"description": "Diphenhydramine can potentiate the anticholinergic effects of TCAs.",
"extended_description": "Diphenhydramine and TCAs both have anticholinergic effects, including dry mouth, constipation, urinary retention, and blurred vision. When combined, these effects may be exaggerated, especially in elderly patients. Close monitoring and dose adjustment may be necessary."
},
{
"drug": "Levocetirizine",
"interacting_drug": "Theophylline",
"description": "Theophylline can reduce the clearance of Levocetirizine, increasing its sedative effects.",
"extended_description": "Theophylline may reduce the renal clearance of Levocetirizine, leading to increased plasma concentrations. This can enhance Levocetirizine's sedative effects, causing drowsiness and cognitive impairment. Monitoring for CNS effects is advised, and dose adjustment may be required."
},
{
"drug": "Fexofenadine",
"interacting_drug": "Verapamil",
"description": "Verapamil can increase Fexofenadine plasma concentrations.",
"extended_description": "Verapamil inhibits the CYP3A4 enzyme, which metabolizes Fexofenadine. This interaction can lead to higher plasma levels of Fexofenadine, increasing the risk of side effects such as drowsiness, headache, and dizziness. Monitoring for adverse effects is recommended."
},
{
"drug": "Cetirizine",
"interacting_drug": "Pimozide",
"description": "Cetirizine can increase the risk of QT interval prolongation when used with Pimozide.",
"extended_description": "Both Cetirizine and Pimozide have the potential to prolong the QT interval. When used together, this risk is amplified, which may lead to life-threatening arrhythmias such as torsades de pointes. Co-administration of these drugs should be avoided."
},
{
"drug": "Diphenhydramine",
"interacting_drug": "Monoamine Oxidase Inhibitors (MAOIs)",
"description": "Diphenhydramine may increase the risk of hypertensive crisis when used with MAOIs.",
"extended_description": "Diphenhydramine has mild sympathomimetic properties, and when combined with MAOIs, there is an increased risk of hypertensive crisis. Symptoms include severe headache, elevated blood pressure, and risk of stroke. This combination should be avoided."
},
{
"drug": "Chlorpheniramine",
"interacting_drug": "Beta-Blockers (e.g., Propranolol)",
"description": "Chlorpheniramine can enhance the sedative effects of beta-blockers.",
"extended_description": "Both Chlorpheniramine and beta-blockers can cause sedation and CNS depression. When used together, the sedative effects may be enhanced, leading to increased drowsiness, fatigue, and impaired coordination. Monitoring for CNS depression is recommended."
},
{
"drug": "Cetirizine",
"interacting_drug": "Hydrocodone",
"description": "Cetirizine can enhance the sedative effects of Hydrocodone.",
"extended_description": "Cetirizine, although less sedating than first-generation antihistamines, can still potentiate the CNS depressant effects of Hydrocodone, leading to increased sedation, respiratory depression, and impaired motor function. This combination should be used with caution, particularly in elderly patients."
},
{
"drug": "Fexofenadine",
"interacting_drug": "Rifampin",
"description": "Rifampin can decrease the plasma concentrations of Fexofenadine.",
"extended_description": "Rifampin induces the CYP3A4 enzyme, which accelerates the metabolism of Fexofenadine. This can result in decreased therapeutic efficacy of Fexofenadine. Patients may require dose adjustments to maintain symptom control."
},
{
"drug": "Desloratadine",
"interacting_drug": "Sodium Bicarbonate",
"description": "Sodium bicarbonate can increase Desloratadine absorption.",
"extended_description": "Sodium bicarbonate alkalinizes the urine, which can increase the absorption of Desloratadine. Elevated plasma levels of Desloratadine can enhance its sedative effects, increasing the risk of side effects such as drowsiness and dry mouth. Monitoring and dose adjustments are recommended."
},

{
"drug": "Diphenhydramine",
"interacting_drug": "Digoxin",
"description": "Diphenhydramine can enhance the toxic effects of Digoxin.",
"extended_description": "Diphenhydramine has anticholinergic properties that may exacerbate Digoxin's side effects, particularly increasing the risk of arrhythmias, such as atrial fibrillation, and potentially leading to Digoxin toxicity, which can present as nausea, vomiting, and visual disturbances."
},
{
"drug": "Chlorpheniramine",
"interacting_drug": "Citalopram",
"description": "Chlorpheniramine may increase the sedative effects of Citalopram.",
"extended_description": "Both Chlorpheniramine and Citalopram cause central nervous system depression. When combined, these sedative effects are enhanced, leading to increased drowsiness, dizziness, and impaired cognitive function. Monitoring for sedation and avoiding activities requiring mental alertness is advised."
},
{
"drug": "Loratadine",
"interacting_drug": "Cimetidine",
"description": "Cimetidine may increase Loratadine levels, increasing the risk of sedation.",
"extended_description": "Cimetidine inhibits the CYP3A4 enzyme, which metabolizes Loratadine. This interaction can result in elevated Loratadine plasma levels, increasing the likelihood of side effects such as drowsiness and dry mouth. Patients should be monitored for excessive sedation."
},
{
"drug": "Fexofenadine",
"interacting_drug": "Erythromycin",
"description": "Erythromycin can increase Fexofenadine concentrations, increasing the risk of side effects.",
"extended_description": "Erythromycin inhibits the CYP3A4 enzyme, which metabolizes Fexofenadine. Elevated Fexofenadine levels can lead to side effects like headache, dizziness, and drowsiness. Monitoring for adverse effects is necessary when these drugs are used together."
},
{
"drug": "Cetirizine",
"interacting_drug": "Alcohol",
"description": "Cetirizine can potentiate the sedative effects of alcohol.",
"extended_description": "Cetirizine, although less sedating than first-generation antihistamines, still has CNS depressant effects. When used with alcohol, the sedative effects are enhanced, leading to increased drowsiness, cognitive impairment, and motor coordination issues. This combination should be avoided, especially when performing tasks requiring alertness."
},
{
"drug": "Desloratadine",
"interacting_drug": "Ketoconazole",
"description": "Ketoconazole can increase Desloratadine plasma concentrations.",
"extended_description": "Ketoconazole inhibits CYP3A4, the enzyme responsible for metabolizing Desloratadine. This interaction can increase Desloratadine levels in the bloodstream, raising the risk of sedative side effects such as drowsiness and dry mouth. Dose adjustments or monitoring for sedation is advised."
},
{
"drug": "Levocetirizine",
"interacting_drug": "Theophylline",
"description": "Theophylline may reduce Levocetirizine clearance, enhancing its sedative effects.",
"extended_description": "Theophylline may reduce the renal clearance of Levocetirizine, leading to elevated plasma concentrations. This can enhance Levocetirizine's sedative effects, causing increased drowsiness and cognitive impairment. Monitoring for CNS side effects is recommended."
},
{
"drug": "Chlorpheniramine",
"interacting_drug": "Tricyclic Antidepressants (e.g., Amitriptyline)",
"description": "Chlorpheniramine can exacerbate the anticholinergic side effects of Tricyclic Antidepressants.",
"extended_description": "Chlorpheniramine and TCAs both have anticholinergic effects, such as dry mouth, urinary retention, constipation, and blurred vision. When combined, these effects may be intensified, increasing the risk of anticholinergic toxicity, especially in elderly patients."
},
{
"drug": "Fexofenadine",
"interacting_drug": "Verapamil",
"description": "Verapamil can increase Fexofenadine plasma concentrations.",
"extended_description": "Verapamil inhibits CYP3A4, the enzyme responsible for metabolizing Fexofenadine. This can result in higher plasma concentrations of Fexofenadine, increasing the likelihood of side effects such as dizziness, headache, and drowsiness. Monitoring for adverse effects is recommended."
},
{
"drug": "Cetirizine",
"interacting_drug": "Hydrocodone",
"description": "Cetirizine can enhance the sedative effects of Hydrocodone.",
"extended_description": "Both Cetirizine and Hydrocodone are CNS depressants. When used together, they can cause profound sedation, respiratory depression, and impaired motor coordination. This combination should be used with caution, particularly in elderly patients or those with respiratory issues."
},
{
"drug": "Diphenhydramine",
"interacting_drug": "Alcohol",
"description": "Diphenhydramine can potentiate the CNS depressant effects of alcohol.",
"extended_description": "Diphenhydramine has sedative properties and, when combined with alcohol, can lead to enhanced drowsiness, dizziness, and impaired motor function. This combination increases the risk of accidents and should be avoided, particularly when operating heavy machinery."
},
{
"drug": "Desloratadine",
"interacting_drug": "Grapefruit Juice",
"description": "Grapefruit juice can increase Desloratadine plasma concentrations.",
"extended_description": "Grapefruit juice inhibits CYP3A4, the enzyme responsible for metabolizing Desloratadine. This can lead to increased Desloratadine levels, raising the risk of sedation and side effects such as dry mouth. Patients should avoid consuming grapefruit juice while taking Desloratadine."
},
{
"drug": "Loratadine",
"interacting_drug": "Rifampin",
"description": "Rifampin can reduce the effectiveness of Loratadine.",
"extended_description": "Rifampin induces CYP3A4, which accelerates the metabolism of Loratadine. This can decrease the plasma concentration of Loratadine, reducing its therapeutic effectiveness. Patients may require a higher dose of Loratadine to maintain symptom control."
},
{
"drug": "Levocetirizine",
"interacting_drug": "Cimetidine",
"description": "Cimetidine can increase Levocetirizine levels, leading to increased sedative effects.",
"extended_description": "Cimetidine inhibits the metabolism of Levocetirizine, resulting in higher plasma concentrations. This can increase Levocetirizine's sedative effects, causing drowsiness, dry mouth, and cognitive impairment. Monitoring for CNS side effects is advised."
},
{
"drug": "Diphenhydramine",
"interacting_drug": "Monoamine Oxidase Inhibitors (MAOIs)",
"description": "Diphenhydramine may increase the risk of hypertensive crisis when used with MAOIs.",
"extended_description": "Diphenhydramine has mild sympathomimetic properties, which can lead to a hypertensive crisis when combined with MAOIs. Symptoms include severe headache, elevated blood pressure, and risk of stroke. This combination should be avoided."
},
{
"drug": "Chlorpheniramine",
"interacting_drug": "Beta-Blockers (e.g., Propranolol)",
"description": "Chlorpheniramine can enhance the sedative effects of beta-blockers.",
"extended_description": "Chlorpheniramine and beta-blockers both have CNS depressant effects. When used together, these effects may be enhanced, leading to increased sedation, dizziness, and impaired cognitive function. Monitoring for sedation is advised."
},
{
"drug": "Cetirizine",
"interacting_drug": "Pimozide",
"description": "Cetirizine may increase the risk of QT interval prolongation when used with Pimozide.",
"extended_description": "Both Cetirizine and Pimozide have the potential to prolong the QT interval. When used together, the risk of life-threatening arrhythmias such as torsades de pointes is increased. This combination should be avoided."
},
{
"drug": "Desloratadine",
"interacting_drug": "Sodium Bicarbonate",
"description": "Sodium bicarbonate can increase the absorption of Desloratadine.",
"extended_description": "Sodium bicarbonate alkalinizes the urine, which can increase the absorption of Desloratadine, leading to elevated plasma levels. This can enhance Desloratadine's sedative effects, increasing the risk of side effects such as drowsiness and dry mouth."
},
{
"drug": "Loratadine",
"interacting_drug": "Fexofenadine",
"description": "Using Loratadine and Fexofenadine together may increase the risk of side effects.",
"extended_description": "Both Loratadine and Fexofenadine are second-generation antihistamines. When used together, the risk of drowsiness and other side effects such as headache and dry mouth may increase. This combination should be used with caution."
},
{
"drug": "Diphenhydramine",
"interacting_drug": "Trazodone",
"description": "Diphenhydramine may enhance the sedative effects of Trazodone.",
"extended_description": "Diphenhydramine has sedative properties that can augment the CNS depressant effects of Trazodone, leading to increased sedation, dizziness, and impaired cognitive function. This combination should be used with caution, particularly in elderly patients."
},

{
"drug": "Amlodipine",
"interacting_drug": "CYP3A4 inhibitors (e.g., Ketoconazole)",
"description": "CYP3A4 inhibitors can increase Amlodipine levels.",
"extended_description": "Amlodipine is primarily metabolized by CYP3A4. Inhibitors of this enzyme, such as Ketoconazole, can increase Amlodipine plasma concentrations, leading to an enhanced hypotensive effect and an increased risk of side effects like dizziness and swelling."
},
{
"drug": "Losartan",
"interacting_drug": "Non-steroidal anti-inflammatory drugs (NSAIDs)",
"description": "NSAIDs can reduce the effectiveness of Losartan.",
"extended_description": "NSAIDs can reduce renal blood flow and decrease the effectiveness of angiotensin II receptor blockers (ARBs) like Losartan. This may result in poor blood pressure control, particularly in patients with renal impairment or elderly patients."
},
{
"drug": "Enalapril",
"interacting_drug": "Potassium-sparing diuretics (e.g., Spironolactone)",
"description": "Combination with potassium-sparing diuretics can increase the risk of hyperkalemia.",
"extended_description": "Both Enalapril, an ACE inhibitor, and potassium-sparing diuretics like Spironolactone increase potassium levels. When used together, they can cause hyperkalemia, which may lead to cardiac arrhythmias and muscle weakness. Monitoring of serum potassium is essential."
},
{
"drug": "Hydrochlorothiazide",
"interacting_drug": "Lithium",
"description": "Hydrochlorothiazide can increase lithium levels, increasing the risk of toxicity.",
"extended_description": "Thiazide diuretics like Hydrochlorothiazide reduce renal clearance of lithium. This may lead to elevated lithium levels, which can result in lithium toxicity characterized by tremor, confusion, and seizures. Serum lithium levels should be monitored regularly."
},
{
"drug": "Metoprolol",
"interacting_drug": "Calcium channel blockers (e.g., Verapamil)",
"description": "The combination of Metoprolol and Verapamil can cause excessive bradycardia.",
"extended_description": "Both Metoprolol (a beta-blocker) and Verapamil (a calcium channel blocker) can reduce heart rate. When taken together, they may cause severe bradycardia and other cardiac conduction disturbances. Monitoring of heart rate and rhythm is recommended."
},
{
"drug": "Ramipril",
"interacting_drug": "Angiotensin II receptor blockers (e.g., Losartan)",
"description": "The combination of ACE inhibitors and ARBs increases the risk of renal dysfunction.",
"extended_description": "Ramipril, an ACE inhibitor, and Losartan, an ARB, both act on the renin-angiotensin-aldosterone system. Using these medications together can increase the risk of acute kidney injury, hyperkalemia, and hypotension. This combination should be avoided unless specifically indicated, and renal function should be closely monitored."
},
{
"drug": "Lisinopril",
"interacting_drug": "Diuretics (e.g., Furosemide)",
"description": "Diuretics can enhance the hypotensive effect of Lisinopril.",
"extended_description": "Diuretics, such as Furosemide, cause fluid loss and can enhance the blood pressure-lowering effect of Lisinopril. This combination may lead to excessive hypotension, particularly in the elderly or patients with renal impairment. Blood pressure should be monitored closely during initiation or dose adjustment."
},
{
"drug": "Atenolol",
"interacting_drug": "Non-dihydropyridine calcium channel blockers (e.g., Diltiazem)",
"description": "Atenolol and Diltiazem can cause profound bradycardia and hypotension.",
"extended_description": "Atenolol, a beta-blocker, and Diltiazem, a calcium channel blocker, both reduce heart rate and blood pressure. When combined, they can cause excessive bradycardia, heart block, and hypotension. Close monitoring of heart rate and blood pressure is necessary when these drugs are used together."
},
{
"drug": "Valsartan",
"interacting_drug": "ACE inhibitors (e.g., Enalapril)",
"description": "Using ARBs like Valsartan with ACE inhibitors can increase the risk of renal impairment and hyperkalemia.",
"extended_description": "Valsartan and ACE inhibitors both block the renin-angiotensin-aldosterone system and, when used together, can increase the risk of renal dysfunction, hyperkalemia, and hypotension. This combination should be used with caution, especially in patients with pre-existing renal disease."
},
{
"drug": "Clonidine",
"interacting_drug": "Tricyclic antidepressants (e.g., Amitriptyline)",
"description": "Tricyclic antidepressants can reduce the effectiveness of Clonidine.",
"extended_description": "Tricyclic antidepressants like Amitriptyline can block the central alpha-2 adrenergic receptors, which reduces the effectiveness of Clonidine in lowering blood pressure. This may lead to inadequate blood pressure control, especially when the two drugs are discontinued abruptly."
},
{
"drug": "Doxazosin",
"interacting_drug": "PDE5 inhibitors (e.g., Sildenafil)",
"description": "The combination of Doxazosin and Sildenafil can cause severe hypotension.",
"extended_description": "Both Doxazosin, an alpha-1 blocker, and Sildenafil, a PDE5 inhibitor, cause vasodilation. When taken together, these medications can lead to a significant drop in blood pressure, potentially causing dizziness, fainting, and syncope. Close monitoring is required when these drugs are used in combination."
},
{
"drug": "Bisoprolol",
"interacting_drug": "Ritonavir",
"description": "Ritonavir can increase Bisoprolol plasma levels, increasing the risk of bradycardia and hypotension.",
"extended_description": "Ritonavir inhibits the CYP2D6 enzyme, which is involved in the metabolism of Bisoprolol. Elevated Bisoprolol levels can result in excessive bradycardia and hypotension. Blood pressure and heart rate should be carefully monitored, and dose adjustments may be needed."
},
{
"drug": "Eprosartan",
"interacting_drug": "Lithium",
"description": "Eprosartan may increase lithium levels, increasing the risk of lithium toxicity.",
"extended_description": "Angiotensin II receptor blockers (ARBs) like Eprosartan can reduce renal clearance of lithium, leading to elevated lithium levels. This increases the risk of lithium toxicity, which may present with symptoms such as tremor, confusion, and kidney dysfunction. Lithium levels should be closely monitored in patients receiving both medications."
},
{
"drug": "Terazosin",
"interacting_drug": "CYP3A4 inhibitors (e.g., Ketoconazole)",
"description": "CYP3A4 inhibitors can increase Terazosin plasma levels, enhancing its hypotensive effects.",
"extended_description": "Terazosin is metabolized by CYP3A4, and inhibitors of this enzyme, such as Ketoconazole, can increase Terazosin plasma levels. This can lead to an exaggerated hypotensive response, causing dizziness, fainting, and orthostatic hypotension. Close monitoring is advised, especially during initiation or dose adjustments."
},
{
"drug": "Prazosin",
"interacting_drug": "Beta-blockers (e.g., Propranolol)",
"description": "Beta-blockers can exacerbate the hypotensive effect of Prazosin.",
"extended_description": "Both Prazosin and Beta-blockers lower blood pressure. When used together, they can cause excessive hypotension, particularly during the first dose of Prazosin. Close blood pressure monitoring is recommended during initiation or dose adjustment."
},
{
"drug": "Olmesartan",
"interacting_drug": "Potassium supplements",
"description": "Olmesartan may increase the risk of hyperkalemia when used with potassium supplements.",
"extended_description": "Olmesartan, like other ARBs, can increase potassium levels in the blood. When combined with potassium supplements or potassium-sparing diuretics, this can lead to hyperkalemia, which may cause arrhythmias, muscle weakness, and fatigue. Serum potassium should be monitored regularly."
},
{
"drug": "Amlodipine",
"interacting_drug": "CYP3A4 inducers (e.g., Rifampin)",
"description": "CYP3A4 inducers can reduce Amlodipine levels and reduce its efficacy.",
"extended_description": "Rifampin, a potent CYP3A4 inducer, can accelerate the metabolism of Amlodipine, reducing its plasma concentrations. This can lead to inadequate blood pressure control. Dose adjustments may be required to maintain therapeutic efficacy."
},
{
"drug": "Lisinopril",
"interacting_drug": "Non-potassium-sparing diuretics (e.g., Hydrochlorothiazide)",
"description": "Lisinopril and diuretics can lead to excessive hypotension and electrolyte imbalances.",
"extended_description": "Lisinopril, an ACE inhibitor, and diuretics like Hydrochlorothiazide can both lower blood pressure. The combination may cause excessive hypotension, particularly after the first dose. Additionally, electrolyte imbalances such as hyponatremia and hypokalemia may occur, necessitating monitoring."
},
{
"drug": "Candesartan",
"interacting_drug": "NSAIDs",
"description": "NSAIDs can reduce the blood pressure-lowering effects of Candesartan.",
"extended_description": "NSAIDs can reduce renal blood flow, which may decrease the effectiveness of ARBs like Candesartan. This can lead to suboptimal blood pressure control, especially in patients with pre-existing renal conditions or in the elderly."
},
{
"drug": "Bisoprolol",
"interacting_drug": "Cimetidine",
"description": "Cimetidine can increase Bisoprolol plasma concentrations.",
"extended_description": "Cimetidine inhibits the metabolism of Bisoprolol, leading to increased plasma concentrations. This may enhance Bisoprolol's hypotensive and bradycardic effects, increasing the risk of side effects such as dizziness and fatigue. Close monitoring is advised."
},
{
"drug": "Diltiazem",
"interacting_drug": "Simvastatin",
"description": "Diltiazem can increase Simvastatin levels, increasing the risk of myopathy.",
"extended_description": "Diltiazem inhibits the metabolism of Simvastatin, leading to increased plasma levels of Simvastatin. This increases the risk of myopathy and rhabdomyolysis. Patients should be monitored for muscle pain, tenderness, or weakness, and Simvastatin dose adjustments may be necessary."
},
{
"drug": "Labetalol",
"interacting_drug": "Clonidine",
"description": "Clonidine can potentiate the hypotensive effect of Labetalol.",
"extended_description": "Both Labetalol and Clonidine lower blood pressure. When used together, there is an increased risk of excessive hypotension. This combination should be used with caution, particularly in patients who may be more sensitive to blood pressure changes."
},

{
"drug": "Fosinopril",
"interacting_drug": "NSAIDs (e.g., Ibuprofen)",
"description": "NSAIDs can reduce the antihypertensive effect of Fosinopril.",
"extended_description": "NSAIDs inhibit prostaglandin synthesis, reducing renal blood flow and diminishing the efficacy of ACE inhibitors like Fosinopril. This can lead to inadequate blood pressure control, especially in patients with renal impairment."
},
{
"drug": "Telmisartan",
"interacting_drug": "CYP3A4 inducers (e.g., Rifampin)",
"description": "CYP3A4 inducers can lower Telmisartan levels, reducing its effectiveness.",
"extended_description": "Rifampin and other CYP3A4 inducers can accelerate the metabolism of Telmisartan, leading to reduced plasma concentrations. This can result in suboptimal blood pressure control, particularly in patients with high blood pressure."
},
{
"drug": "Esmolol",
"interacting_drug": "Calcium channel blockers (e.g., Verapamil)",
"description": "The combination of Esmolol and Verapamil can cause severe bradycardia.",
"extended_description": "Both Esmolol (a beta-blocker) and Verapamil (a calcium channel blocker) can decrease heart rate. When used together, these drugs can cause profound bradycardia, heart block, and hypotension. Continuous monitoring of heart rate and blood pressure is recommended."
},
{
"drug": "Doxazosin",
"interacting_drug": "PDE5 inhibitors (e.g., Sildenafil)",
"description": "Doxazosin and Sildenafil can cause severe hypotension.",
"extended_description": "Doxazosin, an alpha-1 blocker, and Sildenafil, a PDE5 inhibitor, both cause vasodilation. Their combination may result in an excessive drop in blood pressure, leading to dizziness, fainting, or syncope. Monitoring of blood pressure is advised."
},
{
"drug": "Amlodipine",
"interacting_drug": "CYP3A4 inducers (e.g., Carbamazepine)",
"description": "CYP3A4 inducers can decrease Amlodipine levels, reducing its efficacy.",
"extended_description": "Carbamazepine and other CYP3A4 inducers can accelerate the metabolism of Amlodipine, leading to lower plasma concentrations. This can reduce its antihypertensive effect, requiring dose adjustments to maintain adequate blood pressure control."
},
{
"drug": "Olmesartan",
"interacting_drug": "Lithium",
"description": "Olmesartan may increase lithium levels, increasing the risk of toxicity.",
"extended_description": "ARBs like Olmesartan can reduce renal clearance of lithium, leading to elevated lithium levels. This increases the risk of lithium toxicity, with symptoms such as tremor, confusion, and kidney dysfunction. Serum lithium levels should be monitored regularly."
},
{
"drug": "Losartan",
"interacting_drug": "Eplerenone",
"description": "The combination of Losartan and Eplerenone can increase the risk of hyperkalemia.",
"extended_description": "Losartan, an ARB, and Eplerenone, a potassium-sparing diuretic, both raise potassium levels. When used together, this can lead to hyperkalemia, which may cause arrhythmias, weakness, and fatigue. Serum potassium levels should be monitored."
},
{
"drug": "Ramipril",
"interacting_drug": "Angiotensin II receptor blockers (e.g., Valsartan)",
"description": "The combination of Ramipril and Valsartan can increase the risk of renal dysfunction and hyperkalemia.",
"extended_description": "Both Ramipril and Valsartan act on the renin-angiotensin-aldosterone system. When used together, they can increase the risk of acute kidney injury, hyperkalemia, and hypotension. This combination should be avoided unless absolutely necessary, with renal function monitored closely."
},
{
"drug": "Metoprolol",
"interacting_drug": "Clonidine",
"description": "Clonidine can exacerbate the hypotensive effect of Metoprolol.",
"extended_description": "Clonidine and Metoprolol both lower blood pressure. When used together, they can result in excessive hypotension, especially when Clonidine is discontinued suddenly. Gradual tapering of Clonidine is recommended when discontinuing treatment."
},
{
"drug": "Bisoprolol",
"interacting_drug": "Ritonavir",
"description": "Ritonavir can increase Bisoprolol levels, increasing the risk of bradycardia.",
"extended_description": "Ritonavir inhibits the CYP2D6 enzyme, which is responsible for metabolizing Bisoprolol. Elevated Bisoprolol levels can result in profound bradycardia and hypotension. Close monitoring of heart rate and blood pressure is necessary when using these drugs together."
},
{
"drug": "Hydrochlorothiazide",
"interacting_drug": "Digoxin",
"description": "Hydrochlorothiazide can increase the risk of digoxin toxicity.",
"extended_description": "Hydrochlorothiazide, a thiazide diuretic, can cause hypokalemia, which increases the risk of digoxin toxicity. Symptoms of toxicity may include nausea, vomiting, and cardiac arrhythmias. Serum potassium and digoxin levels should be monitored."
},
{
"drug": "Candesartan",
"interacting_drug": "ACE inhibitors (e.g., Enalapril)",
"description": "Combining ARBs like Candesartan with ACE inhibitors can increase the risk of renal dysfunction.",
"extended_description": "Candesartan and ACE inhibitors like Enalapril both target the renin-angiotensin-aldosterone system. When used together, they can increase the risk of renal dysfunction, hyperkalemia, and hypotension. Monitoring of renal function and electrolytes is recommended."
},
{
"drug": "Clonidine",
"interacting_drug": "Tricyclic antidepressants (e.g., Amitriptyline)",
"description": "Tricyclic antidepressants can reduce the antihypertensive effect of Clonidine.",
"extended_description": "Tricyclic antidepressants such as Amitriptyline can block the central alpha-2 adrenergic receptors, diminishing the effectiveness of Clonidine in lowering blood pressure. This may result in inadequate blood pressure control, particularly in patients with hypertension."
},
{
"drug": "Furosemide",
"interacting_drug": "Lithium",
"description": "Furosemide can increase lithium levels, increasing the risk of toxicity.",
"extended_description": "Loop diuretics like Furosemide can decrease renal clearance of lithium, leading to elevated lithium levels. This increases the risk of lithium toxicity, which can manifest as tremor, confusion, and kidney dysfunction. Serum lithium levels should be monitored."
},
{
"drug": "Atenolol",
"interacting_drug": "Calcium channel blockers (e.g., Diltiazem)",
"description": "Atenolol and Diltiazem can cause severe bradycardia and hypotension.",
"extended_description": "Both Atenolol and Diltiazem decrease heart rate and blood pressure. When combined, these drugs may cause profound bradycardia, heart block, and hypotension. Close monitoring of heart rate and blood pressure is advised."
},
{
"drug": "Lisinopril",
"interacting_drug": "Corticosteroids (e.g., Prednisone)",
"description": "Corticosteroids can decrease the effectiveness of Lisinopril.",
"extended_description": "Corticosteroids such as Prednisone can increase sodium retention and reduce the antihypertensive effect of Lisinopril. This may result in higher blood pressure, and additional blood pressure monitoring may be required during corticosteroid therapy."
},
{
"drug": "Amlodipine",
"interacting_drug": "Grapefruit juice",
"description": "Grapefruit juice can increase Amlodipine levels, enhancing its hypotensive effect.",
"extended_description": "Grapefruit juice inhibits CYP3A4, the enzyme responsible for metabolizing Amlodipine. This results in increased Amlodipine plasma concentrations, leading to an enhanced hypotensive effect and an increased risk of side effects like dizziness and swelling."
},
{
"drug": "Valsartan",
"interacting_drug": "Potassium supplements",
"description": "Valsartan may increase the risk of hyperkalemia when used with potassium supplements.",
"extended_description": "Valsartan, like other ARBs, can increase potassium levels. When combined with potassium supplements or potassium-sparing diuretics, this can lead to hyperkalemia, which may cause arrhythmias, weakness, and fatigue. Serum potassium should be monitored regularly."
},
{
"drug": "Diltiazem",
"interacting_drug": "Digoxin",
"description": "Diltiazem can increase Digoxin levels, increasing the risk of toxicity.",
"extended_description": "Diltiazem inhibits the P-glycoprotein transporter, which is responsible for eliminating Digoxin from the body. This can lead to elevated Digoxin levels, increasing the risk of toxicity. Symptoms of toxicity include nausea, vomiting, and arrhythmias."
},
{
"drug": "Hydralazine",
"interacting_drug": "Monoamine oxidase inhibitors (e.g., Phenelzine)",
"description": "Hydralazine and MAO inhibitors can cause excessive hypotension.",
"extended_description": "Hydralazine is a vasodilator that can lower blood pressure, and when combined with MAO inhibitors like Phenelzine, the risk of severe hypotension is increased. This can result in dizziness, syncope, and potentially life-threatening hypotension."
},
{
"drug": "Propranolol",
"interacting_drug": "Rifampin",
"description": "Rifampin can decrease Propranolol levels, reducing its effectiveness.",
"extended_description": "Rifampin induces CYP450 enzymes, leading to increased metabolism of Propranolol. This results in decreased plasma concentrations of Propranolol and reduced efficacy in controlling blood pressure. Dose adjustments may be necessary when using these drugs together."
},

{
"drug": "Enalapril",
"interacting_drug": "Potassium-sparing diuretics (e.g., Spironolactone)",
"description": "Enalapril and Spironolactone can cause hyperkalemia.",
"extended_description": "Both Enalapril, an ACE inhibitor, and Spironolactone, a potassium-sparing diuretic, can increase serum potassium levels. When used together, this increases the risk of hyperkalemia, which can cause arrhythmias, muscle weakness, and potentially life-threatening cardiac events."
},
{
"drug": "Losartan",
"interacting_drug": "Diuretics (e.g., Furosemide)",
"description": "The combination of Losartan and Furosemide may result in hypotension and dehydration.",
"extended_description": "Losartan, an ARB, and Furosemide, a loop diuretic, can both lower blood pressure. The combination can cause excessive hypotension, dehydration, and electrolyte imbalances. Monitoring of blood pressure, renal function, and electrolytes is essential during therapy."
},
{
"drug": "Captopril",
"interacting_drug": "Allopurinol",
"description": "Captopril and Allopurinol can increase the risk of severe hypersensitivity reactions.",
"extended_description": "Combining Captopril, an ACE inhibitor, with Allopurinol may increase the risk of serious hypersensitivity reactions, including angioedema and rash. Patients should be monitored for these reactions, particularly during the initiation of therapy."
},
{
"drug": "Amlodipine",
"interacting_drug": "Cimetidine",
"description": "Cimetidine may increase Amlodipine levels, enhancing its hypotensive effect.",
"extended_description": "Cimetidine inhibits CYP3A4, the enzyme responsible for metabolizing Amlodipine. This inhibition increases plasma Amlodipine levels, leading to an enhanced hypotensive effect and a greater risk of side effects, such as dizziness, fatigue, and peripheral edema."
},
{
"drug": "Bisoprolol",
"interacting_drug": "Clonidine",
"description": "Clonidine can exacerbate the bradycardia caused by Bisoprolol.",
"extended_description": "Both Bisoprolol, a beta-blocker, and Clonidine, an alpha-2 adrenergic agonist, can lower heart rate. When used together, this combination can lead to severe bradycardia, heart block, and hypotension. Close monitoring of heart rate and blood pressure is essential."
},
{
"drug": "Hydrochlorothiazide",
"interacting_drug": "Lithium",
"description": "Hydrochlorothiazide increases the risk of lithium toxicity.",
"extended_description": "Hydrochlorothiazide, a thiazide diuretic, can cause sodium and water depletion, leading to decreased renal clearance of lithium. Elevated lithium levels can lead to toxicity, with symptoms such as tremor, nausea, and confusion. Regular monitoring of lithium and electrolytes is recommended."
},
{
"drug": "Ramipril",
"interacting_drug": "NSAIDs (e.g., Ibuprofen)",
"description": "NSAIDs may reduce the antihypertensive effect of Ramipril.",
"extended_description": "NSAIDs inhibit prostaglandin synthesis, which reduces renal blood flow and the effectiveness of ACE inhibitors like Ramipril. This combination can result in inadequate blood pressure control, especially in patients with renal impairment."
},
{
"drug": "Diltiazem",
"interacting_drug": "Grapefruit juice",
"description": "Grapefruit juice can increase the plasma levels of Diltiazem, enhancing its effects.",
"extended_description": "Grapefruit juice inhibits CYP3A4, an enzyme responsible for metabolizing Diltiazem. This inhibition can result in elevated plasma concentrations of Diltiazem, increasing the risk of bradycardia, hypotension, and other adverse effects. Patients should be advised to avoid grapefruit juice."
},
{
"drug": "Olmesartan",
"interacting_drug": "Cyclosporine",
"description": "Cyclosporine can increase the risk of renal dysfunction when used with Olmesartan.",
"extended_description": "Cyclosporine, an immunosuppressant, can reduce renal function, and when combined with Olmesartan, an ARB, the risk of renal impairment is increased. Renal function should be monitored closely, and dose adjustments may be required."
},
{
"drug": "Fosinopril",
"interacting_drug": "Diuretics (e.g., Hydrochlorothiazide)",
"description": "Fosinopril and diuretics may cause excessive hypotension during the initial treatment phase.",
"extended_description": "The combination of Fosinopril, an ACE inhibitor, and diuretics like Hydrochlorothiazide can lead to a pronounced initial drop in blood pressure, particularly when treatment is initiated. Blood pressure should be closely monitored, and patients should be cautioned about the potential for dizziness or fainting."
},
{
"drug": "Propranolol",
"interacting_drug": "Cimetidine",
"description": "Cimetidine can increase the plasma concentration of Propranolol.",
"extended_description": "Cimetidine inhibits CYP2D6, the enzyme responsible for metabolizing Propranolol. This can increase Propranolol plasma levels, potentially leading to enhanced beta-blocking effects, including bradycardia and hypotension. Close monitoring of heart rate and blood pressure is recommended."
},
{
"drug": "Telmisartan",
"interacting_drug": "Lithium",
"description": "Telmisartan can increase the risk of lithium toxicity.",
"extended_description": "Telmisartan, an ARB, can reduce renal clearance of lithium, resulting in elevated serum lithium levels. This increases the risk of lithium toxicity, which can present as tremors, confusion, and renal dysfunction. Lithium levels should be monitored regularly in patients on both medications."
},
{
"drug": "Metoprolol",
"interacting_drug": "Clonidine",
"description": "The combination of Metoprolol and Clonidine can cause severe bradycardia and hypotension.",
"extended_description": "Both Metoprolol, a beta-blocker, and Clonidine, an alpha-2 adrenergic agonist, lower blood pressure and heart rate. When used together, they can cause profound bradycardia, heart block, and hypotension. If Clonidine is discontinued, the dose of Metoprolol should be adjusted gradually to avoid withdrawal symptoms."
},
{
"drug": "Candesartan",
"interacting_drug": "NSAIDs (e.g., Diclofenac)",
"description": "NSAIDs can decrease the antihypertensive effect of Candesartan.",
"extended_description": "NSAIDs reduce renal blood flow, which can counteract the blood pressure-lowering effects of ARBs like Candesartan. This combination may result in inadequate blood pressure control, especially in patients with renal impairment or those taking high doses of NSAIDs."
},
{
"drug": "Valsartan",
"interacting_drug": "Rifampin",
"description": "Rifampin can decrease Valsartan levels, reducing its antihypertensive effect.",
"extended_description": "Rifampin induces the CYP3A4 enzyme, which accelerates the metabolism of Valsartan. This leads to reduced plasma concentrations of Valsartan, diminishing its effectiveness in controlling blood pressure. Monitoring blood pressure is essential when using these drugs together."
},
{
"drug": "Nadolol",
"interacting_drug": "Calcium channel blockers (e.g., Verapamil)",
"description": "Nadolol and Verapamil can cause severe bradycardia and heart block.",
"extended_description": "Both Nadolol, a beta-blocker, and Verapamil, a calcium channel blocker, decrease heart rate. When used together, they can result in significant bradycardia, heart block, and hypotension. Monitoring of heart rate and blood pressure is essential during co-administration."
},
{
"drug": "Doxazosin",
"interacting_drug": "PDE5 inhibitors (e.g., Tadalafil)",
"description": "The combination of Doxazosin and Tadalafil can cause severe hypotension.",
"extended_description": "Doxazosin and Tadalafil both have vasodilatory effects. When used together, they can cause a significant drop in blood pressure, resulting in dizziness, fainting, or syncope. Blood pressure should be monitored regularly, and dose adjustments may be required."
},
{
"drug": "Eplerenone",
"interacting_drug": "NSAIDs (e.g., Naproxen)",
"description": "NSAIDs can reduce the antihypertensive effect of Eplerenone.",
"extended_description": "NSAIDs reduce renal blood flow, which can decrease the effectiveness of Eplerenone in lowering blood pressure. This interaction may result in suboptimal blood pressure control, particularly in patients with pre-existing renal impairment."
},
{
"drug": "Lisinopril",
"interacting_drug": "Corticosteroids (e.g., Prednisone)",
"description": "Corticosteroids may reduce the antihypertensive effect of Lisinopril.",
"extended_description": "Corticosteroids such as Prednisone can cause fluid retention and increase blood pressure, potentially counteracting the blood pressure-lowering effect of Lisinopril. Blood pressure should be closely monitored, and dose adjustments may be necessary."
},

{
    "drug": "Carvedilol",
    "interacting_drug": "Amiodarone",
    "description": "Carvedilol and Amiodarone may result in severe bradycardia and hypotension.",
    "extended_description": "Both Carvedilol, a non-selective beta-blocker, and Amiodarone, an antiarrhythmic, have negative chronotropic effects. Co-administration can lead to excessive bradycardia, hypotension, and heart block. Patients should be closely monitored with ECG and hemodynamic parameters."
},
{
    "drug": "Hydralazine",
    "interacting_drug": "Monoamine oxidase inhibitors (e.g., Phenelzine)",
    "description": "Hydralazine and MAOIs can cause significant hypotension.",
    "extended_description": "Hydralazine, a direct vasodilator, can potentiate the hypotensive effects of monoamine oxidase inhibitors (MAOIs). This combination may lead to profound hypotension, dizziness, and fainting. Dose adjustments and monitoring of blood pressure are recommended."
},
{
    "drug": "Methyldopa",
    "interacting_drug": "Iron supplements (e.g., Ferrous sulfate)",
    "description": "Iron supplements can reduce the bioavailability of Methyldopa.",
    "extended_description": "Iron salts can form complexes with Methyldopa in the gastrointestinal tract, reducing its absorption and therapeutic efficacy. It is recommended to space the administration of Methyldopa and iron supplements by at least two hours."
},
{
    "drug": "Minoxidil",
    "interacting_drug": "Corticosteroids (e.g., Prednisone)",
    "description": "Minoxidil and corticosteroids can increase the risk of fluid retention and edema.",
    "extended_description": "Minoxidil is a potent vasodilator that can cause fluid retention, and corticosteroids exacerbate this effect. Co-administration may lead to significant edema, hypertension, and cardiac strain. Diuretics are often used to mitigate these side effects."
},
{
    "drug": "Clonidine",
    "interacting_drug": "Tricyclic antidepressants (e.g., Amitriptyline)",
    "description": "Tricyclic antidepressants may reduce the antihypertensive effect of Clonidine.",
    "extended_description": "Tricyclic antidepressants can inhibit the central alpha-2 agonist activity of Clonidine, leading to reduced blood pressure-lowering effects. Abrupt withdrawal of Clonidine in this context can also precipitate a hypertensive crisis."
},
{
    "drug": "Aliskiren",
    "interacting_drug": "ACE inhibitors (e.g., Ramipril)",
    "description": "Aliskiren and ACE inhibitors can increase the risk of hyperkalemia and renal dysfunction.",
    "extended_description": "The combination of Aliskiren, a direct renin inhibitor, and ACE inhibitors increases the risk of hyperkalemia and renal impairment due to synergistic inhibition of the renin-angiotensin-aldosterone system. This combination is contraindicated in patients with diabetes or renal impairment."
},
{
    "drug": "Verapamil",
    "interacting_drug": "Digoxin",
    "description": "Verapamil can increase plasma levels of Digoxin, leading to toxicity.",
    "extended_description": "Verapamil inhibits P-glycoprotein-mediated transport, which reduces Digoxin clearance and increases its plasma concentration. Symptoms of Digoxin toxicity include nausea, bradycardia, and arrhythmias. Digoxin levels should be monitored closely."
},
{
    "drug": "Nifedipine",
    "interacting_drug": "Phenytoin",
    "description": "Phenytoin can decrease the plasma levels of Nifedipine, reducing its efficacy.",
    "extended_description": "Phenytoin induces CYP3A4, which accelerates the metabolism of Nifedipine, a calcium channel blocker. This results in reduced antihypertensive efficacy. Dose adjustments of Nifedipine may be required when used with Phenytoin."
},
{
    "drug": "Esmolol",
    "interacting_drug": "Insulin",
    "description": "Esmolol can mask hypoglycemic symptoms caused by insulin.",
    "extended_description": "Esmolol, a beta-blocker, can blunt the adrenergic response to hypoglycemia, such as tachycardia and tremors. This can delay the recognition of hypoglycemia in insulin-treated patients. Blood glucose levels should be closely monitored."
},
{
    "drug": "Spironolactone",
    "interacting_drug": "Trimethoprim-sulfamethoxazole",
    "description": "The combination of Spironolactone and Trimethoprim can cause severe hyperkalemia.",
    "extended_description": "Both Spironolactone, a potassium-sparing diuretic, and Trimethoprim reduce renal potassium excretion. Co-administration can lead to life-threatening hyperkalemia, characterized by muscle weakness, cardiac arrhythmias, and cardiac arrest. Potassium levels should be closely monitored."
},
{
    "drug": "Labetalol",
    "interacting_drug": "Beta-agonists (e.g., Albuterol)",
    "description": "Labetalol can antagonize the effects of beta-agonists like Albuterol.",
    "extended_description": "Labetalol, a mixed alpha and beta-blocker, can reduce the bronchodilatory and cardiovascular effects of beta-agonists. This interaction is particularly concerning in patients with asthma or COPD. Monitoring respiratory function is advised."
},
{
    "drug": "Perindopril",
    "interacting_drug": "Cyclosporine",
    "description": "Cyclosporine can increase the risk of hyperkalemia when used with Perindopril.",
    "extended_description": "Perindopril, an ACE inhibitor, and Cyclosporine, an immunosuppressant, can independently increase potassium levels. When combined, the risk of hyperkalemia is significantly elevated, necessitating regular monitoring of potassium and renal function."
},
{
    "drug": "Fenoldopam",
    "interacting_drug": "Beta-blockers (e.g., Metoprolol)",
    "description": "Beta-blockers may blunt the reflex tachycardia induced by Fenoldopam.",
    "extended_description": "Fenoldopam, a dopamine receptor agonist, can cause reflex tachycardia due to its vasodilatory effects. Beta-blockers may inhibit this compensatory response, increasing the risk of profound hypotension. Blood pressure and heart rate should be monitored closely."
},
{
    "drug": "Azilsartan",
    "interacting_drug": "Potassium supplements",
    "description": "Azilsartan and potassium supplements can cause hyperkalemia.",
    "extended_description": "Azilsartan, an ARB, can increase serum potassium levels. Co-administration with potassium supplements or potassium-containing salt substitutes increases the risk of hyperkalemia. Potassium levels should be monitored during therapy."
},
{
    "drug": "Isradipine",
    "interacting_drug": "Rifampin",
    "description": "Rifampin can reduce the efficacy of Isradipine by inducing its metabolism.",
    "extended_description": "Rifampin, a potent CYP3A4 inducer, accelerates the metabolism of Isradipine, a dihydropyridine calcium channel blocker. This results in reduced antihypertensive efficacy. Dose adjustments may be necessary."
},
{
    "drug": "Terazosin",
    "interacting_drug": "Erectile dysfunction drugs (e.g., Sildenafil)",
    "description": "Terazosin and Sildenafil can cause severe postural hypotension.",
    "extended_description": "Both Terazosin, an alpha-1 blocker, and Sildenafil, a PDE5 inhibitor, lower blood pressure. When used together, they can cause marked postural hypotension, leading to dizziness and fainting. Caution is advised, and doses should be adjusted."
},

                                        

    {
        "drug": "Furosemide",
        "interacting_drug": "Aminoglycosides (e.g., Gentamicin)",
        "description": "The combination increases the risk of ototoxicity.",
        "extended_description": "Furosemide, a loop diuretic, and aminoglycosides can independently cause ototoxicity. Co-administration significantly heightens this risk, particularly in high doses or in patients with pre-existing renal impairment. Monitor auditory function closely."
    },
    {
        "drug": "Hydrochlorothiazide",
        "interacting_drug": "Digoxin",
        "description": "Hydrochlorothiazide can exacerbate Digoxin toxicity by causing hypokalemia.",
        "extended_description": "Thiazide diuretics like Hydrochlorothiazide increase renal potassium excretion, leading to hypokalemia. Hypokalemia enhances Digoxin binding to myocardial tissue, increasing the risk of toxicity, including arrhythmias. Monitor electrolytes and Digoxin levels."
    },
    {
        "drug": "Spironolactone",
        "interacting_drug": "ACE inhibitors (e.g., Lisinopril)",
        "description": "The combination increases the risk of hyperkalemia.",
        "extended_description": "Both Spironolactone, a potassium-sparing diuretic, and ACE inhibitors reduce renal potassium excretion. Co-administration may result in severe hyperkalemia, manifesting as muscle weakness, arrhythmias, or cardiac arrest. Monitor serum potassium and renal function closely."
    },
    {
        "drug": "Chlorthalidone",
        "interacting_drug": "Lithium",
        "description": "Chlorthalidone can increase Lithium levels, leading to toxicity.",
        "extended_description": "Thiazide-like diuretics reduce renal lithium clearance, increasing its plasma concentration. This can lead to lithium toxicity, presenting with tremors, confusion, ataxia, or seizures. Monitor lithium levels and adjust doses accordingly."
    },
    {
        "drug": "Torsemide",
        "interacting_drug": "NSAIDs (e.g., Ibuprofen)",
        "description": "NSAIDs can reduce the diuretic and antihypertensive effects of Torsemide.",
        "extended_description": "NSAIDs inhibit renal prostaglandin synthesis, which reduces renal blood flow and counteracts the effects of loop diuretics like Torsemide. This interaction may result in fluid retention and diminished diuretic efficacy."
    },
    {
        "drug": "Amiloride",
        "interacting_drug": "Trimethoprim",
        "description": "Amiloride and Trimethoprim increase the risk of hyperkalemia.",
        "extended_description": "Both Amiloride, a potassium-sparing diuretic, and Trimethoprim reduce renal potassium excretion. Combined use may lead to severe hyperkalemia, necessitating careful monitoring of serum potassium levels."
    },
    {
        "drug": "Bumetanide",
        "interacting_drug": "Cisplatin",
        "description": "Bumetanide and Cisplatin increase the risk of nephrotoxicity and ototoxicity.",
        "extended_description": "Bumetanide, a loop diuretic, and Cisplatin, a chemotherapeutic agent, both have nephrotoxic and ototoxic potential. Co-administration can exacerbate these toxicities, particularly in high doses or prolonged use. Renal function and auditory capacity should be monitored closely."
    },
    {
        "drug": "Indapamide",
        "interacting_drug": "Quinidine",
        "description": "Indapamide can exacerbate the QT-prolonging effects of Quinidine.",
        "extended_description": "Hypokalemia induced by Indapamide, a thiazide-like diuretic, can potentiate the QT-prolonging effects of Quinidine, increasing the risk of torsades de pointes. Regular monitoring of electrolytes and ECG is recommended."
    },
    {
        "drug": "Acetazolamide",
        "interacting_drug": "Topiramate",
        "description": "The combination increases the risk of metabolic acidosis.",
        "extended_description": "Both Acetazolamide and Topiramate are carbonic anhydrase inhibitors. Their combined use may lead to additive effects, causing significant metabolic acidosis and associated symptoms such as fatigue, hyperventilation, and confusion. Monitor serum bicarbonate levels."
    },
    {
        "drug": "Eplerenone",
        "interacting_drug": "Potassium supplements",
        "description": "Eplerenone and potassium supplements increase the risk of hyperkalemia.",
        "extended_description": "Eplerenone, a selective aldosterone antagonist, decreases potassium excretion. Co-administration with potassium supplements or potassium-containing salt substitutes can result in severe hyperkalemia. Monitor potassium levels closely."
    },
    {
        "drug": "Furosemide",
        "interacting_drug": "Vancomycin",
        "description": "Furosemide may enhance the nephrotoxicity of Vancomycin.",
        "extended_description": "The combination of Furosemide, a loop diuretic, and Vancomycin increases the risk of nephrotoxicity, particularly in patients with pre-existing renal impairment. Renal function should be closely monitored."
    },
    {
        "drug": "Hydrochlorothiazide",
        "interacting_drug": "Dofetilide",
        "description": "Hydrochlorothiazide can increase the risk of QT prolongation with Dofetilide.",
        "extended_description": "Hypokalemia caused by Hydrochlorothiazide can exacerbate the QT-prolonging effects of Dofetilide, increasing the risk of torsades de pointes. Monitor serum potassium and magnesium levels, and perform regular ECGs."
    },
    {
        "drug": "Spironolactone",
        "interacting_drug": "Tacrolimus",
        "description": "The combination increases the risk of hyperkalemia and nephrotoxicity.",
        "extended_description": "Spironolactone and Tacrolimus independently increase potassium levels and can impair renal function. Co-administration may result in life-threatening hyperkalemia and worsening renal dysfunction. Monitor renal function and potassium levels."
    },
    {
        "drug": "Torsemide",
        "interacting_drug": "Theophylline",
        "description": "Torsemide may reduce the clearance of Theophylline.",
        "extended_description": "Loop diuretics like Torsemide can cause hypokalemia, which impairs Theophylline metabolism and increases its serum levels. This may lead to Theophylline toxicity, characterized by nausea, tremors, and cardiac arrhythmias."
    },
    {
        "drug": "Amiloride",
        "interacting_drug": "ACE inhibitors (e.g., Enalapril)",
        "description": "The combination increases the risk of hyperkalemia.",
        "extended_description": "Amiloride, a potassium-sparing diuretic, and ACE inhibitors both decrease potassium excretion. Combined use can result in severe hyperkalemia, manifesting as muscle weakness and cardiac arrhythmias."
    },
    
        {
          "drug": "Amiloride",
          "interacting_drug": "ACE inhibitors (e.g., Enalapril)",
          "description": "The combination increases the risk of hyperkalemia.",
          "extended_description": "Amiloride, a potassium-sparing diuretic, and ACE inhibitors both decrease potassium excretion. Combined use can result in severe hyperkalemia, manifesting as muscle weakness and cardiac arrhythmias."
        },
        {
          "drug": "Furosemide",
          "interacting_drug": "Aminoglycosides",
          "description": "Increased risk of ototoxicity and nephrotoxicity.",
          "extended_description": "Concurrent use potentiates aminoglycoside-induced ototoxicity through synergistic effects on the VIII cranial nerve. Additionally, loop diuretic-induced volume depletion may increase aminoglycoside concentrations in renal tubules."
        },
        {
          "drug": "Hydrochlorothiazide",
          "interacting_drug": "Lithium",
          "description": "Increased lithium serum levels and toxicity risk.",
          "extended_description": "Thiazides reduce lithium clearance through enhanced proximal tubular reabsorption, potentially leading to lithium toxicity. Regular monitoring of lithium levels is essential."
        },
        {
          "drug": "Spironolactone",
          "interacting_drug": "Digoxin",
          "description": "Altered digoxin pharmacokinetics and increased toxicity risk.",
          "extended_description": "Spironolactone interferes with digoxin assays and may reduce its renal clearance. Monitor digoxin levels and adjust dosage accordingly."
        },
        {
          "drug": "Bumetanide",
          "interacting_drug": "NSAIDs",
          "description": "Reduced diuretic efficacy and potential nephrotoxicity.",
          "extended_description": "NSAIDs inhibit prostaglandin synthesis, antagonizing the natriuretic effect of loop diuretics and potentially causing acute kidney injury in volume-depleted patients."
        },
        {
          "drug": "Torsemide",
          "interacting_drug": "Warfarin",
          "description": "Enhanced anticoagulant effect.",
          "extended_description": "Volume depletion from loop diuretics may increase warfarin concentration. Monitor INR closely and adjust warfarin dosage as needed."
        },
        {
          "drug": "Indapamide",
          "interacting_drug": "Calcium Channel Blockers",
          "description": "Enhanced hypotensive effect and orthostatic hypotension risk.",
          "extended_description": "Synergistic vasodilatory effects may lead to excessive blood pressure reduction. Careful dose titration and monitoring required."
        },
        {
          "drug": "Chlorthalidone",
          "interacting_drug": "Corticosteroids",
          "description": "Increased risk of hypokalemia and metabolic alkalosis.",
          "extended_description": "Both drugs promote potassium excretion through different mechanisms. Regular electrolyte monitoring and potassium supplementation may be necessary."
        },
        {
          "drug": "Metolazone",
          "interacting_drug": "Loop Diuretics",
          "description": "Potentiated diuretic effect with risk of volume depletion.",
          "extended_description": "Sequential nephron blockade produces profound diuresis. Close monitoring of fluid status and electrolytes required. Limited to specific clinical scenarios."
        },
        {
          "drug": "Triamterene",
          "interacting_drug": "Angiotensin Receptor Blockers",
          "description": "Increased hyperkalemia risk.",
          "extended_description": "Similar to ACE inhibitor interaction, combined potassium-retaining effects can lead to dangerous hyperkalemia. Regular potassium monitoring essential."
        },
        {
          "drug": "Ethacrynic Acid",
          "interacting_drug": "Cisplatin",
          "description": "Enhanced ototoxicity risk.",
          "extended_description": "Both medications can cause cochlear damage. Combined use significantly increases risk of permanent hearing loss."
        },
        {
          "drug": "Hydrochlorothiazide",
          "interacting_drug": "Amiodarone",
          "description": "Increased risk of TdP and cardiac arrhythmias.",
          "extended_description": "Thiazide-induced hypokalemia may potentiate amiodarone's QT-prolonging effects. Close ECG monitoring required."
        },
        {
          "drug": "Furosemide",
          "interacting_drug": "Succinylcholine",
          "description": "Prolonged neuromuscular blockade.",
          "extended_description": "Diuretic-induced hypokalemia enhances and prolongs neuromuscular blocking effects. Consider checking electrolytes before anesthesia."
        },
        {
          "drug": "Spironolactone",
          "interacting_drug": "Tacrolimus",
          "description": "Increased tacrolimus levels and nephrotoxicity risk.",
          "extended_description": "Spironolactone may inhibit tacrolimus metabolism via CYP3A4. Monitor tacrolimus levels and renal function closely."
        },
        {
          "drug": "Amiloride",
          "interacting_drug": "Cyclosporine",
          "description": "Enhanced nephrotoxicity risk.",
          "extended_description": "Combined use may exacerbate cyclosporine-induced nephrotoxicity through altered renal hemodynamics."
        },
        {
          "drug": "Bumetanide",
          "interacting_drug": "Amphotericin B",
          "description": "Severe electrolyte imbalances and nephrotoxicity.",
          "extended_description": "Additive effects on potassium and magnesium depletion. Close monitoring of electrolytes and renal function mandatory."
        },
        {
          "drug": "Chlorthalidone",
          "interacting_drug": "Carbamazepine",
          "description": "Increased risk of hyponatremia.",
          "extended_description": "Both drugs can cause SIADH-like effects. Monitor sodium levels regularly, especially in elderly patients."
        },
        {
          "drug": "Indapamide",
          "interacting_drug": "SSRIs",
          "description": "Enhanced hyponatremia risk.",
          "extended_description": "Synergistic effect on sodium retention through different mechanisms. Elderly patients particularly susceptible."
        },
        {
          "drug": "Torsemide",
          "interacting_drug": "Gentamicin",
          "description": "Increased ototoxicity and nephrotoxicity risk.",
          "extended_description": "Loop diuretics enhance aminoglycoside uptake in cochlear tissue and may increase renal tubular concentrations."
        },
        {
          "drug": "Metolazone",
          "interacting_drug": "Digoxin",
          "description": "Increased digoxin toxicity risk.",
          "extended_description": "Thiazide-like diuretic-induced hypokalemia and hypomagnesemia enhance digoxin sensitivity and toxicity risk."
        },
        {
          "drug": "Spironolactone",
          "interacting_drug": "Potassium Supplements",
          "description": "Severe hyperkalemia risk.",
          "extended_description": "Combined potassium-retaining effects can rapidly lead to dangerous hyperkalemia. Generally contraindicated unless specifically indicated."
        },
        {
          "drug": "Furosemide",
          "interacting_drug": "Cisplatin",
          "description": "Enhanced nephrotoxicity and ototoxicity.",
          "extended_description": "Loop diuretics may increase platinum concentration in renal tissue and inner ear, potentiating toxicity risks."
        },
        {
          "drug": "Hydrochlorothiazide",
          "interacting_drug": "Allopurinol",
          "description": "Increased risk of allopurinol hypersensitivity.",
          "extended_description": "Thiazide-induced volume depletion may increase allopurinol and oxypurinol concentrations, enhancing hypersensitivity risk."
        },
        {
          "drug": "Triamterene",
          "interacting_drug": "Metformin",
          "description": "Increased risk of lactic acidosis.",
          "extended_description": "Potassium-sparing diuretic may impair renal function and metformin clearance, particularly in susceptible patients."
        },
        {
          "drug": "Ethacrynic Acid",
          "interacting_drug": "Coumadin",
          "description": "Enhanced anticoagulant effect.",
          "extended_description": "Volume depletion and protein binding displacement may increase warfarin effect. Monitor INR closely."
        },
        {
          "drug": "Bumetanide",
          "interacting_drug": "Carbenoxolone",
          "description": "Increased risk of hypokalemia.",
          "extended_description": "Additive potassium-wasting effects through different mechanisms. Regular electrolyte monitoring essential."
        },
        
            {
                "drug": "Warfarin",
                "interacting_drug": "Aspirin",
                "description": "Aspirin increases the risk of bleeding when combined with Warfarin.",
                "extended_description": "Aspirin inhibits platelet aggregation, while Warfarin reduces clotting factor synthesis. The additive effects increase the risk of gastrointestinal and intracranial hemorrhage. Monitor INR and signs of bleeding closely."
            },
            {
                "drug": "Heparin",
                "interacting_drug": "Clopidogrel",
                "description": "Clopidogrel increases the risk of bleeding when used with Heparin.",
                "extended_description": "Clopidogrel inhibits platelet activation by blocking the P2Y12 receptor, while Heparin enhances antithrombin activity. Co-administration increases the risk of major bleeding events, particularly in invasive procedures."
            },
            {
                "drug": "Rivaroxaban",
                "interacting_drug": "Ketoconazole",
                "description": "Ketoconazole increases Rivaroxaban levels, heightening the risk of bleeding.",
                "extended_description": "Ketoconazole, a strong CYP3A4 and P-glycoprotein inhibitor, reduces the metabolism and clearance of Rivaroxaban, leading to elevated plasma levels. Monitor patients for signs of excessive anticoagulation."
            },
            {
                "drug": "Apixaban",
                "interacting_drug": "Rifampin",
                "description": "Rifampin reduces the efficacy of Apixaban.",
                "extended_description": "Rifampin induces CYP3A4 and P-glycoprotein, increasing the clearance of Apixaban and reducing its anticoagulant effects. Alternative anticoagulants should be considered during Rifampin therapy."
            },
            {
                "drug": "Dabigatran",
                "interacting_drug": "Verapamil",
                "description": "Verapamil increases Dabigatran levels, enhancing the risk of bleeding.",
                "extended_description": "Verapamil inhibits P-glycoprotein, reducing renal excretion of Dabigatran and leading to elevated plasma concentrations. Dose adjustment may be required to minimize bleeding risk."
            },
            {
                "drug": "Enoxaparin",
                "interacting_drug": "Ibuprofen",
                "description": "Ibuprofen increases the risk of bleeding when combined with Enoxaparin.",
                "extended_description": "Ibuprofen, a non-selective COX inhibitor, impairs platelet function and enhances the anticoagulant effects of Enoxaparin, a low-molecular-weight heparin. Avoid concurrent use or monitor for bleeding."
            },
            {
                "drug": "Fondaparinux",
                "interacting_drug": "SSRIs (e.g., Sertraline)",
                "description": "SSRIs can increase the risk of bleeding with Fondaparinux.",
                "extended_description": "SSRIs reduce platelet serotonin uptake, impairing platelet aggregation. When combined with anticoagulants like Fondaparinux, the risk of bleeding complications, including gastrointestinal bleeding, increases significantly."
            },
            {
                "drug": "Warfarin",
                "interacting_drug": "Amiodarone",
                "description": "Amiodarone increases Warfarin levels, prolonging INR.",
                "extended_description": "Amiodarone inhibits CYP2C9 and CYP3A4, enzymes involved in Warfarin metabolism. This leads to increased anticoagulant effects and a higher risk of bleeding. Frequent INR monitoring is required."
            },
            {
                "drug": "Heparin",
                "interacting_drug": "Protamine",
                "description": "Protamine reverses the anticoagulant effects of Heparin.",
                "extended_description": "Protamine sulfate binds to Heparin, forming an inactive complex and neutralizing its anticoagulant activity. Administer Protamine in cases of Heparin overdose or excessive bleeding."
            },
            {
                "drug": "Rivaroxaban",
                "interacting_drug": "Carbamazepine",
                "description": "Carbamazepine reduces the efficacy of Rivaroxaban.",
                "extended_description": "Carbamazepine induces CYP3A4 and P-glycoprotein, increasing the metabolism and clearance of Rivaroxaban, leading to reduced anticoagulant effects. Consider alternative anticoagulants if concurrent use is necessary."
            },
            {
                "drug": "Warfarin",
                "interacting_drug": "Vitamin K",
                "description": "Vitamin K reduces the anticoagulant effect of Warfarin.",
                "extended_description": "Vitamin K is a cofactor for clotting factor synthesis. High dietary intake or supplementation can antagonize Warfarin’s effects, reducing INR and increasing the risk of thrombosis. Monitor INR and adjust Warfarin dosage as needed."
            },
            {
                "drug": "Apixaban",
                "interacting_drug": "Phenytoin",
                "description": "Phenytoin reduces the efficacy of Apixaban.",
                "extended_description": "Phenytoin induces CYP3A4 and P-glycoprotein, increasing the clearance of Apixaban and reducing its anticoagulant effect. Close monitoring or alternative anticoagulants may be required."
            },
            {
                "drug": "Edoxaban",
                "interacting_drug": "Clarithromycin",
                "description": "Clarithromycin increases Edoxaban levels, enhancing bleeding risk.",
                "extended_description": "Clarithromycin inhibits P-glycoprotein and CYP3A4, reducing Edoxaban clearance. This leads to elevated plasma levels and an increased risk of bleeding. Monitor patients for signs of excessive anticoagulation."
            },
            {
                "drug": "Warfarin",
                "interacting_drug": "Cranberry juice",
                "description": "Cranberry juice can increase Warfarin levels, heightening bleeding risk.",
                "extended_description": "Cranberry juice inhibits CYP2C9, reducing Warfarin metabolism and prolonging INR. This interaction can lead to significant bleeding events. Monitor INR closely during cranberry juice consumption."
            },
            {
                "drug": "Heparin",
                "interacting_drug": "Nitroglycerin",
                "description": "Nitroglycerin reduces the efficacy of Heparin.",
                "extended_description": "Intravenous Nitroglycerin can induce Heparin resistance by reducing its binding to antithrombin. Monitor activated partial thromboplastin time (aPTT) closely and adjust Heparin dosing as necessary."
            },
            
                {
                    "drug": "Warfarin",
                    "interacting_drug": "Cimetidine",
                    "description": "Cimetidine increases Warfarin levels, enhancing the risk of bleeding.",
                    "extended_description": "Cimetidine inhibits CYP enzymes, particularly CYP2C9, leading to reduced Warfarin metabolism and elevated INR levels. Monitor for signs of bleeding and adjust Warfarin dosage as needed."
                },
                {
                    "drug": "Dabigatran",
                    "interacting_drug": "Dronedarone",
                    "description": "Dronedarone increases Dabigatran levels, raising bleeding risk.",
                    "extended_description": "Dronedarone inhibits P-glycoprotein, leading to reduced renal clearance of Dabigatran. This results in elevated plasma concentrations and an increased risk of bleeding. Dose adjustment may be required."
                },
                {
                    "drug": "Rivaroxaban",
                    "interacting_drug": "Fluconazole",
                    "description": "Fluconazole increases Rivaroxaban levels, heightening bleeding risk.",
                    "extended_description": "Fluconazole inhibits CYP3A4, reducing the metabolism of Rivaroxaban and leading to increased anticoagulant effects. Monitor closely for signs of excessive bleeding."
                },
                {
                    "drug": "Apixaban",
                    "interacting_drug": "Dexamethasone",
                    "description": "Dexamethasone reduces the efficacy of Apixaban.",
                    "extended_description": "Dexamethasone induces CYP3A4, increasing the clearance of Apixaban and reducing its anticoagulant effect. Consider dose adjustments or alternative therapies."
                },
                {
                    "drug": "Warfarin",
                    "interacting_drug": "Metronidazole",
                    "description": "Metronidazole increases Warfarin levels, raising bleeding risk.",
                    "extended_description": "Metronidazole inhibits CYP2C9, a key enzyme in Warfarin metabolism, leading to increased plasma levels and INR. Monitor closely for signs of bleeding and adjust Warfarin dosage accordingly."
                },
                {
                    "drug": "Edoxaban",
                    "interacting_drug": "Itraconazole",
                    "description": "Itraconazole increases Edoxaban levels, heightening bleeding risk.",
                    "extended_description": "Itraconazole inhibits P-glycoprotein and CYP3A4, reducing Edoxaban clearance. Elevated anticoagulant effects may occur, necessitating dose adjustments and monitoring for bleeding."
                },
                {
                    "drug": "Heparin",
                    "interacting_drug": "Alteplase",
                    "description": "Alteplase increases the risk of bleeding when used with Heparin.",
                    "extended_description": "Alteplase, a fibrinolytic agent, combined with Heparin can cause severe bleeding, particularly in invasive or post-surgical settings. Use this combination with extreme caution and monitor for hemorrhagic events."
                },
                {
                    "drug": "Fondaparinux",
                    "interacting_drug": "Indomethacin",
                    "description": "Indomethacin increases the risk of bleeding with Fondaparinux.",
                    "extended_description": "Indomethacin, a non-selective COX inhibitor, can impair platelet aggregation and enhance the anticoagulant effects of Fondaparinux. Monitor for signs of gastrointestinal or intracranial bleeding."
                },
                {
                    "drug": "Rivaroxaban",
                    "interacting_drug": "Erythromycin",
                    "description": "Erythromycin increases Rivaroxaban levels, raising bleeding risk.",
                    "extended_description": "Erythromycin inhibits CYP3A4 and P-glycoprotein, reducing the clearance of Rivaroxaban and leading to elevated anticoagulant effects. Monitor closely for signs of excessive anticoagulation."
                },
                {
                    "drug": "Warfarin",
                    "interacting_drug": "Barbiturates",
                    "description": "Barbiturates reduce Warfarin efficacy.",
                    "extended_description": "Barbiturates induce CYP enzymes, increasing the metabolism of Warfarin and reducing its anticoagulant effect. This may necessitate an increase in Warfarin dosage to maintain therapeutic INR levels."
                },
                {
                    "drug": "Dabigatran",
                    "interacting_drug": "St. John’s Wort",
                    "description": "St. John’s Wort reduces Dabigatran levels, decreasing its efficacy.",
                    "extended_description": "St. John’s Wort induces P-glycoprotein, increasing Dabigatran clearance and reducing its anticoagulant effect. Avoid concomitant use or consider alternative therapies."
                },
                {
                    "drug": "Enoxaparin",
                    "interacting_drug": "Valproic Acid",
                    "description": "Valproic Acid increases the risk of bleeding when combined with Enoxaparin.",
                    "extended_description": "Valproic Acid inhibits platelet aggregation, which can enhance the anticoagulant effects of Enoxaparin. Monitor for bleeding complications, particularly in patients with other risk factors."
                },
                {
                    "drug": "Warfarin",
                    "interacting_drug": "Trimethoprim-Sulfamethoxazole",
                    "description": "Trimethoprim-Sulfamethoxazole increases Warfarin levels, heightening bleeding risk.",
                    "extended_description": "Trimethoprim-Sulfamethoxazole inhibits CYP2C9, reducing Warfarin clearance and increasing INR. Monitor INR closely and adjust the Warfarin dose as needed."
                },
                {
                    "drug": "Heparin",
                    "interacting_drug": "Tirofiban",
                    "description": "Tirofiban increases the risk of bleeding when used with Heparin.",
                    "extended_description": "Tirofiban, a glycoprotein IIb/IIIa inhibitor, combined with Heparin enhances antithrombotic effects but increases the risk of major bleeding. Close monitoring is required."
                },
                {
                    "drug": "Fondaparinux",
                    "interacting_drug": "Dipyridamole",
                    "description": "Dipyridamole increases the risk of bleeding with Fondaparinux.",
                    "extended_description": "Dipyridamole inhibits platelet activation, which can potentiate the anticoagulant effects of Fondaparinux. Monitor for signs of excessive bleeding, particularly in high-risk patients."
                },

            
    {
        "drug": "Warfarin",
        "interacting_drug": "Amiodarone",
        "description": "Amiodarone increases Warfarin levels, heightening the risk of bleeding.",
        "extended_description": "Amiodarone inhibits CYP2C9 and CYP3A4 enzymes responsible for Warfarin metabolism, leading to elevated INR levels. Close INR monitoring and dose adjustments are necessary."
    },
    {
        "drug": "Dabigatran",
        "interacting_drug": "Ketoconazole",
        "description": "Ketoconazole significantly increases Dabigatran levels, increasing the risk of bleeding.",
        "extended_description": "Ketoconazole inhibits P-glycoprotein, reducing Dabigatran clearance and leading to elevated plasma concentrations. Dose adjustments are required in patients at risk of bleeding."
    },
    {
        "drug": "Rivaroxaban",
        "interacting_drug": "Rifampin",
        "description": "Rifampin reduces Rivaroxaban efficacy by enhancing its clearance.",
        "extended_description": "Rifampin induces CYP3A4 and P-glycoprotein, increasing the metabolism and clearance of Rivaroxaban. This reduces its anticoagulant effect, necessitating alternative therapies."
    },
    {
        "drug": "Heparin",
        "interacting_drug": "Nitroglycerin (IV)",
        "description": "Nitroglycerin reduces Heparin efficacy when co-administered.",
        "extended_description": "Nitroglycerin causes a reduction in Heparin's antithrombotic effects, possibly due to altered binding to antithrombin III. Monitor activated partial thromboplastin time (aPTT) closely."
    },
    {
        "drug": "Apixaban",
        "interacting_drug": "Carbamazepine",
        "description": "Carbamazepine reduces Apixaban levels, decreasing its anticoagulant effect.",
        "extended_description": "Carbamazepine induces CYP3A4 and P-glycoprotein, enhancing the clearance of Apixaban. Consider alternative anticoagulants or dose adjustments."
    },
    {
        "drug": "Warfarin",
        "interacting_drug": "Levothyroxine",
        "description": "Levothyroxine increases the effect of Warfarin, elevating INR levels.",
        "extended_description": "Levothyroxine enhances Warfarin's anticoagulant effect by increasing the turnover of clotting factors. Monitor INR levels and adjust Warfarin dose as needed."
    },
    {
        "drug": "Edoxaban",
        "interacting_drug": "Verapamil",
        "description": "Verapamil increases Edoxaban levels, enhancing the risk of bleeding.",
        "extended_description": "Verapamil inhibits P-glycoprotein, reducing Edoxaban clearance and leading to elevated plasma concentrations. Monitor for signs of bleeding and consider dose adjustments."
    },
    {
        "drug": "Fondaparinux",
        "interacting_drug": "SSRIs (e.g., Sertraline)",
        "description": "SSRIs increase the risk of bleeding with Fondaparinux.",
        "extended_description": "SSRIs can impair platelet aggregation, increasing the risk of bleeding in patients receiving Fondaparinux. Monitor for signs of gastrointestinal or intracranial hemorrhage."
    },
    {
        "drug": "Rivaroxaban",
        "interacting_drug": "Clarithromycin",
        "description": "Clarithromycin increases Rivaroxaban levels, heightening bleeding risk.",
        "extended_description": "Clarithromycin inhibits CYP3A4 and P-glycoprotein, reducing Rivaroxaban clearance and increasing anticoagulant effects. Monitor for excessive bleeding."
    },
    {
        "drug": "Warfarin",
        "interacting_drug": "Phenytoin",
        "description": "Phenytoin reduces Warfarin levels, decreasing its efficacy.",
        "extended_description": "Phenytoin induces CYP enzymes, increasing the metabolism of Warfarin and reducing INR levels. Monitor INR closely and adjust Warfarin dosage as needed."
    },
    {
        "drug": "Heparin",
        "interacting_drug": "Glycoprotein IIb/IIIa inhibitors (e.g., Abciximab)",
        "description": "Glycoprotein IIb/IIIa inhibitors increase the risk of bleeding with Heparin.",
        "extended_description": "These inhibitors impair platelet aggregation, compounding the anticoagulant effects of Heparin. Monitor for hemorrhagic complications, especially in high-risk procedures."
    },
    {
        "drug": "Dabigatran",
        "interacting_drug": "Proton Pump Inhibitors (e.g., Omeprazole)",
        "description": "PPIs may reduce Dabigatran absorption, decreasing its anticoagulant effect.",
        "extended_description": "PPIs increase gastric pH, which can reduce Dabigatran solubility and absorption. Monitor for reduced efficacy and adjust therapy if necessary."
    },
    {
        "drug": "Warfarin",
        "interacting_drug": "Green Tea",
        "description": "Green tea can reduce Warfarin levels, decreasing its efficacy.",
        "extended_description": "Green tea contains vitamin K, which can antagonize the effects of Warfarin. Monitor INR levels and advise patients to limit green tea consumption."
    },
    {
        "drug": "Apixaban",
        "interacting_drug": "Fluoxetine",
        "description": "Fluoxetine increases the risk of bleeding with Apixaban.",
        "extended_description": "Fluoxetine, an SSRI, inhibits platelet aggregation and may enhance the anticoagulant effects of Apixaban. Monitor for signs of bleeding."
    },
    {
        "drug": "Edoxaban",
        "interacting_drug": "Ritonavir",
        "description": "Ritonavir increases Edoxaban levels, raising bleeding risk.",
        "extended_description": "Ritonavir inhibits P-glycoprotein, reducing Edoxaban clearance and increasing plasma concentrations. Monitor closely for anticoagulant effects and bleeding."
    },
    {
        "drug": "Fondaparinux",
        "interacting_drug": "NSAIDs (e.g., Ibuprofen)",
        "description": "NSAIDs increase the risk of gastrointestinal bleeding with Fondaparinux.",
        "extended_description": "NSAIDs inhibit COX enzymes, impairing platelet aggregation and increasing the risk of bleeding in patients on Fondaparinux. Use with caution and monitor for bleeding."
    },
    {
        "drug": "Rivaroxaban",
        "interacting_drug": "Quinidine",
        "description": "Quinidine increases Rivaroxaban levels, enhancing bleeding risk.",
        "extended_description": "Quinidine inhibits P-glycoprotein, reducing Rivaroxaban clearance. Monitor for excessive anticoagulation and adjust dosage if necessary."
    },
    {
        "drug": "Warfarin",
        "interacting_drug": "Cholestyramine",
        "description": "Cholestyramine reduces Warfarin absorption, decreasing its efficacy.",
        "extended_description": "Cholestyramine binds Warfarin in the gastrointestinal tract, reducing its bioavailability. Administer Warfarin several hours before or after Cholestyramine."
    },

        {
            "drug": "Fluoxetine",
            "interacting_drug": "Linezolid",
            "description": "Co-administration increases the risk of serotonin syndrome.",
            "extended_description": "Fluoxetine, an SSRI, and Linezolid, an MAOI, together can lead to excessive serotonergic activity. Clinical features include hyperreflexia, agitation, tremor, and autonomic instability. Avoid concurrent use unless absolutely necessary."
        },
        {
            "drug": "Venlafaxine",
            "interacting_drug": "Tramadol",
            "description": "Tramadol increases the risk of serotonin syndrome when combined with Venlafaxine.",
            "extended_description": "Both Venlafaxine, an SNRI, and Tramadol increase serotonin levels. Combined use can cause serotonin syndrome, characterized by mental status changes, hyperthermia, and neuromuscular abnormalities."
        },
        {
            "drug": "Amitriptyline",
            "interacting_drug": "CYP2D6 inhibitors (e.g., Paroxetine)",
            "description": "CYP2D6 inhibitors increase Amitriptyline levels, heightening the risk of toxicity.",
            "extended_description": "Amitriptyline is metabolized by CYP2D6. Inhibitors of this enzyme can elevate Amitriptyline levels, leading to anticholinergic effects, QT prolongation, and cardiotoxicity."
        },
        {
            "drug": "Sertraline",
            "interacting_drug": "Warfarin",
            "description": "Sertraline increases the anticoagulant effect of Warfarin.",
            "extended_description": "Sertraline can displace Warfarin from protein-binding sites and inhibit its metabolism, increasing INR and the risk of bleeding. Monitor INR closely during co-administration."
        },
        {
            "drug": "Duloxetine",
            "interacting_drug": "NSAIDs (e.g., Ibuprofen)",
            "description": "Increased risk of gastrointestinal bleeding when combined with NSAIDs.",
            "extended_description": "Duloxetine inhibits platelet aggregation, and NSAIDs increase the risk of mucosal damage, leading to a synergistic effect on gastrointestinal bleeding. Monitor for signs of bleeding."
        },
        {
            "drug": "Mirtazapine",
            "interacting_drug": "Clonidine",
            "description": "Mirtazapine reduces the antihypertensive effect of Clonidine.",
            "extended_description": "Mirtazapine's alpha-2 adrenergic receptor antagonist activity counteracts Clonidine's mechanism, potentially leading to hypertension or rebound hypertensive crises."
        },
        {
            "drug": "Escitalopram",
            "interacting_drug": "Citalopram",
            "description": "Co-administration increases the risk of QT prolongation.",
            "extended_description": "Both drugs are SSRIs that can prolong the QT interval. Combined use may lead to severe arrhythmias, including Torsades de Pointes. Avoid co-administration."
        },
        {
            "drug": "Bupropion",
            "interacting_drug": "Selegiline",
            "description": "Increased risk of hypertensive crisis when combined with Selegiline.",
            "extended_description": "Selegiline, an MAO-B inhibitor, and Bupropion together may increase norepinephrine levels excessively, leading to severe hypertension. Avoid co-administration."
        },
        {
            "drug": "Nortriptyline",
            "interacting_drug": "Phenytoin",
            "description": "Phenytoin reduces Nortriptyline levels, decreasing its efficacy.",
            "extended_description": "Phenytoin induces CYP enzymes that metabolize Nortriptyline, potentially leading to subtherapeutic levels. Monitor for reduced antidepressant efficacy and adjust the dose as necessary."
        },
        {
            "drug": "Fluvoxamine",
            "interacting_drug": "Theophylline",
            "description": "Fluvoxamine increases Theophylline levels, heightening toxicity risk.",
            "extended_description": "Fluvoxamine inhibits CYP1A2, reducing Theophylline clearance. This can lead to nausea, seizures, and cardiac arrhythmias. Monitor Theophylline levels closely."
        },
        {
            "drug": "Desvenlafaxine",
            "interacting_drug": "St. John's Wort",
            "description": "Increased risk of serotonin syndrome when combined with St. John's Wort.",
            "extended_description": "St. John's Wort induces serotonergic activity, which, when combined with Desvenlafaxine, may lead to excessive serotonergic effects, including agitation, confusion, and hyperthermia. Avoid concurrent use."
        },
        {
            "drug": "Paroxetine",
            "interacting_drug": "Tamoxifen",
            "description": "Paroxetine reduces the efficacy of Tamoxifen.",
            "extended_description": "Paroxetine inhibits CYP2D6, an enzyme required to activate Tamoxifen into its active metabolite, endoxifen. This may reduce the therapeutic effect of Tamoxifen in breast cancer treatment."
        },
        {
            "drug": "Imipramine",
            "interacting_drug": "Alcohol",
            "description": "Alcohol potentiates the sedative effects of Imipramine.",
            "extended_description": "Imipramine, a tricyclic antidepressant, and alcohol both have CNS depressant effects. Combined use can lead to profound sedation, respiratory depression, and impaired motor coordination."
        },
        {
            "drug": "Citalopram",
            "interacting_drug": "Ondansetron",
            "description": "Increased risk of QT prolongation when combined with Ondansetron.",
            "extended_description": "Both drugs can prolong the QT interval, raising the risk of life-threatening arrhythmias, including Torsades de Pointes. Monitor ECG closely in patients requiring this combination."
        },
        {
            "drug": "Venlafaxine",
            "interacting_drug": "Metoprolol",
            "description": "Venlafaxine increases the levels of Metoprolol, leading to bradycardia.",
            "extended_description": "Venlafaxine inhibits CYP2D6, reducing the metabolism of Metoprolol. This can result in exaggerated beta-blockade, causing bradycardia and hypotension. Monitor heart rate and blood pressure."
        },
        {
            "drug": "Duloxetine",
            "interacting_drug": "Ciprofloxacin",
            "description": "Ciprofloxacin increases Duloxetine levels, heightening the risk of adverse effects.",
            "extended_description": "Ciprofloxacin inhibits CYP1A2, reducing the clearance of Duloxetine. This can increase the risk of nausea, dizziness, and serotonin syndrome. Dose adjustments may be necessary."
        },
        {
            "drug": "Bupropion",
            "interacting_drug": "Levodopa",
            "description": "Increased risk of seizures when combined with Levodopa.",
            "extended_description": "Both Bupropion and Levodopa lower the seizure threshold. Combined use can significantly increase the risk of seizures, particularly in patients with a history of epilepsy."
        },
        {
            "drug": "Fluoxetine",
            "interacting_drug": "Methadone",
            "description": "Fluoxetine increases Methadone levels, raising the risk of QT prolongation.",
            "extended_description": "Fluoxetine inhibits CYP2D6 and CYP3A4, reducing Methadone clearance. Elevated Methadone levels may prolong the QT interval, increasing the risk of Torsades de Pointes."
        },
        {
            "drug": "Amitriptyline",
            "interacting_drug": "Quetiapine",
            "description": "Increased risk of CNS depression when combined with Quetiapine.",
            "extended_description": "Both Amitriptyline and Quetiapine have sedative properties. Combined use may lead to excessive sedation, orthostatic hypotension, and impaired cognitive function. Use with caution."
        },
        {
            "drug": "Sertraline",
            "interacting_drug": "Carbamazepine",
            "description": "Carbamazepine reduces Sertraline levels, decreasing its efficacy.",
            "extended_description": "Carbamazepine induces CYP3A4, enhancing the metabolism of Sertraline. This may result in subtherapeutic antidepressant levels, requiring dose adjustments."
        },
        
            {
                "drug": "Nortriptyline",
                "interacting_drug": "Ritonavir",
                "description": "Ritonavir increases Nortriptyline levels, leading to heightened toxicity risk.",
                "extended_description": "Ritonavir inhibits CYP2D6, reducing the metabolism of Nortriptyline. This can cause anticholinergic side effects, sedation, and cardiotoxicity. Monitor for toxicity and consider dose adjustments."
            },
            {
                "drug": "Mirtazapine",
                "interacting_drug": "Ketoconazole",
                "description": "Ketoconazole increases Mirtazapine levels, increasing sedation and adverse effects.",
                "extended_description": "Ketoconazole is a potent CYP3A4 inhibitor, which slows Mirtazapine metabolism. This can exacerbate sedation, weight gain, and other adverse effects. Monitor closely or reduce the Mirtazapine dose."
            },
            {
                "drug": "Duloxetine",
                "interacting_drug": "Omeprazole",
                "description": "Omeprazole increases Duloxetine plasma levels, enhancing adverse effects.",
                "extended_description": "Omeprazole inhibits CYP2C19, which is involved in Duloxetine metabolism. This can lead to nausea, dizziness, and increased risk of serotonin syndrome. Adjust Duloxetine dosing if needed."
            },
            {
                "drug": "Escitalopram",
                "interacting_drug": "Amiodarone",
                "description": "Amiodarone and Escitalopram together can cause QT prolongation.",
                "extended_description": "Both Escitalopram and Amiodarone prolong the QT interval. Combined use increases the risk of Torsades de Pointes. Avoid this combination or closely monitor with ECG."
            },
            {
                "drug": "Fluoxetine",
                "interacting_drug": "Propranolol",
                "description": "Fluoxetine increases Propranolol levels, leading to bradycardia and hypotension.",
                "extended_description": "Fluoxetine inhibits CYP2D6, decreasing Propranolol clearance. This can lead to excessive beta-blockade, causing fatigue, bradycardia, and hypotension. Monitor cardiovascular status."
            },
            {
                "drug": "Paroxetine",
                "interacting_drug": "Atomoxetine",
                "description": "Paroxetine increases Atomoxetine levels, increasing the risk of adverse effects.",
                "extended_description": "Paroxetine inhibits CYP2D6, the enzyme responsible for Atomoxetine metabolism. This can lead to increased Atomoxetine plasma levels, causing tachycardia, hypertension, and irritability."
            },
            {
                "drug": "Amitriptyline",
                "interacting_drug": "Clarithromycin",
                "description": "Clarithromycin increases Amitriptyline levels, heightening the risk of toxicity.",
                "extended_description": "Clarithromycin inhibits CYP3A4, reducing Amitriptyline clearance. Elevated levels can cause anticholinergic effects, sedation, and QT prolongation. Monitor for signs of toxicity."
            },
            {
                "drug": "Sertraline",
                "interacting_drug": "Diltiazem",
                "description": "Diltiazem increases Sertraline levels, leading to increased side effects.",
                "extended_description": "Diltiazem inhibits CYP3A4, reducing Sertraline metabolism. This can result in dizziness, nausea, and heightened risk of serotonin syndrome. Dose adjustments may be necessary."
            },
            {
                "drug": "Bupropion",
                "interacting_drug": "Valproate",
                "description": "Co-administration with Valproate increases the risk of seizures.",
                "extended_description": "Both drugs affect the central nervous system, and their combination lowers the seizure threshold. Use cautiously in patients with a history of epilepsy or other seizure disorders."
            },
            {
                "drug": "Venlafaxine",
                "interacting_drug": "Macrolide antibiotics (e.g., Erythromycin)",
                "description": "Macrolides increase Venlafaxine levels, heightening the risk of toxicity.",
                "extended_description": "Macrolides inhibit CYP3A4, reducing Venlafaxine clearance. This can lead to increased blood pressure, serotonin syndrome, and cardiovascular side effects. Monitor closely."
            },
            {
                "drug": "Duloxetine",
                "interacting_drug": "Clozapine",
                "description": "Duloxetine increases Clozapine levels, heightening the risk of toxicity.",
                "extended_description": "Duloxetine inhibits CYP1A2, slowing Clozapine metabolism. This can increase Clozapine levels, leading to sedation, hypotension, and agranulocytosis. Monitor for adverse effects."
            },
            {
                "drug": "Mirtazapine",
                "interacting_drug": "Phenytoin",
                "description": "Phenytoin reduces Mirtazapine levels, decreasing its efficacy.",
                "extended_description": "Phenytoin induces CYP3A4, which accelerates Mirtazapine metabolism. This may lead to subtherapeutic antidepressant effects. Monitor for clinical response and adjust the dose as needed."
            },
            {
                "drug": "Fluoxetine",
                "interacting_drug": "Thioridazine",
                "description": "Fluoxetine increases Thioridazine levels, heightening the risk of QT prolongation.",
                "extended_description": "Fluoxetine inhibits CYP2D6, slowing Thioridazine metabolism. Elevated levels increase the risk of QT prolongation and potentially fatal arrhythmias. Avoid this combination."
            },
            {
                "drug": "Nortriptyline",
                "interacting_drug": "Topiramate",
                "description": "Topiramate increases Nortriptyline levels, enhancing sedative effects.",
                "extended_description": "Topiramate reduces Nortriptyline clearance through CYP2D6 inhibition, leading to increased sedative and anticholinergic effects. Monitor closely and adjust the Nortriptyline dose."
            },
            {
                "drug": "Escitalopram",
                "interacting_drug": "Chlorpromazine",
                "description": "Increased risk of QT prolongation when combined with Chlorpromazine.",
                "extended_description": "Both Escitalopram and Chlorpromazine can prolong the QT interval. Combined use increases the risk of life-threatening arrhythmias, including Torsades de Pointes. Avoid co-administration."
            },
            {
                "drug": "Paroxetine",
                "interacting_drug": "Metoprolol",
                "description": "Paroxetine increases Metoprolol levels, leading to bradycardia and hypotension.",
                "extended_description": "Paroxetine inhibits CYP2D6, reducing Metoprolol clearance. This can cause excessive beta-blockade, resulting in fatigue, bradycardia, and hypotension. Monitor cardiovascular function."
            },
            {
                "drug": "Venlafaxine",
                "interacting_drug": "Digoxin",
                "description": "Venlafaxine reduces Digoxin levels, potentially decreasing efficacy.",
                "extended_description": "Venlafaxine increases renal clearance of Digoxin, which may lead to subtherapeutic levels and reduced efficacy in controlling heart rate or heart failure. Monitor Digoxin levels."
            },
            {
                "drug": "Fluvoxamine",
                "interacting_drug": "Warfarin",
                "description": "Fluvoxamine increases Warfarin levels, heightening bleeding risk.",
                "extended_description": "Fluvoxamine inhibits CYP enzymes involved in Warfarin metabolism, leading to elevated INR and an increased risk of bleeding. Regular INR monitoring is essential."
            },
            {
                "drug": "Bupropion",
                "interacting_drug": "Zolpidem",
                "description": "Bupropion increases Zolpidem levels, leading to excessive sedation.",
                "extended_description": "Bupropion inhibits CYP2B6, reducing Zolpidem clearance. Elevated Zolpidem levels can cause prolonged sedation, dizziness, and impaired motor coordination. Adjust Zolpidem dosing if necessary."
            },
            {
                "drug": "Amitriptyline",
                "interacting_drug": "Cyclobenzaprine",
                "description": "Increased risk of CNS depression and anticholinergic effects.",
                "extended_description": "Both Amitriptyline and Cyclobenzaprine have sedative and anticholinergic properties. Combined use may cause excessive drowsiness, dry mouth, and blurred vision. Avoid this combination or use with caution."
            },
        
            
                {
                    "drug": "Haloperidol",
                    "interacting_drug": "Ketoconazole",
                    "description": "Ketoconazole increases Haloperidol plasma concentrations, increasing the risk of QT prolongation.",
                    "extended_description": "Ketoconazole inhibits CYP3A4, reducing Haloperidol metabolism. Elevated levels of Haloperidol can cause QT prolongation, Torsades de Pointes, and sudden cardiac death. Use with caution and monitor ECG."
                },
                {
                    "drug": "Clozapine",
                    "interacting_drug": "Carbamazepine",
                    "description": "Carbamazepine reduces Clozapine levels, decreasing therapeutic efficacy.",
                    "extended_description": "Carbamazepine induces CYP3A4, increasing the metabolism of Clozapine. This can result in reduced antipsychotic efficacy and a risk of treatment failure. Monitor Clozapine levels and adjust dosing."
                },
                {
                    "drug": "Olanzapine",
                    "interacting_drug": "Fluvoxamine",
                    "description": "Fluvoxamine increases Olanzapine levels, enhancing the risk of sedation and weight gain.",
                    "extended_description": "Fluvoxamine inhibits CYP1A2, reducing Olanzapine clearance. This can lead to increased sedation, metabolic side effects, and anticholinergic toxicity. Consider dose reduction of Olanzapine."
                },
                {
                    "drug": "Risperidone",
                    "interacting_drug": "Valproic Acid",
                    "description": "Co-administration may increase the risk of sedation and extrapyramidal symptoms.",
                    "extended_description": "Risperidone and Valproic Acid both affect the central nervous system, increasing the risk of side effects such as drowsiness, tremors, and muscle stiffness. Monitor closely for adverse effects."
                },
                {
                    "drug": "Quetiapine",
                    "interacting_drug": "Phenytoin",
                    "description": "Phenytoin reduces Quetiapine plasma levels, decreasing its efficacy.",
                    "extended_description": "Phenytoin induces CYP3A4, accelerating Quetiapine metabolism. This can result in reduced therapeutic effects, potentially leading to symptom exacerbation. Consider increasing the Quetiapine dose."
                },
                {
                    "drug": "Aripiprazole",
                    "interacting_drug": "Paroxetine",
                    "description": "Paroxetine increases Aripiprazole levels, enhancing the risk of side effects.",
                    "extended_description": "Paroxetine inhibits CYP2D6, reducing Aripiprazole metabolism. Elevated levels of Aripiprazole can lead to akathisia, anxiety, and extrapyramidal symptoms. Monitor for adverse effects and consider dose adjustment."
                },
                {
                    "drug": "Ziprasidone",
                    "interacting_drug": "Amiodarone",
                    "description": "Combination increases the risk of QT prolongation and arrhythmias.",
                    "extended_description": "Both Ziprasidone and Amiodarone prolong the QT interval. Combined use significantly increases the risk of life-threatening arrhythmias such as Torsades de Pointes. Avoid co-administration."
                },
                {
                    "drug": "Lurasidone",
                    "interacting_drug": "Diltiazem",
                    "description": "Diltiazem increases Lurasidone plasma concentrations, enhancing side effects.",
                    "extended_description": "Diltiazem inhibits CYP3A4, reducing Lurasidone clearance. This can lead to sedation, hypotension, and extrapyramidal symptoms. Reduce the Lurasidone dose or monitor closely."
                },
                {
                    "drug": "Clozapine",
                    "interacting_drug": "Lithium",
                    "description": "Increased risk of neurotoxicity and seizures.",
                    "extended_description": "The combination of Clozapine and Lithium can lead to neurotoxicity, manifesting as confusion, ataxia, and tremor, and may lower the seizure threshold. Monitor for signs of toxicity."
                },
                {
                    "drug": "Haloperidol",
                    "interacting_drug": "Methadone",
                    "description": "Increased risk of QT prolongation and Torsades de Pointes.",
                    "extended_description": "Both Haloperidol and Methadone prolong the QT interval. Combined use significantly heightens the risk of fatal arrhythmias. ECG monitoring is recommended."
                },
                {
                    "drug": "Risperidone",
                    "interacting_drug": "Fluoxetine",
                    "description": "Fluoxetine increases Risperidone levels, heightening the risk of side effects.",
                    "extended_description": "Fluoxetine inhibits CYP2D6, reducing Risperidone metabolism. Elevated Risperidone levels can cause sedation, weight gain, and extrapyramidal symptoms. Dose adjustment may be necessary."
                },
                {
                    "drug": "Quetiapine",
                    "interacting_drug": "Erythromycin",
                    "description": "Erythromycin increases Quetiapine levels, heightening the risk of adverse effects.",
                    "extended_description": "Erythromycin inhibits CYP3A4, reducing Quetiapine clearance. This can lead to excessive sedation, orthostatic hypotension, and metabolic side effects. Consider reducing the Quetiapine dose."
                },
                {
                    "drug": "Olanzapine",
                    "interacting_drug": "Smoking (Tobacco)",
                    "description": "Smoking decreases Olanzapine levels, reducing therapeutic efficacy.",
                    "extended_description": "Tobacco smoking induces CYP1A2, increasing Olanzapine metabolism. This can result in subtherapeutic levels and reduced efficacy. Monitor response and adjust the dose if necessary."
                },
                {
                    "drug": "Clozapine",
                    "interacting_drug": "Ciprofloxacin",
                    "description": "Ciprofloxacin increases Clozapine levels, increasing the risk of toxicity.",
                    "extended_description": "Ciprofloxacin inhibits CYP1A2, slowing Clozapine metabolism. Elevated Clozapine levels can cause sedation, agranulocytosis, and seizures. Monitor closely and adjust the Clozapine dose."
                },
                {
                    "drug": "Lurasidone",
                    "interacting_drug": "Rifampin",
                    "description": "Rifampin reduces Lurasidone plasma concentrations, decreasing its efficacy.",
                    "extended_description": "Rifampin induces CYP3A4, increasing Lurasidone metabolism. This can result in reduced therapeutic efficacy and symptom exacerbation. Avoid this combination or adjust the Lurasidone dose."
                },
                {
                    "drug": "Aripiprazole",
                    "interacting_drug": "Carbamazepine",
                    "description": "Carbamazepine reduces Aripiprazole levels, potentially decreasing efficacy.",
                    "extended_description": "Carbamazepine induces CYP3A4, accelerating Aripiprazole metabolism. This may result in subtherapeutic levels and reduced antipsychotic effects. Consider increasing the Aripiprazole dose."
                },
                {
                    "drug": "Risperidone",
                    "interacting_drug": "Ketoconazole",
                    "description": "Ketoconazole increases Risperidone levels, increasing the risk of side effects.",
                    "extended_description": "Ketoconazole inhibits CYP3A4, reducing Risperidone clearance. Elevated levels can lead to sedation, weight gain, and extrapyramidal symptoms. Dose adjustment may be necessary."
                },
            
                
                    {
                        "drug": "Haloperidol",
                        "interacting_drug": "Ketoconazole",
                        "description": "Ketoconazole increases Haloperidol plasma concentrations, increasing the risk of QT prolongation.",
                        "extended_description": "Ketoconazole inhibits CYP3A4, reducing Haloperidol metabolism. Elevated levels of Haloperidol can cause QT prolongation, Torsades de Pointes, and sudden cardiac death. Use with caution and monitor ECG."
                    },
                    {
                        "drug": "Clozapine",
                        "interacting_drug": "Carbamazepine",
                        "description": "Carbamazepine reduces Clozapine levels, decreasing therapeutic efficacy.",
                        "extended_description": "Carbamazepine induces CYP3A4, increasing the metabolism of Clozapine. This can result in reduced antipsychotic efficacy and a risk of treatment failure. Monitor Clozapine levels and adjust dosing."
                    },
                    {
                        "drug": "Olanzapine",
                        "interacting_drug": "Fluvoxamine",
                        "description": "Fluvoxamine increases Olanzapine levels, enhancing the risk of sedation and weight gain.",
                        "extended_description": "Fluvoxamine inhibits CYP1A2, reducing Olanzapine clearance. This can lead to increased sedation, metabolic side effects, and anticholinergic toxicity. Consider dose reduction of Olanzapine."
                    },
                    {
                        "drug": "Risperidone",
                        "interacting_drug": "Valproic Acid",
                        "description": "Co-administration may increase the risk of sedation and extrapyramidal symptoms.",
                        "extended_description": "Risperidone and Valproic Acid both affect the central nervous system, increasing the risk of side effects such as drowsiness, tremors, and muscle stiffness. Monitor closely for adverse effects."
                    },
                    {
                        "drug": "Quetiapine",
                        "interacting_drug": "Phenytoin",
                        "description": "Phenytoin reduces Quetiapine plasma levels, decreasing its efficacy.",
                        "extended_description": "Phenytoin induces CYP3A4, accelerating Quetiapine metabolism. This can result in reduced therapeutic effects, potentially leading to symptom exacerbation. Consider increasing the Quetiapine dose."
                    },
                    {
                        "drug": "Aripiprazole",
                        "interacting_drug": "Paroxetine",
                        "description": "Paroxetine increases Aripiprazole levels, enhancing the risk of side effects.",
                        "extended_description": "Paroxetine inhibits CYP2D6, reducing Aripiprazole metabolism. Elevated levels of Aripiprazole can lead to akathisia, anxiety, and extrapyramidal symptoms. Monitor for adverse effects and consider dose adjustment."
                    },
                    {
                        "drug": "Ziprasidone",
                        "interacting_drug": "Amiodarone",
                        "description": "Combination increases the risk of QT prolongation and arrhythmias.",
                        "extended_description": "Both Ziprasidone and Amiodarone prolong the QT interval. Combined use significantly increases the risk of life-threatening arrhythmias such as Torsades de Pointes. Avoid co-administration."
                    },
                    {
                        "drug": "Lurasidone",
                        "interacting_drug": "Diltiazem",
                        "description": "Diltiazem increases Lurasidone plasma concentrations, enhancing side effects.",
                        "extended_description": "Diltiazem inhibits CYP3A4, reducing Lurasidone clearance. This can lead to sedation, hypotension, and extrapyramidal symptoms. Reduce the Lurasidone dose or monitor closely."
                    },
                    {
                        "drug": "Clozapine",
                        "interacting_drug": "Lithium",
                        "description": "Increased risk of neurotoxicity and seizures.",
                        "extended_description": "The combination of Clozapine and Lithium can lead to neurotoxicity, manifesting as confusion, ataxia, and tremor, and may lower the seizure threshold. Monitor for signs of toxicity."
                    },
                    {
                        "drug": "Haloperidol",
                        "interacting_drug": "Methadone",
                        "description": "Increased risk of QT prolongation and Torsades de Pointes.",
                        "extended_description": "Both Haloperidol and Methadone prolong the QT interval. Combined use significantly heightens the risk of fatal arrhythmias. ECG monitoring is recommended."
                    },
                    {
                        "drug": "Risperidone",
                        "interacting_drug": "Fluoxetine",
                        "description": "Fluoxetine increases Risperidone levels, heightening the risk of side effects.",
                        "extended_description": "Fluoxetine inhibits CYP2D6, reducing Risperidone metabolism. Elevated Risperidone levels can cause sedation, weight gain, and extrapyramidal symptoms. Dose adjustment may be necessary."
                    },
                    {
                        "drug": "Quetiapine",
                        "interacting_drug": "Erythromycin",
                        "description": "Erythromycin increases Quetiapine levels, heightening the risk of adverse effects.",
                        "extended_description": "Erythromycin inhibits CYP3A4, reducing Quetiapine clearance. This can lead to excessive sedation, orthostatic hypotension, and metabolic side effects. Consider reducing the Quetiapine dose."
                    },
                    {
                        "drug": "Olanzapine",
                        "interacting_drug": "Smoking (Tobacco)",
                        "description": "Smoking decreases Olanzapine levels, reducing therapeutic efficacy.",
                        "extended_description": "Tobacco smoking induces CYP1A2, increasing Olanzapine metabolism. This can result in subtherapeutic levels and reduced efficacy. Monitor response and adjust the dose if necessary."
                    },
                    {
                        "drug": "Clozapine",
                        "interacting_drug": "Ciprofloxacin",
                        "description": "Ciprofloxacin increases Clozapine levels, increasing the risk of toxicity.",
                        "extended_description": "Ciprofloxacin inhibits CYP1A2, slowing Clozapine metabolism. Elevated Clozapine levels can cause sedation, agranulocytosis, and seizures. Monitor closely and adjust the Clozapine dose."
                    },
                    {
                        "drug": "Lurasidone",
                        "interacting_drug": "Rifampin",
                        "description": "Rifampin reduces Lurasidone plasma concentrations, decreasing its efficacy.",
                        "extended_description": "Rifampin induces CYP3A4, increasing Lurasidone metabolism. This can result in reduced therapeutic efficacy and symptom exacerbation. Avoid this combination or adjust the Lurasidone dose."
                    },
                    {
                        "drug": "Aripiprazole",
                        "interacting_drug": "Carbamazepine",
                        "description": "Carbamazepine reduces Aripiprazole levels, potentially decreasing efficacy.",
                        "extended_description": "Carbamazepine induces CYP3A4, accelerating Aripiprazole metabolism. This may result in subtherapeutic levels and reduced antipsychotic effects. Consider increasing the Aripiprazole dose."
                    },
                    {
                        "drug": "Risperidone",
                        "interacting_drug": "Ketoconazole",
                        "description": "Ketoconazole increases Risperidone levels, increasing the risk of side effects.",
                        "extended_description": "Ketoconazole inhibits CYP3A4, reducing Risperidone clearance. Elevated levels can lead to sedation, weight gain, and extrapyramidal symptoms. Dose adjustment may be necessary."
                    }
                
                
    
    
        
        

                                        
                                

















]










